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Abstract
A shift in the global chronic wound care market from traditional wound dressings to 
advanced bio-derived products has demonstrated the demand for the 1st generation of skin 
substitute products. Although these demonstrated the proof-of-concept for tissue 
engineering, the manufacturing processes were mainly laboratory based, labour intensive 
and not amenable to scale-up. The aim of this thesis was to carry out a technical and 
economical evaluation of alternative manufacturing options for the next generation of 
cell-derived wound healing products delivered in an amorphous gel format.
Experimental work was carried out to demonstrate the feasibility of an alternative 
manufacturing process culturing human dermal fibroblasts (HuFFs) to generate 
extracellular matrix. A microcarrier-based process was selected and results showed the 
HuFFs proliferated well on both Cytodex 2 and biodegradeable Vicryl discs. Limitations 
with both approaches are discussed.
Economic feasibility o f the microcarrier based processes was evaluated, and this was 
compared to the conventional manual and automated roller bottle processing route. 
Impact of manufacturing options on the cost o f goods and net present value were 
assessed. Deterministic analysis indicated that the key process economic drivers are the 
cell density and the ratio o f cells to extracellular matrix. Additionally, stochastic analysis 
was applied to rank each process options in terms of risk-reward characteristics and this 
showed sensitivity to the production capacity required. Further process economics 
analysis evaluated the feasibility behind recombinant growth factor production using both 
E.coli and yeast processing routes, and the analysis highlighted critical titre levels 
required for this option to be feasible.
The work in this thesis demonstrates the use of simulation tools and risk analysis to 
support the quality of decision making to enable a cost effective manufacture of advanced 
wound healing products.
2
Acknowledgements
I would like to thank the many individuals who helped and inspired me to walk this road. 
I would like to express my gratitude to my supervisor, Dr. Suzanne Farid, for the 
continual encouragement and constant support from the beginning, and throughout this 
process. Her advice and enthusiasm has always been an unfailing source o f energy which 
has been priceless. 1 would also like to thank Dr. Susanna Levy for the advice and 
support.
I would like to express my gratitude to Nick Medcalf, Dr. Mary-Ann Dowling, Dr. Mark 
Smith for the guidance and helpful advice. Thanks to Dr. Jonanthan Maughan, Sophie 
Hidden for help with cell culture, to Sarah Freestone for help with immunostaining, and 
special thanks to Andrew Prior for all the help with histology staining and sectioning. 
Most of I would like to say thanks to the many people I have met at Smith & Nephew RC 
of which this project would not have been possible.
I would like to say thanks to my colleagues at UCL for their constant support. Special 
thanks to Tarit Mukhopadhay, Wellae Williams-Dalson and Naveraj Gill for their 
friendship, and the many discussions shared over the teas and coffees. Thanks to Edmund 
George for help in code writing to run the simulations of the cost models.
Funding by the Engineering and Physical Sciences Research Council (EPSRC) and Smith 
& Nephew (S&N) is gratefully acknowledged.
I would also like to thank my family for their love and support, and to my partner in life, 
Kirk, for his unwavering love and support.
3
Contents
Abstract 2
Acknowledgements 3
List of Tables 8
List of Figures 10
Abbreviations 13
Chapter 1 Scope and Background 15
1.1 Introduction
1.2 Advanced Wound healing products
1.3 Aims and Organisation of thesis
Chapter 2 Literature Review 21
2.1 Introduction
2.2 Current Products and Process review
2.3 Manufacturing Choices
2.4 Cell Culturing Conditions
2.5 Conclusion
Chapter 3 Materials and Methods 41
3.1 Introduction
3.2 Culture Conditions
3.2.1 Static cultures
3.2.2 Stirred tank microcarrier cultures
3.3 Metabolite analysis o f the media
3.3.1 Glucose, lactate, glutamine, glutamate, and ammonia
3.3.2 Vascular endothelial growth factor (VEGF)
4
3.4 Cell Analysis
3.4.1 Qualitative measures
3.4.2 Quantitative measures
3.5 Other Analysis
3.5.1 Qualitative analysis
3.5.2 Quantitative analysis
Chapter 4 Operational evaluation of the production process of an advanced wound- 
healing product 53
4.1 Introduction
4.2 Static culture studies
4.3 Microcarrier culture studies
4.4 Proposed process for generation of biomass
4.5 Conclusions
Chapter 5 Economic methodology and Implementation 81
5.1 Introduction
5.2 Modelling framework
5.3 Data mining and collection for process models
5.4 Key output parameters
5.5 Dealing with uncertainty: Risk analysis and Monte Carlo simulation
Chapter 6 Economic assessment of manufacturing strategies for advanced wound 
healing products 90
6.1 Introduction
6.2 Assessment of bioreactor designs
6.2.1 Methodology
6.2.2 Results and Discussion
6.3 Case study I Background
6.4 Deterministic Analysis
6.4.1 Set up of the model
5
6.4.2 Results and Discussion o f the deterministic analysis
6.5 Sensitivity Analysis
6.5.1 Setting up o f the sensitivity analysis
6.5.2 Results and discussion
6.6 Stochastic Analysis
6.6.1 Setting up the Stochastic analysis
6.6.2 Results and discussion of the stochastic analysis
6.7 Conclusions
Chapter 7 Assessing manufacturing strategies for growth factor production
7.1 Introduction
7.2 Case Study Background
7.3 Deterministic Analysis
7.3.1 Methodology
7.3.2 Results and Discussion
7.3.3 Sensitivity Analysis
7.3.4 Multiple growth factor production
7.4 Conclusions
Chapter 8 Regulatory Issues
8.1 Introduction
8.2 Autologous vs allogenic
8.3 Regulatory frameworks
8.4 Conclusions
Chapter 9 Conclusions and Future work
9.1 Introduction
9.2 Summary of the technical and future work
9.3 Economic analysis summary and modelling improvements
References
Appendix A Titles o f Papers to be submitted for publishing 165
Appendix B Detailed protocols used for experiments 166
Appendix C Spreadsheets from Excel as examples, and calculations required for the 
economic analysis 178
7
List of Tables
Table 1.1 Maximum market potential for cell derived skin products
Table 1.2 Estimation of sales figures for the selected cell derived skin substitutes
Table 2.1 List o f growth factors and cytokines used in wound healing 
Table 2.2 Description of growth factor therapy products
Table 2.3 Culture systems available for growth of anchorage-dependent animal cells
Table 3.1 The required amount of supplements to add to the basal media 
Table 3.2 Chemistry specifications
Table 4.1 Summary of the metabolite analysis for static culture showing specific rates of
consumption and production, and the ratios
Table 4.2 Properties of the microcarriers used in the culture
Table 4.3 Summary key metrics for the static and bioreactor cultures
Table 5.1 Summary table o f unit operations and process models
Table 5.2 Individual facto rs,/, for a stainless steel bioprocessing plant and the
corresponding derived Lang factor (Novais et al., 2001).
Table 5.3 Breakdown of the COG/g model used (Farid et al., 2001)
Table 6.1 Criteria used in the analysis of bioreactor designs
Table 6.2 Compiled averaged scores obtained from the panel
Table 6.3 Key assumptions for the aRB, mRB, STR and Wave route
Table 6.4 Summary of the economic parameters for comparison of the process routes.
Table 6.5 Comparative cost ratios
Table 6.6 Scenario setups for RB, STR and the Wave
Table 6.7 Impact of demand on the equipment requirements for the Deterministic 
analysis at the varying scales of operation
Table 6.8 Impact of changing the scale o f operation upon the choice of process routes
Table 7.1 Production methods used to produce the commercial topical growth factors
Table 7.2 Assumptions for the case base for the three process routes
Table 7.3 Summary of COG/g, FCI and NPV across the three routes
Table 7.4 Impact of Titre on the USP:DSP ratio, and direct costs vs. indirect costs
Table 7.5 Multi-growth factor production via the 3 production routes
Table 7.6 Summary of the NPV values for the different approaches
9
List of Figures
Figure 2.1 Experimental set-up of rotary column bioreactor.
Figure 4.1 Light microscopy pictures of human dermal fibroblasts cultured in T-flasks at 
a) Day 2 and b) Day 5.
Figure 4.2 Growth curves of the static culture.
Figure 4.3 Cumulative glucose consumption and lactate production plots.
Figure 4.4 Cumulative VEGF production in the static t-flask culture.
Figure 4.5 Production o f collagen in the static t-flask culture.
Figure 4.6 Light microscopy picture showing the dermal fibroblasts attached and 
proliferating on the Nunc 2D Microhex.
Figure 4.7 Light microscopy pictures o f fibroblasts on Cytodex 2 spherical beads.
Figure 4.8 LIVE/DEAD staining of fibroblasts on Cytodex 2 beads at Day 5, 8, 28 and 
34.
Figure 4.9 Immunostaining of Cytodex 2 microcarriers and cells to show where the 
collagen is laid down.
Figure 4.10 Histological stains to show the presence of cells, and ECM being laid down 
surrounding the microcarriers.
Figure 4.11 SEM pictures showing the aggregate of Cytodex 2 beads and cells grown in 
the STR with increasing magnification.
Figure 4.12 SEM pictures to show a) loose aggregate of cells and Cytodex 2 beads, b) 
the cells and extracellular matrix laid down.
10
Figure 4.13 Fibroblasts cultured on Vicryl mesh discs in a 3L bioreactor.
Figure 4.14 Immunostaining of the Vicryl disc culture.
Figure 4.15 Process Flowsheet to indicate the unit operations required for the routes 
adopting (I) the dextran microcarrier, and (II) the Vicryl microcarrier.
Figure 5.1 The hierarchical framework adopted.
Figure 6.1. Normalised plot to show the assessment of the reactors.
Figure 6.2 Flowsheet o f the Roller Bottle (RB) Process and the microcarrier-based 
processed using STRs or disposable Wave Bioreactors.
Figure 6.3 Schematic indicating the flow o f information through the tool 
Figure 6.4 Comparison o f the annual direct cost o f goods per gram (COG/g) on a task 
basis, for the RB method (manual and automated), the Wave Bioreactor method and STR 
method, to produce the same product output of 100kg per year.
Figure 6.5 Breakdown for relative total annual cost o f goods for the RB (manual and 
automated), STR and Wave routes.
Figure 6.6 Tornado diagrams showing the %Change in NPV from the base case for the 
three processes.
Figure 6.7 Cumulative distribution plots o f the three options overlapped
Figure 6.8 Ratio of the expected COG/g ratios across the operational scale of 1 kg to
10,000kg relative to the automated RB route.
Figure 6.9 Plot of the p(NPV>0) vs. output for the various process routes.
11
Figure 7.1 Flowsheet for the production o f growth factors using the Yeast route 
(Secretory, STR and Wave)
Figure 7.2 Flowsheet for the production o f growth factors using the E.coli route (Non- 
secretory, STR)
Figure 7.3 Breakdown of the equipment costs for the three processing routes.
Figure 7.4 Comparison of the direct to indirect costs across the three routes with (■  ) 
Materials, (■ ) Labour, (□ ) Utilities and (□  ) Indirect costs.
Figure 7.5 Annual direct cost o f goods/g on a task basis for the STR-yeast vs WAVE- 
yeast.
Figure 7.6 Breakdown of the direct costs in terms of Upstream (USP) to Downstream 
(DSP) to Ancillary (ANC) activities.
Figure 7.7 COG/g for the three process options across titres.
Figure 7.8 NPV for the a) STR-Yeast and b) WAVE-yeast across titres and 
demonstrating the effect of demand upon the NPV.
Figure 8.1 Flow-chart to determine the regulatory pathway (361 HCT/P or 351 HCT/P).
12
ABBREVIATIONS
aRB Automated roller bottle
ATS/SN Advanced Tissue Sciences/Smith & Nephew
bFGF Basic fibroblast growth factor
CIP Cleaning-in-place
COG Cost of Goods
DMEM Dulbeccos’ modified eagles’ media
DSP Downstream processing
EMEA European medicines evaluation agency
FDA Food and Drug Administration
HVAC Heating ventilation and air-conditioning
HuFF Human dermal neonatal foreskin fibroblasts
IRR Internal rate of return
KGF-2 Keratinocyte growth factor 2
kLa mass transfer coefficient for oxygen transfer
MADM Multi-attribute decision-making
MCDM Multi-criteria decision-making
MDCK Madin-Darby cainine kidney cells
mRB Manual roller bottle
MTT [3-(4,5-dimethyldiazol-2-yl)-2,5 diphenyl tetrazolium bromide]
NHS National health service
NPV Net present value
13
OCT Optimal Cutting temperature compound
PBS Phosphate buffer saline
PDGF Platelet derived growth factor
QA Quality assurance
QC Quality control
RB Roller bottle
RC Research centre
SIP Steam-in-place
STR Stirred tank reactor
TE Tissue engineered
TEPC Total equipment purchase cost
TGF-pi Transforming growth factor—pi
TGF-P2 Transforming growth factor—P2
TGF-P3 Transforming growth factor—P3
UCL University College London
USP Upstream processing
WFI Water for injection
14
CHAPTER 1
S c o p e  a n d  B a c k g r o u n d
1.1 Introduction
The pioneering 1st generation tissue engineered products were skin substitute products 
developed for wound healing. It has been met with many challenges and one of the 
conclusions drawn by people in the industry is that the manufacture of these advanced 
wound dressings is subject to costs similar to drug manufacture and yet the profit margins 
are that o f medical devices (Bouchie, 2004). Thus, there is a growing pressure to reduce 
the development costs. Chronic wounds include pressure ulcers, venous ulcers, and 
diabetic foot ulcers and these can persist for years, requiring cost-intensive treatments. A 
leg ulcer is defined as the Toss o f skin below the knee on the leg or foot, which takes 
more than six weeks to heal’ (NHS CRD, 1997). In the U.S. alone, the incidence of 
chronic wounds is estimated at 3 to 5 million which is costing $2.8 billion dollars 
annually. Venous leg ulcers are a common, chronic, recurring condition. They are 
estimated to have a prevalence of 1.5 to 3 per 1000 of the UK population (NHS CRD, 
1997). This prevalence increases with age, and is estimated at 20 per 1000 aged 80 years 
(Royal college of Nursing, 2000a). The economic cost of leg ulcers to the NHS is 
estimated at £300-600 million a year (Simon et al, 2004). Between 17% and 65% of 
people with a leg ulcer experience severe or continuous pain with a major impact on the 
quality of life (Briggs and Nelson, 2003).
Foot complications are also common in people with diabetes. The prevalence of 
neuropathy in people with diabetes is 23 to 42%, and that of vascular disease is 9-23%
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(SIGN, 2001). It is expected that 15% of people with diabetes will develop a foot ulcer 
associated with peripheral neuropathy or ischaemia or both (NHS CRD, 1999). Again, 
the diabetic foot ulcer is also very painful and hard to heal. The danger associated with 
these chronic ulcers is the risk of amputation and morbidity.
For many bums victims, the use of their own skin for grafting is not an option because 
the patient is too weak for surgery, or simply put, does not have enough healthy skin 
available. Thus, clinicians will use cadaver skin or animal skin as a temporary solution, 
even though these will be rejected eventually anyway. In Western Europe, it is estimated 
that severe bums, with about 150 patients per year to be treated by tissue-engineered skin 
substitutes, represent a much smaller market (Jones et al., 2002).
The global wound care market is a growing industry that is shifting from traditional 
wound dressings to advanced wound dressings (Frost and Sullivan, 2004). This is due to 
the aging population, which leads to an increase in the incidence of chronic wounds and 
the increase spending in health. Table 1.1 is from the report carried out to examine the 
future prospects o f tissue engineering.
Table 1.1 Maximum market potential for cell derived skin products
Market Market size 
2001
(millions of 
euros)
Region Source
Global wound management 
market potential
6,250 World Landesbank Baden- 
Wurttemberg Equity 
Research, 2001
Maximum market potential 
for tissue-engineered skin, 
only applicable to chronic 
wounds
625 World Landesbank Baden- 
Wurttemberg Equity 
Research, 2001
Global market for skin 
replacement products for 
wound repair
800 World Russell & Cross, 
2001
Market for skin substitutes 300 USA Russell & Cross, 
2001
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Although these products demonstrated the proof of concept, they have faced many 
challenges getting to market. The poor business model of high development costs and 
low profit margins contributed to major players filing for bankruptcy in 2002 as sales 
were too low to cover operating costs (Bouchie, 2004). In addition, the previous lack of 
regulatory framework, especially in the EU has contributed to the demise of some of 
these products, since they lie in the overlap between the biologies and devices (Moore, 
2002). This has caused delays in getting approval and consequently led to massive 
overspending, with the net result o f being sold to a larger company (Bouchie, 2004).
1.2 Advanced Wound-healing products
The skin is the largest organ in the body and serves to form a protective barrier against 
the environment. Significant losses of portions o f skin due to injury or illness can lead to 
debilitating conditions and the possibility of death. Besides acute injuries such as bums, 
the social and financial tolls of chronic wounds are very high. Thus scientific 
breakthroughs in wound management have led to the use of cell derived skin substitutes 
(e.g. Apligraf®, Dermagraft®, Transcyte®) and recombinant growth factors (Regranex® 
gel). The dynamics of a chronic wound are quite different from that o f acute wounds but 
it is thought that the introduction of cells and the appropriate factors into the engineered 
skin product will address the imbalance and promote wound healing.
The first products to reach the market were approved for the treatment of severe, full 
thickness bums e.g. Epicel (Genzyme Biosurgery, US), Integra (Integra Life Sciences, 
US), and Transcyte (Advanced Biohealing Inc, US). Most of the first generation tissue- 
engineered products are developed to mimic the human skin as closely as possible. Some 
of the first products that were developed to treat chronic wounds and severe bums are 
listed in the table below. (These are situations where the wounds are hard-to heal and it 
can become a life-threatening situation). Apligraf (Organogenesis, US) was the first 
product to gain approval from the FDA for the treatment of venous leg ulcers. Having 
emerged from bankruptcy in 2002, Organogenesis now has the greatest market share with 
this product. Table 1.2 shows the estimated sales figures of these products.
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Table 1.2 Estimation of sales figures for the selected cell derived skin substitutes
Trade Name Company Year Sales ( Millions of 
euros)
Apligraf Organogenesis Inc (USA), 
Novartis (USA/CH)
2006 44.6
Dermagraftt Advanced Tissue 
Sciences(USA), Smith & 
Nephew (UK)
2003 10.4
CellActiveSkin* IsoTis (NL) 2002 0.545
Epidex+ Modex Therapeutics (CH) 2002 0.157
BioSeedS,
BioseedM,
MelanoSeed
BioTissueTechnologies
(D)
2002 0.450
Epicel** Genzyme Biosurgery 
(USA)
2001 n.a. 75 patients 
treated annually 
worldwide
Production stopped in 2005 and business sold to Advanced Biohealing Inc, US.
Production stopped in late 2002 because the product was not profitable.
"Production was stopped by Modex Therapeutics (CH), product licensed to Autoderm (Germany) in spring 
2003.
**No FDA approval needed as it was considered as a medical procedure.
According to Pruitt and Levine, (1984), Smith, (1995), Ehrenreich and Ruszczak, (2006), 
the ideal synthetic wound dressing, or biologic skin substitute should have the following 
characteristics:
absence of antigenicity
tissue compatibility
absence of local/systemic toxicity
impermeable to exogenous microorganisms
water vapour transmission e.g. like skin
rapid and sustained adherence to wound surface
conformable to the surface irregularities
elasticity to permit motion of underlying tissue
resistant to linear and shear stresses
tensile strength
inhibition of wound surface flora and bacteria 
long shelf life, and minimal storage requirements
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biodegradable 
low cost
minimize the nursing care of the wound, and patient discomfort
translucent to allow observation of the wound healing
reduction in healing time
not increase the rate of infection
patient acceptance and compliance
These cell derived advanced wound healing products brought to market were expensive 
(Jones et al., 2002) and this delayed the adoption of these products by the market. One of 
the reasons for the high price o f these products was due to the high production costs 
involved. Additionally, the set size was also one o f the limitations. The short shelf-life 
made the logistics of transportation of these products to the patient a critical issue. Thus 
the need to address some of these limitations exists for the next generation of cell derived 
biological dressings.
1.3 Aims and organisation of thesis
The preceding section has provided a general background to the field o f cell derived 
products for wound healing e.g. skin-substitutes, and Chapter 2 presents a more in-depth 
literature review. As highlighted in this introductory chapter, the first generation cell 
derived products for wound healing have struggled to achieve their potential market 
success. This has been largely attributed to inflexible, labour-intensive and costly 
manufacturing processes that are not amenable to scale-up. Thus, the aim of this project 
was to explore an alternative approach for generating second generation products that 
would provide increased flexibility and lower costs. This was based on the provision o f 
products in a radically different formulation as a gel which would open up the way for 
more robust and scalable manufacturing process. Additionally, this project will seek to 
identify the crucial parameters involved in making the next generation of cell derived 
products for wound healing by examining the process economics as well.
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Chapter 2 starts with the introduction of the biology o f wound-healing, and then presents 
a more in-depth analysis o f the current products and the processes o f manufacture. It then 
examines the manufacturing challenges and reviews the various bioreactor designs, 
followed by the culture conditions required for the culture o f human dermal neonatal 
foreskin fibroblasts (HuFFs).
Chapter 3 gives the methodology required for the technical experiments and this section 
describes the methods and assays used. Chapter 4 presents the results of the experimental 
work, beginning with the initial characterisation of the dermal fibroblasts, the static 
culture and then the results from bioreactor cultures in stirred tank fermenters. It then 
expands to discuss other equipment issues in scaling up and discuss the technical 
limitations.
Chapter 5 explains the framework presented for the economic modelling. It presents a 
methodology for modelling the process economics and shows economic indicators such 
as net present value (NPV), and cost of goods (COG) can be incorporated as the outputs. 
Chapters 6 shows the case study for comparing the different reactor options, namely 
roller bottles (RBs) to stirred tank reactors (STRs) and the disposable Wave bioreactor. 
The results of deterministic analysis and stochastic analysis using Monte Carlo 
simulation were presented. Chapter 7 present the economic analysis of growth factor 
manufacture using the microbial routes and the main limiting factor was identified to be 
the titre level. Sensitivity analysis showed achieving a critical titre level of greater than 
lOOmg/L meant profitability for the process routes.
Chapter 8 covers the regulatory issues faced by these TE-products. Finally, Chapter 9 
provides a summary of the key conclusions and then presents suggestions for future 
work. Finally, titles of the drafted papers by the author to be submitted for publication are 
mentioned as Appendix A. Protocols used for the experimental work are included as 
Appendix B. Additional details involved in the economic cost modelling are included in 
Appendix C.
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CHAPTER 2
L it e r a t u r e  r e v ie w
2.1 Introduction
This chapter provides the literature on skin replacement products, and the manufacturing 
processes for them. It starts with a brief background on the biology of wound-healing 
which is a very complex process and then delves into the existing treatments and 
processes. A discussion of manufacturing choices for adherent cells is then discussed. 
Finally, culturing conditions published in the literature are reviewed so as to provide a 
basis for the experimental work.
It was the breakthrough work published in 1975 by Rheinwald and Green, which 
prompted the revolution in tissue engineering of skin substitutes. Building on previous 
attempts at skin replacement in the 1960s, they successfully serially sub-cultured 
keratinocytes. Increasingly, many methods have been published which describe the 
deployment of autologous and allogeneic cells onto wounds. Currie et al. (2003) and 
Veazey et al. (2004) demonstrated the use of aerosol sprays to deliver cells to bums. 
Constructs o f fibroblasts/collagen gels (Kuroyangi et al., 2001), fibroblasts and chitosan 
(Ma et al., 2001), cells and fibrin (Gorodetsky et al., 1999, Cox et al., 2004), cells and 
plasma products (Ito et al., 2003), tissue equivalents (Eaglestein and Falanga, 1998), cells 
and other polymeric surfaces (Yamato et al., 2001) have been also developed. The use of 
biodegradable microspheres for regeneration of wounded skin has been proposed by 
LaFrance and Amstrong (1999). Wound healing is a complex condition involving a 
myriad of factors and some information about wound biology is given.
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Wound repair is a dynamic process, but follows a time sequence and can be considered in 
stages of inflammation, tissue formation and tissue remodelling. Immediate wound 
coverage is generally one of the key cornerstones of therapy, thus in the past grafts from 
other sources such as cadavers or animals have been used. However, this has its 
associated risks (e.g. transmitting infection), thus there is the need for bioactive cell 
derived biological dressings. Additionally, these grafts are eventually rejected thus 
making them a temporary solution rather than a permanent one.
The skin comprises of the epidermis and the dermis, where fibroblasts and keratinocytes 
are the main cell types, which produce and maintain the extracellular matrix (ECM). 
Fibroblasts are one o f the key cells, which migrate to the wound site and secrete a variety 
o f factors and matrix proteins to stimulate wound healing. The ECM laid down by the 
cells is a complex mixture o f cross-linked proteins and glycosaminoglycans (GAGs). 
This ECM interacts with the cells in a crosstalk manner. The growth factors, which are 
involved in wound healing are listed in Table 2.1.
Table 2.1 List o f growth factors and cytokines used in wound healing
PDGF Platelet derived growth factor
TGF-3 Transforming growth factor-(3
TGF-a Transforming growth factor-a
FGF Fibroblast growth factor (acidic, basic)
KGFs Keratinocyte growth factors
EGF Epidermal growth factor
IGF-1 Insulin-like growth factor 1
VEGF Vascular Endothelial Growth Factor
TNF-a Tumour necrosis factor a
IL -l-a Interleukin-1 -a
IL-l-(3 Interleukin-1-P
IFN y Interferon y
IFN a-20 Interferon a-2[3
These cytokines and growth factors act in a concerted manner and control wound healing; 
thus identifying the key ones would be desirable as well as controlling the level 
expressed. Collagen is the primary structural protein and many forms exist. Adhesion
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proteins bind to these collagen proteins. Typically, the predominant form of collagen of 
interest will be type I, secreted by the human foreskin fibroblasts (HuFFs) since this will 
be present in significant quantities.
Fibronectin is a globular protein and again interacts with the cells. Proteoglycans are part 
o f the multifunctional ECM and act as important cell surface molecules. One of the small 
proteoglycans, decorin binds to collagen fibrils and plays a role in the fibril assembly. 
Additionally, it has an effect on the cell morphology and can modulate the binding of 
cells to the matrix constituents such as collagen and fibronectin. These small 
proteoglycans also helps to sequester the growth factors within the ECM (Hildebrand, 
1994).
With normal wound healing, the first response is clot formation and at the same time, 
inflammatory cytokines are released to do a variety o f functions: recruit macrophages and 
lymphocytes to fight off infection, regulation o f blood flow to the affected area; stimulate 
angiogenesis and deposition of ECM. The latter processes form granulation tissue. This 
is very important because it fills the wound with tissue that brings inflammatory cells to 
provide protection and at the same time a substrate for re-epithelialization. After the 
wound closes with an epithelium, factors such as TGF-p stimulate the remodelling into a 
scar.
With the case o f impaired healing, it is postulated that there may no longer be a 
granulation response because the fibroblasts and keratinocytes at the wound perimeters 
may have stopped proliferation and start to senesce (i.e. the cells have grown old and are 
no longer able to grow). It could also no longer be responding to the cytokine stimulation. 
It has been reported that the expression and proteolysis of VEGF is increased in chronic 
wounds (Lauer et al. 2000). Therefore, it is believed that providing either living healthy 
cells or altering the level of cytokines such as the case of Dermagraft® (Advanced 
Biohealing Inc) and Apligraf® (Organogenesis) will shift the imbalance at the wound site 
to the normal healing response (Gentzkow et al., 1996). Thus, it would be useful to 
observe how environmental factors can affect the levels of growth factors or cytokines
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and thus vary the final composition of the bioactive cell derived product. For example, in 
peritoneal fibroblasts, it has been shown that increasing the concentration of glucose 
stimulated the production of type I collagen and TGF-pi mRNA levels (Saed, 2003). 
Thus by altering the levels of glucose, the levels o f TGF-p will be affected and thus 
affect the collagen secretion by the cells.
Additionally, if the mode of action for accelerated wound healing is to use biologically 
active matrix, then the development of a biomass product rich in a variety of growth 
factors is a viable approach. Indeed, cell derived biological dressing such as Dermagraft 
and Apligraf probably act as a vehicle for delivering growth factors to wounds 
(Eaglestein and Falanga, 1997). It has been demonstrated that Apligraf does not survive 
transplantation for more than six weeks in acute human wounds and serves a temporary 
role as a biological dressing (Griffiths et al., 2004).
2.2 Current Products and Process review
The current products brought to market can be divided into three categories: autologous 
skin grafts, allogeneic skin substitute products, and growth factor therapy. At present, an 
example of commercial autologous therapy is Myskin, produced by CellTran (UK). 
Launched in 2004, Myskin is used to treat bums and chronic wounds. This product is 
only available in the UK, partly due to logistic and transportation issues. The pricing of 
Myskin is quite attractive, as it is expected to have an average price of £500 for several 
applications.
Myskin is made up of a flexible medical-grade silicon substrate backing polymer coated 
with a chemically controlled plasma polymer film that supports the growth of 
keratinocytes, derived from a small biopsy obtained from the patient. This silicone layer 
is formulated with a surface coating that has been deposited by plasma polymerisation of 
acrylic acid. This polymer film is engineered to promote cell growth, and subsequent 
release when applied on to the wound. During the manufacturing process, the 
keratinocytes are co-cultured with irradiated murine cells. It is supplied as a 5cm
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2diameter circular disc of surface area 19.6 cm , and individually packaged on a sterile, 
buffered, serum-free mixture o f DMEM(76%) and HAMS F12 (23%) in an agar gel 
form.
Both Apligraf and Dermagraft originate from neo-natal foreskin and hence are allogenic 
therapies. Apligraf® (developed and manufactured by Organogenesis, marketed by 
Novartis until June 2003, formerly known as Graftskin, Living Skin Equivalent) was first 
approved in the treatment of venous ulcers and subsequently, the treatment of diabetic 
foot ulcers. Apligraf (Organogenesis) is a bilayered skin substitute consisting of living 
cell and structural proteins. The lower dermal layer is a bovine type I collagen fibroblast- 
containing matrix and the upper epidermal layer is formed by viable keratinocytes. The 
process o f manufacturing Apligraf is a modification o f the procedure used by Bell et al. 
(1981) and subsequently described in detail by Parenteau et al. (1992). The total 
manufacturing time takes 17 to 20 days (Eaglestein and Falanga, 1997).
Essentially, the basic steps to the process are cell stock preparation, formation o f the 
matrix, epidermalisation, stratification and maturation. Fibroblasts and keratinocytes are 
obtained from screened neonatal foreskins and used to establish the cell banks (Wilkins et 
al., 1994). Solution of purified acid-extracted bovine type I collagen is mixed with 
fibroblasts and is cast onto the porous membrane of the culture insert and the neutralised 
mixture solidifies into a gel. This then is cultured, and after 4-6 days, the fibroblasts 
cause this mixture to contract and form a dermal equivalent. Finally, keratinocytes are 
seeded onto this dermal equivalent in the epidermalisation stage and cultured for another 
2 days to allow coverage. This is then exposed to air to allow stratification o f the 
epidermis and the bilayer is cultured at the air-liquid interface to ensure epidermal 
organization and maturation.
This product is supplied as a circular dish, which is approximately 75mm in diameter and 
0.75 mm thick. The packaging is a sealed polyethylene bag with a 10% CCVair 
atmosphere and an agarose nutrient medium. It is shipped overnight based on the date of
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patient application and stored at room temperature. The shelf life of the product was 
about a week, but has been extended to 10 days and retails at $1199 (Medicare, 2004).
Transcyte is a temporary covering derived from fibroblasts. It is made by seeding cells 
onto a nylon mesh in fiberglass casings, and when closed the casing acts as a bioreactor. 
The bioreactors are stacked together in an incubator. This is used to treat bums. Problems 
from manufacture are that tiny perturbations caused shear stresses which affect the 
formulation of scaffold. It is not space efficient or very robust, and dependent on the skill 
o f the operator. This was also delivered in a fixed format only. Dermagraft® was first 
approved to treat diabetic foot ulcers, and it was developed by Advance Tissue Sciences 
(ATS), in collaboration with Smith & Nephew. After ATS filed for bankruptcy in 2002, 
the product was subsequently bought out by Smith and Nephew. In Nov 2005, Smith and 
Nephew announced the sale of the Dermagraft and Transcyte business, and this was 
purchased by Advanced Biohealing Inc in May 2006. Dermagraft (Advanced Biohealing 
Inc) is a living, metabolically active, immunologically inert dermal tissue. It is 
cryopreserved and human fibroblast-derived. It consists of cultured neonatal fibroblasts, 
which are seeded on to bioresorbable polyglactin mesh. The product is supplied frozen in 
a clear bag that contains one piece measuring 2inch x 3inch and sold for $450 (Naughton, 
2002).
The basic manufacturing steps are cell stock preparation, matrix formation, and cellular 
in-growth. Screened fibroblasts obtained from the neonatal foreskins by enzymatic 
isolation are cultured and banked at passage 5. Cells are expanded in roller bottles. These 
dermal fibroblasts are seeded onto polygalactin acid mesh (Vicryl®, Ethicon Inc) which 
was laser welded to the pouch. This is then cultured for 15 days. This semi-automated 
system consisted of several bags stacked next to each other and attached to a manifold 
which circulated media at a slow recirculation rate. Dermagraft is supplied frozen with a 
shelf life of one year.
Byproducts from the manufacturing processes o f Apligraf and Dermagraft are the spent 
media, which is rich in soluble growth factors and have been sold off to make anti-aging
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facial creams. For example, Nouricel (ATS/S&N) comprises the spent media from the 
Dermagraft process and was sold to Biozhem Cosmeuticals Inc (Mckenna, 2002). 
Organogenesis are also utilising the spent media from the culture of their Apligraf for 
similar purposes as well, in targeting the cosmeuticals industry, with their own product, 
Revitix, which will be on sale in 2007. Neocutis is another company that is selling 
creams for anti-aging purposes with growth factor mixture derived from cultured fetal 
fibroblasts. Gold et al. (2007) reported on the use o f growth factors and cytokines as such 
in a topical cream to reduce the appearance of wrinkles.
Another company in this field is Ortec International where its primary product is Orcel, 
and this is a bilayerd cellular matrix aimed at the chronic and acute wounds market. Orcel 
consists of bovine type I pepsinised collagen sponge seeded with keratinocytes and 
fibroblasts derived from the neo-natal foreskin tissue. However, they still need to 
complete clinical trials for the ulcers market. The culture duration is 10 to 15 days and 
expected be on the market at $ 1100 .
Intercytex, another UK company, is seeking to commercialise its lead products, ICX- 
PRO for chronic wounds, ICX-TRC for hair regeneration and ICX-SKN for skin grafts. 
Again, the cells are derived from US neo-natal foreskins. ICX-PRO is human dermal 
fibroblasts presented in a fibrin-based gel matrix and Intercytex hopes to bring this 
product to market in 2008. It has a shelf life of 21 days.
These 1st generation cell derived advanced wound healing products are produced as 
‘tissue bandages’ in the form of discs or sheets. However, this fixed size limitation 
requires hospitals to have stocks of material and surgeons to alter the shape to cope with 
the variation of wounds seen with each individual patient. Original manufacturing 
methods were largely based on laboratory practice and were slow, labour-intensive and 
did not implement much automation. The repetitive nature of the work represented a 
problem for retaining skilled labour, and resulted in high staff turnover ratio.
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Since emerging from Chapter 11 bankruptcy, Organogenesis has moved successfully 
from a manual process requiring skilled technicians to one that is semi-automated to 
control media additions to the Petri dish like vessels (Mason and Hoare, 2007). Although 
Dermagraft was produced by a more automated process, it has been reported that many 
batches o f product had to be discarded due to uneven growth in the pouches, thus 
increasing overall production costs (Moore, 2002).
Transportation o f these cell derived advance wound healing products has been a major 
stumbling block and added to the financial drain on the company’s resources. Some of 
these cell derived advanced wound products are shipped fresh for use in therapy, but the 
short shelf life meant that any delays in transportation resulted in useless expired product. 
Although cryopreservation overcomes this limitation and allows off the shelf use, 
couriering a product in dry ice to attempt to keep it frozen is expensive. Additionally, this 
requires the hospital to invest in infrastructure such as -70°C freezers and maintenance of 
them to store the frozen product. Most clinics do not possess this necessary infrastructure. 
The doctor, who applies this frozen product, needs to be well trained in the defrosting 
technique, plus it is important to thoroughly rinse the product free from the toxic 
cryoprotectant, DMSO, dimethylsulfoxide.
A different approach for treatment o f wounds has been the use o f growth factors e.g. 
Regranex gel (Johnson and Johnson), Fiblast spray (Kaken Pharmaceuticals). The active 
ingredient in Regranex gel is a recombinant platelet-derived growth factor (PDGF). 
Fiblast spray is currently available only in Japan and contains basic fibroblast growth 
factor (bFGF). Currently, other cytokine products for cosmetic improvement of scars and 
planned for use in wound healing is under development by a UK company, Renovo. 
Table 2.2 summarise the details about the products brought to market.
The only growth factor product that has enjoyed commercial success has been Regranex 
gel and this is probably due to the fact that wound healing being such a complicated 
process, has meant that there is not a one simple solution. Different growth factors have
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been tested, and the results demonstrating efficacy have been shown for some growth 
factors e.g. bFGF, (Robson et al., 1992), and PDGF (Wieman, 1998).
Table 2.2 Description of growth factor therapy products
Product Company Product and Process 
Description
Cost Year
approved
Sources
Regranex
gel
Johnson and 
Johnson
Topical application 
containing a secreted 
growth factor rPDGF
Kept refrigerated
£275 
for a
15g
tube
1998 www'.rxlist.com 
w ■ w w . re manex.com
Fiblast
spray
Kaken
Pharmaceuticals
Topical application 
containing a bound 
growth factor rbFGF
Freeze-dried powder, 
reconstituted upon 
usage.
£60 
pounds 
for a 
500ml 
spray
2001 Annual Report 
from Kaken 
Pharmaceuticals
Prevascar Renovo Topical application 
of rIL-10 growth 
factor
N/A Expected
2008
www.renovo.com
Juvista Topical application 
ofrTGF-p
N/A Expected
2008
www.reno\o.com
Thus, provision of 2nd generation cell derived advanced wound healing products in 
radically different formulations such as an easy-to-use preformed gel delivered via a 
disposable tube using robust scalable manufacturing processes appears to be an attractive 
alternative. This approach is explored further in this thesis.
2.3 Manufacturing Choices
2.3.1 Autologous vs. allogenic cells
Before the production can start one o f the important determining factors affecting the 
choice of manufacturing route is the source of cells. Cell based therapies that opt for the 
autologous route usually delivers the product ‘fresh’ to the patient and cryopreservation is 
not adopted. Choosing the allogeneic route allows for cryopreservation which increases 
the shelf life of the product, and the product can be shipped a great distance to the patient
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(IPTS report, 2003). It is felt that the autologous route will be based on a service-driven 
industry model, rather than the product-driven model. The source of cells for the 
allogeneic route has been derived from neonatal foreskins for the products brought to 
market. There is a belief that because these cells are very young that they contribute 
towards a scarless healing, and this can be considered a marketing advantage over the 
autologous route. The autologous route will represent a lower regulatory burden when 
compare to allogeneic methods.
2.3.2 Scaffold choices
The cells require a scaffold to grow on and this can be incorporated into the product to 
form part of the cell delivery vehicle. A wide variety of biodegradable scaffold materials 
are being developed, which can be separated into many categories, but essentially, there 
are natural and synthetic biodegradable polymers. Examples o f natural biodegradable 
polymers are fibrin, collagen, gelatin, albumin, starch, dextran, chitosan, and chitin. 
Synthetic biodegradable polymers are polylactic acid, polyglycolic acid, poly(lactide-co- 
glycolide), polyorthoesters, polyhydroxybutyrate, polyhydroxyvalerate, polyanhydride. 
There are some other classes of scaffolds which change their physical properties in 
response to external stimuli e.g. pH sensitive and thermoresponsive polmers (Kidchob et 
al., 1998, Recum et al., 1998, Yamato et al., 2001). However, for the scope of this 
project, the biodegradable material used will be the synthetic material, PLGA 
(polylactide glycolic acid), with the commercial name, Vicryl.
2.3.3 Reactor vessel choices
The last dominant variable to be considered is the type of reactor vessel which is suitable 
and whether to run the culture as batch, fed-batch or continuous and this is reviewed in 
the following section based on the industrial processes with animal cells. Many systems 
were developed to match the need for the production of mammalian cells and this has 
been demonstrated by the successful manufacture of vaccines, tPA, human interferon, 
blood proteins such as Factor VIII. However, the development of bioreactors for adherent
30
cells for tissue engineering is still very much of a challenge since the cells are primary 
and are more delicate.
Since these cells are primary cell lines, the cell expansion step prior to production culture 
cannot be too long, thus this implies an upper size limitation to the reactor. Hu at al. 
(1985) showed that for FS-4 fibroblasts serially passaged over 3 consecutive microcarrier 
cultures decreased from 2.2 doublings in the 1st passage to 1.5 doublings in the third 
passage. Van Wezel et al. (1967) reported the decrease in the final density achievable for 
kidney cells from monkeys with each successive subculture, until the cells ceased to grow 
at the sixth or seventh passage altogether.
The use of adherent cells limits the possibilities in reactor choice, and in general, the next 
step up from lab-scale experiments in T-flasks has been to conduct the cell culture in 
roller bottles. These are cylindrical screw-capped bottles, which are usually made of 
plastic or reusable glass. The size of the bottle is about 1 litre or so and is filled to about 
30% of culture medium. These bottles are then placed on a roller rack and rotated slowly, 
and incubated either, in an incubator or an incubation room. The cells attach to the inner 
wall of the bottle. This cell layer is bathed into the medium, and there is alternate 
exposure o f the gas phase and medium as the bottle slowly rotates.
Eventually the entire surface is covered by the cell, and normal diploid cells will suffer 
from contact inhibition and stop growing. They are then detached by enzymatic treatment 
e.g. trypsin, and then inoculated into other roller bottles. Roller bottles have been used 
commercially for the production of erthropoetin EPO by Amgen (Tsao et al., 1992, 
Eridani, 1990). This worked well for Amgen, as it allowed them to get product into 
clinical trials quickly, and meet the total estimated demand in the US in 1998 which was 
1 kg per year (Kretzmer, 2002). The use of spiral designs, ceramic packing, glass tubes in 
the roller bottles are methods to increase the surface area and still retain the monolayer 
culture. Table 2.3 compares some different systems and it can be observed that roller 
bottles may not be the most efficient system to culture cells.
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For small-scale production, roller bottles (RBs) have many advantages. RBs are 
inexpensive to set up and allows for a rapid change of throughput in response to need. 
The relative simplicity to replace the cell growth medium to one that is designed for 
product formation is an advantage, for example, replacing the serum-containing medium 
with serum-free medium for production of viruses. The transparency of the roller bottles 
allows quick visual inspection and microbial contaminated bottles can be quickly 
identified and discarded.
The disadvantages become obvious for large-scale production. Numerous bottles are 
required, and there is no on-line environmental monitoring and control, as it is 
impractical and virtually impossible. The aseptic handling of the bottles means that 
labour has to be extensively well trained to ensure success. The risk o f microbial 
contamination is high, since each batch requires many bottles and there are several 
manual steps. The advent of automation has allowed some of these problems to be 
addressed but the cost o f the robotic arm is, certainly not cheap.
Table 2.3: Culture systems available for growth of anchorage-dependent animal cells
Source: Taken from Atkinson and Mavituna, Biochemical Engineering and Biotechnology Handbook, pg 
476
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The reasoning behind the use of multitray units such as the Cell Factory is the ease in 
scale up, as it is like lego bricks. Nunc’s cell factories are disposable, polystyrene, 
ventable chambers that come in stacks. Inoculation, feeding, and harvest are 
straightforward. No specific training is required and the cells can be visualised directly in 
the chambers via an inverted microscope (Meisenholder, 1999). The CellCube from 
Coming Science Products is an easily expandable system for growing adherent cells. 
With these disposable polystyrene modules, each holds about 3.5L of media and contains 
25 parallel plates for a total growing area of 21,000cm2 per cube. The interlinked cubes 
stand on one another with media entering the bottom and exiting the top (Griffiths, 2001).
These units are supplied, assembled and sterile ready for use. Also been made of 
disposable plastic meant the issue of risk of contamination is lower. However, the 
potential disadvantage is that it requires a lot of medium. Additionally, the inability to 
completely remove all the cells from the trays is quite a disadvantage. This problem can 
be turned around by adding fresh medium to the remaining cells, which can act as 
inoculum for the next culture. However, this maybe suitable for initial cell expansion but 
it is not an option as a final reactor for cell derived skin substitute, due to the inability to 
retrieve the final product without compromising sterility.
Rotary reactors, such as the NASA device, have been developed. However, this system is 
not applicable to large scale due to its complexity. There has been some mention in 
literature of various configurations, which uses rotary motion. It has been reported that a 
rotary column reactor was used for anchorage dependent cells (Nakao et al., 1996). It 
could be that the rotary motion is conducive to enhance the secretion of extracellular 
matrix by fibroblasts. Fig 2.1 shows the rotary column reactor that was used.
The idea of culturing adherent cells on microcarriers was proposed in 1967 by Van 
Wezel, and a few decades on, a variety of microcarriers have been developed and used in 
cell culture for the production of biologicals such vaccines, and proteins (DePalma, 
2002). Microcarriers are spherical beads of 150-200pm diameter, which can be
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suspended in a culture medium. Cells can attach and grow on the bead surface, as a 
monolayer of up to 100-200 cells per microcarrier.
Figure. 2.1 Experimental set-up of rotary column bioreactor. The arrows with *indicate 
the flow of the culture medium. 1 = Level sensor, 2 = pH sensor and 3 = DO sensor. 
(Nakao et al., 1996)
Microcarrier cultures are generally considered to have the greatest advantages for scale 
up of anchorage-dependent cells, and this quasi-suspension culture is space saving and 
cost-effective with regard to use of culture media and expensive supplements such as 
serum (Malda and Frondoza, 2006). Use of microcarriers opens up the options normally 
only available to suspension cell cultures. Simple stirred tank batch fermenters can be 
easily adapted to suit the mixing conditions required to maintain a homogeneous culture 
of microcarriers, and such cultures have been operated at a scale of 1000L. The cell yield 
from such batch cultures typically reaches a maximum of ~ 106 cells/ml (Wurm, 2004).
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nMedium re-feeding or perfusion can raise cell yields to >10 cells/ml. Thus it is important 
to appreciate that it is not only the volume of the bioreactor that determines the scale of 
operation -  a 100L microcarrier culture operated by medium perfusion may produce a 
higher yield than a 1000L culture operated in a batch mode (Boedecker et al., 1994).
This established technology has been used extensively for viral vaccines (Van Wezel et 
al., 1980, Montagnon et al., 1984, Barteling and Vreemijk, 1991, Moran, 1999), and a 
wide variety of cell lines has been tested. Culture of chrondrocytes on microcarriers was 
first suggested by Freed et al. (1993), additionally, other cells lines such as human adult 
mesenchymal stem cells (Doctor et al., 2002), and hepatic cells (Werner et al., 1999), 
pancreatic islets (Del Guerra et al., 2001), and a variety of fibroblast cells has been 
demonstrated to attach and proliferate on microcarriers (Nilsson et al., 1986, Forestell et 
al., 1992). Most o f the conventional microcarrier systems employ the use of solid 
microcarriers.
With the conventional microcarrier system, the available surface area for growth is 
limited, since increasing the microcarrier concentration beyond a certain limit will not 
lead to an increase in cell concentration because the increased agitation which is needed 
to suspend the microcarrier slurry becomes damaging to the cells. Thus, macroporous 
microcarriers were developed to overcome this limitation. The development of 
macroporous microcarriers allowed an increase in cell density per litre of culture, due to 
the increase in surface area (Nilsson et al., 1986). Macroporous microcarriers are 
commonly made from gelatin (Gustafson et al., 2007), collagen, cellulose, glass, 
polyethylene and polystyrene. (Nikolai and Wu, 1992) After inoculation of the cultures, 
the cells attach to the external surface of the microcarriers and subsequently migrate 
inwards to populate the interior of the beads.
Issues of concern documented by the use of microcarrier culture have been the 
hydrodynamic shear from stirring and sparging (Cherry and Papoutsakis, 1986, 1988, 
Lakhotia and Papoutsakis, 1991, Croughan et al., 1987, Croughan and Wang, 1988), lack 
o f sound, scale up approaches (Aunins, 1993) and oxygen limitation, especially with
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macroporous microcarriers (Kong et al., 1999). Additionally, some investigators found 
that the cells grew well but when infected to produce the virus particles, the cells 
detached from the microcarriers and died, resulting in low productivity. Thus, they 
resorted to using the Cell cube as the processing route (Buckland, 2006).
Microcarrier cultures have typically used stirred tank reactors but recent efforts using the 
disposable Wave bioreactor have been reported; the Wave bioreactor is a disposable 
sterile bag bioreactor upon a rocking-cradle platform (Singh, 1999). MDCK cells for 
influenza virus vaccine production have been shown to be cultured successfully in the 
Wave bioreactor and demonstrated better attachment compared to the stirred tank 
reactors (Genzel et al., 2006). This requires the use of a rocking cradle to give a wave 
agitation, which is gentle but sufficient to provide nutrient distribution. Moreover, cell 
damage due to gas bubbles is reduced, as there is no sparging of air. As it utilises the 
principle of disposables, it requires no cleaning or additional sterilization. It is easy to 
operate, and maintains sterility through a high containment. The bioreactor is completely 
closed and additions and samples are done via needless syringe connectors or tube-fuser. 
Vent gases are sterilised through filters. However, the downside to Wave bioreactor is 
that the rocking cradle is expensive and it only gives a scale-up of up to a working 
volume of 500L.
The next section discusses the culturing conditions reported in literature and formed the 
basis for the culturing conditions applied in the technical work carried out.
2.4 Cell culturing conditions
Carbohydrates provide a variety of functions in mammalian cells. The early work by 
Eagle et al. (1958) and others have led to development of many different media to be 
used. The operating medium of choice is Dulbecco’s modified Eagles’s medium 
(DMEM) supplemented with bovine calf serum, glutamine, ascorbate and nonessential 
amino acids. It has been shown that at a glucose concentration of 80pM the glucose 
utilised by human diploid cells is only 7% of that utilised by cultures initially at 5mM
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(Zielke et al., 1984). Much work has been carried out by the same team into the glucose 
and glutamine metabolism. Additionally, the same group has shown glucose metabolism 
and glutamine metabolism are interlinked and the concentration of one can act to inhibit 
the other (Zielke et al., 1978). The presence of 2mM of glutamine inhibited glucose-6 -14C 
oxidation by 88% and stimulated the glucose-1-14C by 77% in log phase cells (Zielke et 
al., 1978) and normal growth is maintained if the glucose concentration is above 25pM. 
They showed that as glucose concentration increased from 0 to lOmM the oxidation rate 
of L -(l-14C)-glutamine decreased from 80 to 15 mmol 14C02  released /mg protein hr 
(Zielke et al., 1984). The level o f glucose is very important since high glucose 
concentrations affect the expression of collagens and fibronectin and it has been shown 
by Benazzoug et al. (1998) to affect the ratio of collagens production.
Glutamine can also be used as a major source of energy for cells. Bamabe and Butler 
(2000 ) estimated that in the presence of high glucose concentrations, glutamine provided 
the energy of maintenance of up to 28% of the intracellular ATP pool and remainder is 
then provided by glucose metabolism for murine hybridomas. It is estimated that 
glutamine oxidation provides around 30% energy requirement of human diploid 
fibroblasts (Zielke et al., 1976, 1978, 1984). Glutamine is a necessary supplement to be 
added for the proliferation of fibroblasts. It serves to act as a key link between the carbon 
metabolism and proteins. It is not very stable and decomposes readily to form ammonia 
and glutamate. Glutamine can also act to stimulate collagen production in collagen 
producing cells, Kama et al. (2001). They found that that the intermediates of glutamine 
interconversion: glutamate and pyrroline-5-carboxylate (P5C) also act to stimulate the 
production of collagen however, they evoke different levels of response. Thus, it is 
considered that the glutamine-induction of collagen biosynthesis is through its 
intermediate (Kama et al., 2001). Therefore it would be important to monitor the levels of 
glutamine throughout the culture.
Ascorbate is added to the culture to stimulate the production of collagen. Ascorbate in 
low concentrations is necessary for the crosslinking of collagens, and the formation of 
hydroxyproline. The half-life of ascorbate is very short, and 88 to 98% of the compound
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will have degraded after 24hr, (Peterkofsky, 1972) thus it is expected to be added 
constantly. It has been reported that the levels of ascorbate will affect the expression of 
collagens (Booth et al., 1980, Davidson et al., 1997, Fisher et al., 1991, Leveque et al., 
2003, Phillips et al., 1994, Tajima et al., 1996).
When components of human or animal origin are added to the culture medium, there is a 
potential risk of transfer of viruses, and or prions. Thus if these components are added to 
the culture medium the sources have to be identified and contaminants inactivated or 
removed. Yet, despite the use of serum from ‘disease-free’ countries, the reliability of 
testing and inactivation are called into question and the regulatory authorities have 
advised the use o f serum-free media. Thus without serum, there is the need to search for 
the right serum-free media, or somehow wean the cells off the dependence on serum. 
Additionally, the protective effects of serum against shear will have to be replaced and 
this perhaps can be done by the use of chemical agents such as Pluronics. Cell protectants 
have been added to suspension cells to help improve the viability of the cells. These 
media additives have helped to cope with shear and hydrodynamic effects (Croughan et 
al., 1987, Murhammer and Goochee, 1990, Christi, 2000, Van der Pol and Tramper, 
1998). They lower the interfacial tension and help to prevent cell-to-bubble attachment. 
Pluronic F-68 is a block copolymer and is supplemented into the medium at 0.2% (w/v). 
Pluronic L-35 at 0.2%(w/v) has also been used and demonstrated to offer protection. This 
is a smaller molecule than Pluronic F-68 and a superior foam suppressor. Pluronics and 
Methocel A15LV have been deemed most effective.
Part of the serum component also consists of lipids and fatty acids, thus the use of lipids 
and fatty acids such as linolenic acid has been tested. It has been reported that linolenic 
acid has beneficial effects in the prevention of shear damage to cells (Butler et al., 1999). 
It has been reported that the use o f dexamethasone and EGF has enabled passages to be 
carried out of primary human diploid fibroblasts (Baker et al., 1978, Bettger et al., 1981) 
in serum-free media. Due to time constraints and resources, all experiments will be 
carried out using serum, and it is believed, that the development of serum-free media is a 
field to itself, thus will not be covered in this thesis.
38
The measurement of oxygen uptake rate (OUR) provides a good estimate of intracellular 
oxygen demand when the supply rate of oxygen is constant. Active cell cultures will 
deplete the oxygen from the medium at a rate that is proportional to the cell mass, if  there 
is no other limiting metabolite. Thus oxygen uptake rate (OUR) can be used as a tool to 
estimate cell mass and to control the cell culture process (Zabriskie, 1985). OUR values 
ranging from 0.05 to 0.5mmol O2 /109cells/hr have been reported for various mammalian 
cells (Butler, 1987). The OUR of mammalian cells is affected by the glucose 
concentration and higher OUR at low glucose concentrations have been reported (Frame 
& Hu, 1985).
The supply of oxygen to the cells in culture is a particular problem when culture volumes 
are increased from the laboratory scale. The solubility of oxygen in aqueous solution is 
relatively low -  0.2 mmol per litre of culture. At a typical consumption of 0.05 - 0.5 
pm ol/106cells/hr, this means that for a litre o f culture (at 106 cells/ml) would be depleted 
o f oxygen in 0.4 - 4 hrs unless there is a constant supply of oxygen. Oxygen plays an 
important role in cellular metabolism, the most important is the electron transfer oxidase 
system, and additionally acts as the final carrier. In order to promote fibroblast 
proliferation and the production of collagen, oxygen is required. This is because oxygen 
is incorporated by two amino acids, proline, and lysine in the collagen chain synthesis. 
Collagen will not be synthesised unless adequate amounts of both proline and lysine are 
hydroxylated with oxygen. Synthesis requires one atom of oxygen for every three amino 
acids in sequence. Thus, maintenance of a sufficient level of dissolved oxygen is 
required.
Much literature has accumulated reporting that hypoxia induces collagen synthesis in 
tissues. It has been reported that hypoxic conditions accelerates the posttranslational 
process of collagen synthesis in cultured fibroblasts. The right level of oxygen required 
for HuFFs need only be about 4.3% O2, since greater than this the concentration becomes 
increasingly toxic to fetal tissues. It has been shown that skin fibroblasts grow best at 
3 1mm Hg (Balin et. al., 2002). The level of oxygenation may not need to be so high since 
it has been shown that hypoxia (i.e. absence of oxygen) can act to stimulate the cells and
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up-regulate the production of collagen (Yoko Horino et al., 2002, Yuji Takahashi et al., 
2000).
Waymouth (1981) indicated that the optimal pH for mammalian cell growth for two 
human skin fibroblasts cell lines were pH7.5 -  pH7.6, and pH7.6 -  pH7.8. In the 
bioreactor, the pH is stabilized with the use of buffers. It is normally recommended to use 
an additional organic buffer like HEPES (N-2-hydroxyethylpiperazine-N’-2- 
ethanesulfonic acid) and l-2mM bicarbonate to maintain adequate concentrations of 
dissolved CO2. HEPES is relatively expensive but it is frequently used because its pKa 
falls in the physiological range (7.31 at 37°C). The direct effect o f temperature on cells is 
obvious, but the temperature will also affect the pH of the medium due to increased 
solubility of CO2 at lower temperatures. The pKa o f buffer and the degree of ionization of 
serum components is also affected by temperature. The pH of a typical medium at room 
temperature is around 0.2 units lower than at 37°C. Therefore, a room operating 
temperature solution at pH7.55 would be 7.31 when warmed to operating temperature. 
(HEPES is usually used in the range of 10 to 50mM.) At concentrations of more than 
15mM the buffer is sometimes growth-inhibitory. Phenol red is used in small-scale 
culture as an indicator of pH but it can become toxic, especially in serum-free conditions. 
Therefore, for large-scale manufacturing, it must be avoided. The optimum operating 
temperature will be controlled around 37°C since this will simulate body temperature. 
Temperature is an environmental variable that can affect a variety of animal cell 
parameters such as growth, shear sensitivity, cell morphology.
2.5 Conclusion
Reviewing the literature has shown the possibility of using established equipment of 
stirred tanks and microcarrier technology to be a way forward for the use of culturing 
cells for tissue regeneration. The literature published about culturing conditions has 
provided a set of conditions which will be used in the technical experiments. The next 
two chapters describe the assays and experimental protocols used followed by results and 
conclusions of the technical investigations.
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CHAPTER 3
M a t e r ia l s  a n d  m e t h o d s
3.1 Introduction
This chapter serves to explain the assays and the general cell culture techniques used in 
the technical experiments carried out to test the feasibility of the culture of fibroblasts to 
develop a TE-product and to develop a scalable process for a primary human fibroblast 
cell-derived wound healing product. The cells used in all the experiments were kindly 
donated by Smith and Nephew RC, and are neonatal human dermal foreskin fibroblasts, 
which were from the Master Cell Bank used for Dermagraft production, frozen at passage 
5. These cells have been through rigorous testing to demonstrate their safety and are free 
from adventitious agents. Where necessary, protocols written up for use are included in 
Appendix B.
3.2 Culture conditions
All cell culture, including media preparation was carried out in class II laminar flow 
biological safety cabinet. The operating media used was Dulbecco’s modified Eagles 
medium (DMEM) with 10%(v/v) foetal calf serum (FCS). Additionally, there was a need 
to supplement the media and the following table shows the various amounts added. The 
various reagents and basal media were obtained from Sigma, UK.
41
Table 3.1 The required amount of supplements to add to the basal media
Supplements Working
Concentration
Stock
concentration
Volume
percentage
Foetal Calf Serum 10% (v/v) Neat 10%
HEPES Buffer 20mM 1M 2%
L-Glutamine 2mM 200mM 1%
Penicillin/Streptomycin 50 IU/ml P 5000IU/ml P 1%
50pg 5000pg/mlS
Non Essential Amino 
acids
1% 100 x 1%
Glutamine keeps well as a dry powder however once made up into solution it must be 
kept frozen to prevent degradation. It is the most unstable of the essential amino acids 
and decomposes rapidly to form the pyrrolidine carboxylic acid and ammonia in solution. 
Additionally, many components of the medium cannot be heated together. Cystine and 
ascorbic acid cannot be autoclaved in the same solution, the ascorbic acid becomes 
oxidised and destroyed. Thus where necessary, medium or supplements were sterile 
filtered. Glucose and ascorbic acid are destroyed in alkali solutions. Therefore ascorbic 
acid was ordered in crystalline form for stability, and when needed, dissolved in the 
DMEM solution, and then sterile filtered through a 0.22 pm filter.
The incubator was set at 37°C and 5% CO2. When resurrecting the cells from its cryo- 
preserved state, DMEM with all the supplements added in was used. It is important to 
avoid excessive alkalinity of the medium during the recovery of the cells. Thus prior to 
the addition of the vial contents, the culture vessel containing the growth medium was 
placed into the incubator for at least 15 minutes to allow the medium to reach its normal 
pH.
Some cell lines may undergo osmotic shock if a large volume of fresh medium is added 
too quickly to the cell suspension upon thawing. Several smaller volume stepwise 
additions (1 to 2ml each time) of fresh medium to the cell suspension at 20 to 37°C over 
a period of 10 to 20 minutes may improve their recovery and survival.
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Passaging o f cells occurred at a frequency o f every 3 to 4 days depending on microscopic 
observation o f flasks to avoid reaching overconfluency. Additionally media exchange 
would take place to ensure sufficient nutrients are supplied and waste is removed. See 
protocols in Appendix B.
3.2.1 Static cultures
2 a 2
Triplicate 25cm flasks were seeded at 1.5 x 10 cells/cm , and maintained for 28 days. 
The cells were bathed in 5ml o f media and for each time point flasks were either 
trypinsinsed to give a time point, or scraped using a cell scraper to give small lump of 
biomass to be analysed for collagen content. The media were collected for measuring 
metabolites levels and presence o f growth factors.
3.2.2 Stirred tank microcarrier cultures
Cells were mainly grown in t-flasks and roller bottles to generate the required cell 
numbers required to inoculate the bioreactor. For stirred tank cultures, a 5L bioreactor 
(Sartorius, UK) was utilised at UCL, and a 3L (Applikon, UK) at York RC. The 
microcarriers tested were Nunc 2D microhex, Cytodex 2 and finally Vicryl discs. The 
nunc 2D microhex was cultured at a microcarrier concentration o f 5g/L in 5L bioreactor 
for 28 days, after initial promising experiments in shake flasks. Cytodex 2 was carried out 
at a microcarrier concentration o f lOg/L for 1L working volume culture in the 3L reactor 
and the Vicryl discs was at lg/L at working volume o f 1L in the 3L reactor as well. 
However, the spin filter on the Applikon reactor blocked, thus overall media working 
volume for Cytodex 2 and Vicyl discs were maintained at 1.5L.
The commercial microcarriers were prepared according to manufacturer’s instructions. 
Briefly, Nunc Microhex was transferred via aseptic pouring or pumped into the reactor 
through a peristaltic pump. Cytodex 2 beads were hydrated in PBS and then autoclaved in 
the bioreactor, and then media rinses were used to remove the PBS and condition the
43
Cytodex microcarriers before use. Vicryl discs after hole punched and collected by 
picking it up using surgical forceps were collected into a glass jar and gamma irradiated 
to sterilize prior to use. These discs were then pumped into the bioreactor through a 
sterile inlet. The next following parameter to consider was to establish what suspension 
speeds are required for cell culture.
The flow regime within the vessel is crucial to ensure sufficient mass transport to the 
cells and although increased agitation promotes the transport this is offset by detrimental 
shearing forces (Cherry and Papoutsakis, 1988, Croughan et al., 1987, Lakhotia et al., 
1992). Zweitering’s correlation (Zweitering, 1958) was used to calculate the minimum 
suspension speeds to operate at based on the just suspension speed, NJS.
S = dimensionless constant accounting for impeller and reactor geometry 
u = kinematic viscosity (m /s) 
dp = diameter o f a particle (m) 
g = gravitational constant (9.81 m/s )
Ap = density difference between the particle and the fluid (kg/m3)
*5
P l  = density of the fluid (kg/m )
X = weight of the solids/weight of the liquid x 100, dimensionless 
D = diameter of the impeller (m)
Just complete suspension exists when all particles are in motion and no particle remains 
on the tank base for more than 1 to 2 seconds. Under this condition, all the surface of the 
particles is presented to the fluid, thereby ensuring maximum surface area is available for 
the cells in the fluid to attach and proliferate.
To calculate the maximum speed for the system, Kolmogorov microscale of isotrophic
turbulence, X, was used. According to Cherry and Papoutsakis, (1988) and Croughan et
al. (1988) detrimental effects occur when the Kolmogorov scale for eddy size drops 
 ^ 1below V3 to /2 the diameter of the microcarrier. The interaction of microcarrier beads
( 1)
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only with eddies smaller than the microcarrier could result in shear stresses on the surface 
of the microcarriers that are harmful to the cells. Eddies larger than the microcarrier 
surround the microcarriers completely and may rotate or translate them without creating 
an excessive amount of stress.
The eddy concentration is proportional to (u3/e) ' 4 so relating the three equations allow 
the calculation o f maximum speed.
P
£  = ---------
pV
N l "  n pp l d ?
where N, = Impeller speed
Np = Power number 
s = local rate o f energy dissipation per unit mass of fluid 
u = kinematic viscosity
Additionally, from Z weltering’s equation, the minimum suspension speed is seen to be 
affected greatly by the density difference, and Vicryl having a density o f 1.3g/cm3, means 
that it sinks quite readily, thus carboxymethylcellulose, (CMC), an inert polymer was 
added to the DMEM media to alter the viscosity of the media for the culture of cells on 
the biodegradable discs. This allowed the discs to suspend at a speed, which does not kill 
the cells. CMC did not affect the culture and was not metabolised by the cells. CMC has 
also been used as a viscosifier and bulking agent in the formulation of bioproducts, 
toothpaste and in the food industry. See Appendix B for the range of speeds chosen for 
the STR cultures.
(2)
(3)
(4)
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3.3 Metabolite Analysis of the media
Key nutrients and waste products were monitored in the media, to ensure that the cells 
were being maintained and conditions were adequate. Starvation due to the depletion of 
glucose can lead to altered glycosylation patterns. The accumulation of waste products 
such as lactate and ammonia will affect the pH and can inhibit growth, for example, it has 
been reported the 3mM ammonia can inhibit hybridomas (Mercille and Massie, 1994). 
Additionally, the presence of growth factors released into the media was traced as it gave 
an indication o f the potential bioactive component for wound healing. Vascular 
endothelial growth factor (VEGF) is the most soluble and abundant growth factor that is 
produced by fibroblasts thus this was the chosen growth factor to test. Amino acid 
analysis was carried out to see if at any time during the culture for the production of the 
tissue mass, were there any shortages of certain amino acids, which could act as a 
limiting step in the production of extracellular matrix proteins, e.g. collagen.
Ascorbic acid was also monitored to ensure that the concentration was at the right level 
and not toxic. Ascorbic acid was measured by means of reduction of the tetrazolium salt 
MTT [3-(4,5-dimethylthiazolyl-2,5-diphenazinium methyl sulphate) at pH 3.5 to a 
formazan. Thus to determine the level o f ascorbic acid, in a sample blank determination 
only the L-ascorbate fraction as part of all reducing substances present in the sample is 
oxidatively removed by ascorbate oxidase (AAO) in the presence of oxygen. The 
dehydroascrobate formed does not react with the MTT/PMS. Then by taking the 
difference between the absorbance of the sample and the sample blank, gives the quantity 
of the ascorbate present in the sample. The ascorbic assay was a test kit purchased from 
R-Biopharm, UK, Cat. No. 0409677.
3.3.1 Glucose, lactate, glutamine, glutamate and ammonia
Glucose, lactate, glutamate, and glutamine were analysed offline, and measured in 
triplicates through a biochemical analyzer: YSI Analyzer 2700 SELECT. The glucose
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and lactate concentrations from a sample can be obtained simultaneously, likewise, 
glutamine and glutamate. Table 3.2 shows the chemistry specifications:
Table 3.2 Chemistry specifications
Name Detection range to Calibration
point
Precision 
CV, n = 10
Membrane working life 
(days)
Glucose 9g/L at 25 fil sample 
size
2.50 g/L 2% 21
Lactate 2.67 g/L at 25pl sample 
size
0.50g/L 2% 14
Glutamate 10 mmol at 20 pi sample 
size
5 mmol 2% 7
Glutamine 8 mmol/L at 20pl 
sample size
5 mmol/L 4% 5
The enzyme glucose oxidase is immobilized onto the YSI dextrose membrane and the 
following reaction takes place:
Glucose + O2 glucose oxidase H2O2 + D-Glucono-d-Lactone
The enzyme L-lactate oxidase is immobilised in the YSI lactate membrane and the 
following reaction takes place:
L-lactate + 0 2 H20 2 + Pyruvate
Ammonia accumulates throughout the culture, due to degradation of glutamine and is a 
waste product from metabolism as well. The ammonia assay is a spectrophotometric 
assay and takes advantage o f the Berthelot reaction, where ammonia, hypochlorite and 
phenol react to produce a dye molecule indophenol blue in an aqueous solution. The 
concentration o f the NH3 can be determined by monitoring the absorbance o f the dye 
molecule at X = 640nm. The indophenol blue molecule is also subject to 
photodegradation, thus the reading is only stable for about an hour.
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3.3.2 Vascular endothelial growth factor (VEGF)
The VEGF concentrations in the media were measured in triplicates through an enzyme- 
linked immunosorbant assay (ELISA). These assays use enzymes for detection and the 
most common ELISA is a noncompetitive ‘sandwich’ assay using 96-well plates 
precoated with the capture antibody. The plates were incubated with the sample to permit 
formation of the antibody-antigen complex. Then a second, enzyme labelled antibody 
was then used to tag the complex and the enzymatic activity was determined via a 
colorimetric reaction. The amount of antigen bound to the wells was determined from a 
standard curve o f absorbance vs. log of antigen concentration. The kit to measure VEGF 
was purchased from RnD Systems (DuoSet ELISA development kit DY293B).
3.4 Cell Analysis
The analysis o f the cells was carried out both qualitatively and quantitatively. This gave 
indications of the viability and cell yield.
3.4.1 Qualitative measures
Light microscopy was mainly used with the inverted microscope. However, in certain 
cases, confocal microscopy was used to obtain better images and this was used in 
conjunction with LIVE/DEAD stain of the cells cultured on the microcarriers. The 
LIVE/DEAD viability/cytotoxicty kit was obtained from Molecular Probes, Cat. L3224. 
Scanning electron microscropy was performed to certain tissue samples from the 
bioreactor culture to determine the level of coverage of cells on the microcarriers.
3.4.2 Quantitative analysis
Cell counts were measured using a haemocytometer for the static culture, but the reactor 
cultures, MTT assay was applied when cell counting was difficult via the 
haemocytometer.
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The cell count measures the status of a cell culture at a given time and is essential when 
subculturing or assessing the effects of experimental treatments on cells. Most commonly 
used is the haemocytometer because it is inexpensive, accurate and versatile. Cell count 
is often expressed as the no. of cells per ml of medium or per cm of area of attached 
surface. The Haemocytometer is a modified glass slide, which has been engraved with 
two counting grids o f known areas. Each of the grids contains 9 squares, and each being 
1mm2 in area. The haemocytometer is supplied with a glass coverslip of a precise 
thickness, thus when the coverslip is correctly positioned the volume of the liquid placed 
into the counting chamber is a known constant.
Viability counts for the haemocytometer method generally involve the dye exclusion test, 
which relies on the ability o f living cells to exclude the dye and so the dead cells are 
permeable and the dye crosses the cell membrane. Note, however, this is really more of 
an indication of the integrity of the cell membrane but not necessary how the cell is 
functioning. The dye used is trypan-blue (Sigma, UK)
1. Use the average of the total cells counts to calculate N and derive the cell 
concentration as follows:
C = Na x D x 104
Na = average number of cells counted per 1mm square (cells per chamber divided 
by the number of squares counted)
C = unknown concentration of cells = cells/ml
104 = conversion factor to convert the volume over 1mm2 square to 1 ml.
D = dilution factor
2. For viable cell number or percent viability
No. o f viable cells/ml = Nv x D x 104
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Nv = number o f cells unstained 
D  = dilution factor
Percent (%) viability = no. of cells unstained x 100
Total number of cells
There are some precautions to bear in mind with cell counting, and these are that the 
more cells counted, the more accurate the cell count. Additionally, living cells that have 
been recently trypsinised for either subculture or thawed from a freezing medium 
containing dimethyl sulfoxide (DMSO) may have leaky membranes, thus causing them to 
take up the dye.
Another method of quantifying the cells is to use the MTT [3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide] assay (Mosmann, 1983). The MTT assay is based on 
the ability of a mitochondrial dehydrogenase enzyme from viable cells to cleave the 
tetrazolium rings of the MTT to form a formazan product, resulting in a colour change. 
The number of cells is directly proportional to the level of the formazan product. A 
modification of the MTT assay can also be used and is known as the WST-1 assay 
(available from Roche Diagnostics Cat. No. 1664807). It does not need the final 
solubilising step and after incubation with the WST-reagent, the plate can be read straight 
away.
3.5 ECM analysis
This section looks at the assays involved that were used to try to estimate the level of 
extracellular matrix proteins produced both qualitatively and quantitatively. Collagen is 
the most abundant molecule so this was selected as the key marker to track. Neonatal 
dermal fibroblasts produce mainly of the type I form and some type III initially which is 
then converted to type I. Glycosaminoglycans (GAGs) are assayed as well.
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3.5.1 Qualitative analysis
Immunostaining of the tissue sample for collagen was used to give a qualitative 
indication of the presence of collagen, and the areas of deposition. Fresh tissue mass 
samples were first rinsed with PBS to remove any media components and then 
cryopreserved using OCT compound and then snap frozen using liquid nitrogen. The 
cryopreserved samples were cryosectioned and prepared onto slides. The slides were 
defrosted just before the start o f the immunostaining protocol. The protocol is described 
in Appendix B.
Additionally, samples were prepared for histology staining to determine the presence of 
collagen and GAGs. The samples for histology staining and SEM were dehydrated 
through an alcohol series from 10 to 100%, with gradual increments o f 10%. For the 
histology staining procedures, the samples were then fixed in chloroform and then wax 
embedded. Then using the Leica RM2165 rotary microtome, sections were cut at 5pm 
thickness. Two sections were placed on each slide after being floated out on a water bath 
at 45°C. Then load the slides into the autostainer.
3.5.2 Quantitative analysis
Each a  chain consists of about 1000 amino acid residues and is coiled into an extended, 
left-handed polyproline II helix and within a collagen triple-helical domain; there are 
three of these a  chains which are in turn twisted into a right-handed superhelix. Collagen 
is a very stable protein and the stability is due to the hydrogen bonds in this triple helix, 
which is formed at every third residue of the a  chain. Therefore, this amino acid residue 
has to be glycine since it cannot have side chains and so, the amino acid sequence of each 
a  chain consists of about 300 Gly-X-Y tripeptide repeats, where X can be any amino acid 
residue and Y is usually proline or hydroxyproline. Additionally, since hydroxyproline is 
only found when there is collagen present, this mean that the content of collagen could be 
estimated based on an assumption that a percentage of collagen is hydroxyproline 
(Woessner, 1961). The oxidation of hydroxyproline to a pyrrole derivative will react with
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p-dimethylaminobenzaldehyde (p-DAB) in an acid medium to give a coloured product. 
This colour can be enhanced with organic solvents. The assay was carried out in a 96- 
well microplate, and using a plate reader to determine the absorbance at 570nm. The 
tissue samples underwent a papain digestion prior to the hydroxyproline assay.
The dimethylmethylene blue (DMB) assay to measure the amount of sulphated 
glycosaminoglycans (s-GAG) also relied on the digestion of the tissue with papain 
solution followed by staining with dimethylene blue, the absorbance, which was then 
read in a spectrophotometer and translated into an amount by comparison with a 
calibration standard curve chrondroitin-4-sulfate.
This completes Chapter 3 which describes the various methods used and the next chapter 
presents the results from these experimental studies.
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CHAPTER 4
O p e r a t io n a l  e v a l u a t io n  o f  t h e  p r o d u c t io n  
PROCESS OF AN ADVANCED WOUND HEALING 
PRODUCT
4.1 Introduction
Many tissue-engineered solutions for the treatment of chronic non-healing wounds 
depend on the delivery of cells to the injured site, e.g. Dermagraft (Smith & Nephew), 
Apligraf (Organogenesis) (Balasubramani et al., 2001). Although there have been very 
promising results in a laboratory set-up, large scale production of cell laden matrices is 
expensive and quality control is difficult to manage. An alternative approach is to design 
a frozen cellular-based bioactive matrix that is conductive and inductive of the key 
responses in the tissue cells surrounding the wound that affect the essential healing 
processes. This chapter explores possible methods for generating this bioactive matrix by 
culturing human dermal fibroblasts on microcarriers. This can then be reformulated into a 
gel or a bioactive patch for application.
The use of microcarriers as initial supports for cell growth has long been recognised. 
(Van Wezel, 1967). The benefits of using microcarriers for the culture of adherent cells 
include cost savings in labour, process consumables, and laboratory space. Using 
particulate culture gives a greater surface area to volume ratio, and allows for a high- 
density culture of cells with more effective use of media. In this chapter, the suitability of 
smooth, solid microcarrier discs and microporous microcarrier beads is assessed. Solid 
mcirocarriers typically allow for easier handling when washing and harvesting the cells 
from the carriers (Lundgren and Bliiml, 1998). On the other hand, porous microcarriers
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provide a larger surface area to volume ratio for cells to attach and deposit extracellular 
matrix (Ng et al., 1996). For regenerative medicine approaches, the use of a 
biodegradable microcarrier is particularly attractive, since product harvest is greatly 
facilitated; the cells and extracellular matrix (ECM) do not need to be stripped from the 
microcarriers (e.g. by trypsinisation) since the microcarriers will degrade leaving the 
bioactive matrix (Curran et al., 2005). Gorodetsky et al. (1999) demonstrated the use of 
fibrin microbeads as biodegradable carriers for the culture of cells for wound healing. 
Hence, this chapter also evaluated the potential of a biodegradable carrier.
Aggregation is often seen in extended microcarrier cultures with fibroblasts (Varani et al., 
1996). This chapter explores when aggregation occurs and whether it results in a 
detrimental effect on the cell viability, for example, by creating creating diffusional 
limitations or localized build up of waste metabolites. On the other hand the interstitial 
spaces formed within the aggregates may facilitate deposition of extracellular matric and 
potentially trap growth factors. This will be explored in the chapter.
Section 4.2 presents the results of the static culture of these human dermal fibroblasts, 
and then identifies the extent of deposition of extracellular matrix by the cells. The results 
from the microcarrier studies are presented in Section 4.3 and this is compared to the 
static culture. The microcarriers studied were smooth polystyrene disks (Nunc 2D 
Microhex), crosslinked dextran microporous spheres (Cytodex 2) and finally, 
biodegradable Vicryl discs. Finally, Section 4.4 looks at equipment considerations for 
the large scale processing, and discusses the implications of the processing route 
suggested.
4.2 Static culture studies
This section outlines the key results from the static culture studies that were carried out 
using 25cm t-flasks for 7 days, and 28 days using complete media. Preliminary growth 
curve studies were carried out first to determine the growth rate of the neonatal dermal 
fibroblasts and their morphology. Fig. 4.1 highlights the cell morphology as streaky, long
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and narrow as expected. Fibroblasts have an elongated form which can exhibit a width of 
less than 5pm, in contrast to other cell types that often exhibit a diameter of about 8- 
15pm. As can be seen from Fig. 4.1 the fibroblasts initially attach and spread on the 
surface (Day 2) and by Day 5 they were found to be confluent and packing more densely. 
Thus when cells have reached overconfluency, the cells will be packed together very 
tightly. The specific growth rate was calculated to be 0.0127hr_1, i.e. a doubling time of 
55hours, (similar to the 45 hours doubling time found by researchers at Smith and 
Nephew using the same cell line). Croughan et al. (1987) reported a specific growth rate 
of O.Olbhr'1 for FS-4 fibroblasts on Cytodex 1 microcarriers. Confluency in the static t- 
flask generally yielded a minimum of lx  105 cell/cm2 cell density.
a) b)
Day 2 Day 5
Figure 4.1 Light microscopy pictures of human dermal fibroblasts cultured in T-flasks at 
a) Day 2 and b) Day 5. A green filter was used in order to give better detail and contrast 
at Day 5.
The ratio of cells:ECM is an important indicator of productivity of the reactor. Here the 
ECM content was considered proportional to the collagen yield since collagen was 
considered to be the most abundant extracellular matrix protein. Collagen was found to 
require long culture times of 28 days for it to be detected quantitatively. Hence the static 
culture study was set up for 28 days to determine the cells to collagen ratio and compare 
it with the microcarrier cultures. In order to maintain the culture for 28 days, full media 
exchanges were carried out every 4 days using the low and high glucose media
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respectively. Media samples were taken before and after each media exchanges to verify 
the glucose and lactate concentrations. Each flask was sacrificed each day to obtain a cell 
count, or scraped using a disposable cell scraper to harvest the biomass to check for 
collagen. Scraping was used rather than trypsinisation since the use o f trypsin may 
destroy the extracellular matrix laid down (personal communication with N. Medcalf, 
Smith & Nephew RC, York). Fig. 4.2a shows the growth curves obtained and the cell 
densities achieved. This is comparable to values reported by Varani et al. (1985) where a 
maximum monolayer cell density o f HuFFs at 2.4±0.8 x 105 cell/cm2 cell density was 
achieved after a 20 day period.
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Figure 4.2 Growth curves of the static culture. Cells were seeded at 1.5 x 104 cells/cm2, 
and cultured for 28 days. The conditions o f high (4.5g/L) glucose (--□--) and low 
(l.Og/L) glucose (--■--) media were tested using replicate flasks.
The impact o f using a high glucose media (4.5g/L) and low glucose media (l.Og/L) was 
investigated and the results summarized in Fig 4.2 to 4.4. From Fig 4.2 it can be seen that 
the glucose concentration does not significantly affect the cell growth rate. However, 
different consumption and production rates were observed as shown in Fig. 4.3.
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Figure 4.3 Cumulative glucose consumption and lactate production plots.
—o— denotes glucose consumption, --A— denotes lactate production in high (4.5g/L) 
glucose formulation. — denotes glucose consumption, and — A — lactate production in 
low (l.Og/L) glucose formulation.
Translating the data into lactate production to glucose consumption ratios as shown in 
Table 4.1 indicated that low glucose media gave better control of lactate waste 
production. Therefore, high levels of accumulation of lactate in the media did not occur 
in the low glucose media compared to the high glucose media used.
The specific rate of production of ammonia and consumption of glutamine was not 
affected by the difference in glucose concentration, and subsequently gave the same ratio. 
The specific rate of production for VEGF corresponded to those reported by Pinney et al. 
(2000) of 0.5-4ng/24hrs/106cells for human neonatal fibroblasts cultured on a lactate- 
glycolate copolymer scaffold for 12 to 16 days.
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Table 4.1 Summary of the metabolite analysis data for static culture of fibroblasts
High glucose DMEM media
Specific glucose consumption rate (mmol/10 cells/hr) 0.20
Specific lactate production rate (mmol/10 cells/hr) 0.35
Lactate .Glucose molar ratio 1.7
Specific glutamine consumption rate (mmol/106cells/hr) 0.04
Specific ammonia production rate (mmol/106cells/hr) 0.02
Ammonia:glutamine molar ratio 0.5
Specific VEGF production rate (pg/106cells/hr) 10.02
Low glucose DMEM media
Specific glucose consumption rate (mmol/106cells/hr) 0.13
Specific lactate production rate (mmol/10 cells/hr) 0.19
Lactate .Glucose molar ratio 1.5
Specific glutamine consumption rate (mmol/10 cells/hr) 0.05
Specific ammonia production rate (mmol/106cells/hr) 0.02
Ammonia:glutamine molar ratio 0.5
Specific VEGF production rate (pg/106cells/hr) 13.42
This indicated that a more optimal feeding strategy could be implemented in the 
manufacturing, by the use of low glucose media and a concentrated glucose solution 
addition; this will give rise to a reduced need of media exchanges to remove the waste 
products and replenish the nutrients. This, in turn will allow the growth factors to 
accumulate to a higher concentration in the culture. Additionally, a more efficient usage 
of media is possible and can contribute towards lowering the cost of culture in 
manufacturing. The most efficient culture for manufacturing would be to operate in fed- 
batch mode during the growth phase, and then switch to perfusion mode to maintain the 
culture from stationary phase onwards; this approach was adopted in microcarrier culture 
studies.
The spent media from the static flasks were also checked for levels of vascular 
endothelial growth factor (VEGF), and this is presented in Fig. 4.4
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Figure 4.4 Cumulative VEGF production in the static t-flask culture. —o— denotes VEGF 
levels in the high (4.5g/L) glucose fed flasks, and denotes VEGF levels in low 
(l.Og/L) glucose fed flasks.
The level of VEGF accumulated to an overall level of lOOOpg/ml in the media samples 
during the first week of culture, and from the Day 1, it was produced. As VEGF is the 
most abundant growth factor in the media, this would be easier to detect. Fig 4.4 
indicated that VEGF is produced throughout the culture period. The results suggest that 
the lower glucose concentration of lg/L encourages a slightly higher production of VEGF 
throughout the culture period than the 4.5g/L glucose concentration. Literature reports 
differ in their findings on the relationship between glucose concentration and VEGF 
production. Reports with similar trends to those presented here include Sone et al., 
(1996), who found for bovine retinal pigmented epithelial cells that VEGF production 
significantly increased when glucose concentration decreased from 5.5 to 0.5mM; 
however, no change was found when glucose concentration decreased from 33 or 16.5 to 
5.5mM. Additionally, Noriko et al., (2002) found that prolonged culturing under high
glucose conditions led to impaired growth rate and lower VEGF levels. In contrast some 
authors (Omori et al. 2004, Williams et al. 1997, Kim et al. 2000) have cited that high 
glucose concentrations induce higher VEGF production for many other cell types.
The deposition of collagen over time with the low and high glucose media is illustrated in 
Fig. 4.5. When a cell density of 105 cells/cm2 was achieved, the cells were deemed to 
becoming over confluent and from Fig. 4.5, collagen production in static culture did not 
really start until the cells were confluent. The hydroxyproline assay was used to 
determine the amount of collagen present. Fig.4.5 indicates that this is a time-dependent 
process and that to get a detectable amount of cross-linked mature collagen requires a 
culture period greater than a month.
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Figure 4.5 Production of collagen in the static t-flask culture. —0— denotes production of 
collagen in the high (4.5g/L) glucose fed flasks, — denotes the low (l.Og/L) glucose 
fed flasks.
This behaviour has been reported for mouse fibroblasts by Goldberg and Green, (1964) 
and they showed that collagen could not be detected during the log phase, and upon start
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of stationary phase the collagen begins to accumulate. Indeed, they reported that 
significant quantities of collagen production were detected around Day 22. Examining the 
yield o f collagen in static culture to the number of cells present gave an indication of cells 
to matrix ratio of 3:5. This piece of information was then used for the economic study 
and forms the basis to some of the assumptions made in the case study presented in the 
subsequent chapters. Fig 4.5 also seems to suggest that the fibroblasts fed with low 
glucose media produced higher levels of collagen than those fed by high glucose media. 
Although the presence of ascorbic acid helps to stimulate the collagen and proteoglycans 
production but according to Fisher et al. (1991), this effect is inhibited by glucose at a 
concentration of 25mM. Thus as both the low and high glucose fed flasks had ascorbic 
acid addition, the higher levels seen in the low glucose condition was attributed to this. 
Thus for manufacture, the optimal level of glucose concentration to maintain log phase 
would be lg/L.
4.3 Microcarrier culture studies
The growth characteristics of fibroblasts and the production of ECM were explored on 
different types of microcarriers: smooth, microporous and biodegradable (Table 4.2). 
Commercial carriers were then examined and two types of microcarriers were selected 
for comparison: a non-porous carrier, Nunc 2-D Microhex, and a microporous carrier, 
Cytodex 2. The Nunc Microhex was tested first, since the material is similar to tissue 
culture plastic, thus the attachment kinetics and cell proliferation were assumed to act in a 
similar manner. Nunc Microhex is supplied sterile, thus the microcarriers were 
transferred into the culture aseptically.
Cytodex 2 was tested since the micro-porous nature of the microcarrier is expected to 
contribute towards the attachment and proliferation of the cells (personal communication 
with production engineer, Mark Baumgartner, Smith & Nephew, La Jolla). Additionally, 
the microporous nature also molecules of up to molecular weight of lOOkDa to penetrate 
this microporous layer, thus this encourages the cell to secrete the adherent materials to 
ensure attachment (Lundgren and Bliiml, 1998). This was supplied as a dried powder,
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which required hydration and sterilization prior to use. As it was autoclavable, this makes 
it quite an attractive choice for commercial manufacturing. Cytodex 2 is made from 
cross-linked dextran, the microcarrier can be degraded away by dextranase quite 
effectively. Thus after the culture, the microcarrier can be removed through enzymatic 
digestion and centrifugation to retain the biomass (Lindskog et al., 1987).
It would be ideal to have a biodegradable microcarrier, but currently there is not a 
commercial one available. Therefore, as it is known that cells proliferate well on Vicryl 
mesh, which is biodegradable and biocompatible, 2mm disks were made by hole- 
punching the mesh, and then using forceps, placed into a preweighed glass vial. Vicryl 
mesh will start the degrading process if wetted, thus the work surface for hole punching 
was first wiped with 70% ethanol, and allowed to dry before hole punching began. This 
was then gamma sterilized before culture. Clearly, from a manufacturing perspective, to 
spray dry the polymer to form microspheres would be the more suitable method to 
produce the required biodegradable microcarriers.
Table 4.2 Properties of the microcarriers used in the culture
Microcarrier Material Density Surface
Area
2 -1 cm g
Shape and Size range
2D-Microhex Polystyrene 1.05 760 Regular hexagon, side length 
= 125 pm, 25 pm in thickness
Cytodex 2 Cross-linked 
dextran, with 
positively charged 
trimethyl-2- 
hydroxyaminopropyl 
groups at the surface
1.04 4400 Spherical, micro-porous 
Diameter = 114 -  198 pm
Vicryl Mesh PGLA 1.3 N/A Diameter =2mm circular disc, 
porous, thickness = 0.016cm
4.3.1 Nunc 2D Microhex culture
Nunc 2D Microhex carriers were first utilised to determine if the dermal fibroblasts could 
grow on microcarriers. Experiments were carried out in 125ml shake flasks initially (in 
the incubator at 37°C, 5% CO2), and the cells that were attached were trypsinised to
62
enable viable cell count to be determined. Initial stirring speed of 45 rpm to set on the 
shaker plate to just suspend the carrier, and after attachment this was raised to 55rpm 
during the shake flask culture. Fig.4.6 shows the dermal fibroblasts were able to attach 
and proliferate to form clumps. The cells still retain their morphology and it was 
observed that when the carriers reach confluency, the carriers become much more 
opaque. The presence o f empty carriers was still seen at Day 9. Some dead cells were 
observed to be present in the supernatant, and it was considered that these could be cells 
that failed to meet the microcarrier and attach onto it. Since cells meeting microcarriers in 
suspension is considered to be a random event, it is quite likely, that if the cells have not 
attached within the first 24hrs of inoculation they will die. These shake flask cultures 
showed that the cells were able to attach and grow as presented by Fig.4.6, thus 
bioreactor runs were then attempted.
Day 7
Figure 4.6 Light microscopy picture showing the dermal fibroblasts attached and 
proliferating on the Nunc 2D Microhex, Day 2 (initial attachment), Day 7 proliferate to 
stick together to form clumps and Day 9 of the shake flask culture.
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Bioreactor runs using Nunc 2D Microhex carriers indicated that the cells were not able to 
proliferate well and accumulate extracellular matrix, and plenty of empty carriers were 
observed (See Table 4.3 for summary of results comparing the static and various STR 
cultures).
Further microscopy showed that straight scratches were sometimes seen on the flat 2D 
microcarriers and this led to the speculation that cells attached to the carriers could be 
sheared off as the microcarriers slid over each other. Furthermore, since the cells growing 
on the surface are exposed, they are more susceptible to turbulence created by the 
rotating impeller. Analysis showed that significant quantities o f collagen could not be 
detected. Thus although these experiments served to show that particulate culture with 
dermal fibroblasts was possible, it was concluded that this was not a suitable microcarrier 
for cell expansion or extracellular matrix production. Varani et al. (1985) reported that 
the substrate surface affected the morphology and growth characteristics of microcarrier 
cell culture.
The next section investigates the potential benefits of employing a microporous carrier to 
overcome the limitations seen with the Nunc carriers.
4.3.2 Cytodex 2 culture
Cells were resurrected and expanded from RBs initially, and then subsequently 
inoculated into the STR at 4.5 x 103 cells/cm2. This initial low starting cell density helps 
to control the aggregation that takes place when culturing dermal fibroblasts on 
microcarriers. The culture time was 34 days. The reactor used was 3L and operated at 1L 
initially, and then eventually fedbatched to 1.5L. Stirrer speed increased from 60rpm to 
80rpm over time, as the aggregrates got bigger. Temperature of 37°C was maintained 
using a heating jacket, and a mixture o f complete high glucose and low glucose DMEM 
was used. When lactate levels reached above the lg/L mark, perfusion was started. 
Flowever, after 2 days of perfusion culture, the spin filter blocked, thus, it was decided to
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operate using 0.75L media exchanges, by allowing the aggregates to settle and pump out 
the spent media. This was carried out based on the monitoring of glucose concentration, 
thus when glucose was below 0.5g/L, 0.75L of media exchange took place. The culture 
with Cytodex 2 carriers showed that the cells were able to proliferate as can be seen from 
the light microscropy pictures and the LIVE/DEAD staining in Fig 4.7 and 4.8. 
Additionally, for prolonged culture, extracellular matrix was laid down and collagen was 
detected, as can be seen qualitatively, from Fig.4.9 and 4.10. There was some distortion 
of the spherical nature o f the microcarrier following the immunostaining protocol as can 
be seen Fig. 4.9. This was partly due to the snap freezing by liquid nitrogen. Again, the 
distortion of the spherical nature of the microcarriers was observed, in the histological 
stains in Fig 4.10 due to the dehydration required for the histology staining during the 
sample preparation. The microporous nature of the microcarrier can be seen to have 
absorbed more of the histological staining.
The better growth characteristics on the Cytodex 2 microcarriers was partly attributed to 
the spherical nature o f the microcarriers which probably caused less sliding and shear 
effects upon the cells compared to the Nunc Microhex culture. The microporous nature of 
the carriers also facilitated the deposition of matrix proteins thus increasing the strength 
of adherence.
Cellular morphology was examined by scanning electron micrograph (SEM) and revealed 
the presence of three dimensional multicellular aggregates consisting of cell covered 
Cytodex 2 beads all bridged together. The substantial aggregation involving the cells and 
the beads can be seen very clearly by the SEM pictures that were taken as shown by Fig 
4.11. This shows that the fibroblasts have been deposited in the voids and that the outer 
surfaces of the beads still have some empty areas.
Fig 4.12 a and b show that the dense growth of the cells; the extracellular matrix laid 
down on Cytodex 2 beads indicated presence of channels throughout this lump of tissue. 
This helps to support the thinking that there were no transfer limitations or nutrient
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starvation. Furthermore apoptosis was not observed and the ratio of lactate to glucose of
1.1 further supports this since values close to 1 indicate aerobic cell metabolism.
Figure 4.7 Light microscopy pictures of fibroblasts on Cytodex 2 spherical beads, at xlO 
magnification at a) Day 18 and b) Day 25.
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Day 5 Day 8
Day 28 Day 34
Figure 4.8 LIVE/DEAD staining of fibroblasts on Cytodex 2 beads at Day 5, 8, 28 and 
34. Green indicates the cells are alive, and red indicates dead cells.
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Figure 4.9 Immunostaining of Cytodex 2 microcarriers and cells to show where the 
collagen is laid down. Green fluorescence shows the presence of collagen and the red is 
the propidium iodide stain for the cells at Day 28.
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a)
b)
c)
Figure 4.10 Histological stains to show the presence of cells, and ECM being laid down 
surrounding the microcarriers. All taken at x 20 magnification, at Day 34 using light 
microscropy. a) H&E stain to show the cells and the architecture of the tissue, b) The 
stain for GAGs, and c) Sirius red stain for Collagen.
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Figure 4.11 SEM pictures showing the aggregate of Cytodex 2 beads and cells grown in 
the STR with increasing magnification.
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a)
Figure 4.12 SEM pictures to show a) loose aggregate of cells and Cytodex 2 beads, b) 
the cells and extracellular matrix laid down. Clear fibrils can be observed.
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It was concluded that Cytodex 2 would be a suitable candidate for the process as the cells 
proliferated and over the course of culture were able to secrete extracellular matrix as the 
cell clumps and beads got larger and heavier. Dextranase can be used to dissolve the 
carriers leaving only cell clumps which could be harvested using centrifugation or 
tangential flow filtration. The spent media could be concentrated using ultrafiltration to 
give a rich cocktail o f growth factors to use in the formulation to enhance the bioactivity 
o f the gel. Thus for manufacturing, the growth factors could be concentrated, and then 
diafiltered into a stable buffer to produce a spray to be used in conjunction with the gel, 
or simply sold off for cosmetic use.
A simpler and neater manufacturing approach would be to adopt a biodegradable 
microporous microcarrier; this would avoid the need and potential damage and loss in 
yield caused by the use of enzymes in between the transfers during the cell expansion and 
also for the final harvest. Ideally, the biomaterial of the microcarrier would be engineered 
to last the period of culture, thus harvesting the cells could be carried out easily by a 
simple centrifugation step of the contents of the bioreactor. As Dermagraft was grown on 
Vicryl mesh, it was decided to purchase the mesh and hole punch to create discs for the 
cells to proliferate upon due to the constraints of time and resources of the project, rather 
than spray drying to make biodegradable porous PGLA microspheres.
The next section describes the culture of a biodegradable microcarrier.
4.2.4 Biodegradable culture
Vicryl discs were seeded into a 3L bioreactor at 1L working volume, and eventually to
1.5L maximum working volume. This culture was seeded at a higher cell density of
 ^ 23.8x10' cells/cm , in order to shorten the time for the cells to reach confluency over the 
carrier and thus shorten the culture time to 21 days. Settling of the vicryl discs laden with 
cells occurred constantly, and the stirring speed was raised to 80 rpm intermittently to 
ensure movement of all the discs with cells to avoid merging into one very large 
aggregate.
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Figure 4.13 Fibroblasts cultured on Vicryl mesh discs in a 3L bioreactor. Light 
microscopy at x40 magnification.
Light microscopy showed that the cells grown in the reactor were able to attach and 
proliferate on the Vicryl mesh discs, and also acted in the similar manner observed for 
Dermagraft which was that the cells were able to fill in the gaps of the mesh. This can be 
observed clearly in Fig. 4.13 where the fibers of the mesh can be seen very clearly, and 
the cells have covered the disc. Fig. 4.14 shows the immunostaining of the collagen 
deposited after 15 days. This culture was maintained for 21 days and then harvested since 
previous degradation studies carried out by Smith and Nephew RC indicated that the 
Vicryl degrades completely after this period making it difficult to obtain tissue samples 
for immunostaining. Without the rigidity of the mesh fibers, the cell mass formed at this 
stage is too premature and can dissolve and disintegrate into the media supernatant.
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Figure 4.14 Immunostaining of the Vicryl disc culture. The green is where the collagen 
has been deposited and the red is the propidium iodide stain for the cells. Immunostaining 
and the confocal microscope were utilized to take the picture.
Table 4.3 summarises the key results and highlights the differences between the static and 
the stirred tank (STR) cultures. Neves et al. (2005) showed that for fibrochrondrocytes 
the stirring-induced mixing was able to increase the deposition of GAGs and collagen for 
cartilage constructs. Thus it can be observed there was more deposition of collagen with 
the STR culture when compared to the static culture. (An additional 3 x 5ml t-flask static 
culture was cultured and maintained alongside the stirred tank culture with the Cytodex 2 
beads and harvested at the same time, and the collagen content of this was similar to the 
28 days static culture. These cells in the t-flasks were kept and maintained initially to 
serve as a check that the cells for inoculation were fine in the event the STR culture failed 
due to a contamination. The biodegradable discs had lower collagen content because 
they were not cultured for 28 days. Most of the collagen deposition only really takes
74
place after 4 weeks into culture, as it becomes sufficiently crosslinked to enable detection 
using the hydroxyproline assay.
Table 4.3 Summary key metrics for the static and STR cultures
Static
culture
Bioreactor
culture
(Nunc)
Bioreactor 
culture 
(Cytodex 2) 
10g/L
Bioreactor 
culture 
(Vicryl discs) 
lg/L
Seeding density 
(cells/cm2)
1.5 x 104 1.0 x 104 4.5 x 103 3.8 x 105’
Final cell density 
(cells/cm2)
-1 .5  x 10s -1 .9  x 104 -7.54 x 104 -5.9  x 105’
Collagen yield % of 
biomass
7% N/A 17% 3%
VEGF levels (pg/ml) 400-1000 -1800 -2500 -2000
Overall
Lactate/Glucose
ratio
1.5 (low glue) 
1.7 (high glue)
2.8 1.1 2.3
Overall
Ammonia/Glutamine
ratio
0.5 1.4 0.1 0.9
Duration Time 
(days)
28 28 34 21
2
[* the surface area for growth is based on nominal surface area (n x  d /4). lg in total of
2mm diameter disks was used. Approximately 1875 discs were used in total.]
The results showed that the STR cultures have higher levels of VEGF than static culture, 
and this phenomenon is similar to what has been reported by Pinney et al. (2000), where 
the investigators found the presence of VEGF mRNA was 22-fold greater in three- 
dimensional cultures compared to monolayer cultures. This can be attributed to more 
efficient media usage, as the STR cultures have more cells per media volume than the 
static cultures. Table 4.3 also shows that a similar 10-fold expansion of cells was 
achieved for both the static culture and the bioreactor Cytodex 2 culture.
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Table 4.3 indicates the ratio of waste products to substrates as lactate to glucose and 
ammonia to glutamine. Having the lactate/glucose ratio closer to one meant the culture 
was operating in the more aerobic region, and probably that the nutrients were consumed 
and eventually incorporated into the production of extracellular matrix rather than just 
waste products, lactate and ammonia. This was observed in the Cytodex bioreactor 
culture and to a lesser extent in the static culture. Values above 2 typically indicate 
anaerobic metabolism.
The high lactate/glucose ratio for the Vicryl seemed to indicate the possibility of oxygen 
limitation however there was sufficient oxygenation as the culture had intermittent 
sparging to maintain DO. Thus with the intermittent sparging and the higher 
ammonia/glutamine ratio, this indicated that the cells were probably exposed to more 
stressful conditions than the Cytodex culture. As CMC was utilized to increase the 
viscosity of the DMEM media to allow suspension of the Vicryl discs this probably 
increased the diffusional limitations thereby contributing to the higher ratios for the 
Vicryl culture. Thus this implies the importance of having density that is only slightly 
heavier than water, so the microcarriers both suspend easily and settle readily. This also 
implies that altering the viscosity o f the media utilized alters the diffusivity profiles of the 
nutrients, thus for scaling up this would not be ideal, as diffusional limitations are more 
likely to be compounded upon scale up.
4.4 Proposed process for generation of biomass
4.4.1 Introduction
This section is a summary of what the proposed process could be for the generation of 
biomass consisting of cells and extracellular matrix. It will then discuss some of issues 
and limitations in scale-up that should be considered and explored further. Thus from the 
experimentation, two process culture routes are possible, whereby the first is to utilise the 
commercially available Cytodex 2 microcarriers and subsequently include an incubation
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step with the dextranase enzyme to remove the microcarriers, followed by a 
centrifugation or filtration step to harvest the biomass generated. The second would be to 
culture the cells on the biodegradable Vicryl mesh formed as beads and harvest the entire 
lot to formulate into the gel, thus minimising the level of purification required. Vicryl has 
been used as medical sutures, thus biocompatibility is not as much of an issue, and indeed 
could form part of the formulation. There would be necessity to control the pH o f this 
formulated gel, as the degradation of the polymer could cause a pH drop, and this could 
inhibit the bioactivity of the biomass gel. Tatard et al, (2005) proposed the use of PLGA 
microcarriers coated with adhesion molecules for cell therapy, and demonstrated the use 
of these microparticles for PC 12 cells. Fig. 4.15 shows the process flowsheets that are 
proposed. Advantages and disadvantages of each route are discussed in the following 
sections.
4.4.2 Processing Issues and Equipment Considerations
Process route (I) is more complicated and (II) has less steps. However, the fermenter 
culture for route (I) is easier to operate as Cytodex 2 microcarriers suspend better. 
Additionally, as the Cytodex 2 microcarriers are autoclavable sterilizing in situ is an 
attractive advantage in comparison to route (II). It would be necessary to characterize the 
biodegradable characteristics of the microcarrier first so as to allow sufficient control of 
process (II) to ensure the correct harvest time. This is balanced by the fact that Process (I) 
needs studies to characterize the amount of dextranase required and time of incubation to 
degrade away the dextran, and then a rinse and centrifugation to remove the enzyme.
The maximum size of reactor would be the 1000L as any bigger size would probably 
require too long a cell expansion chain and hence the passage number o f the cells. 
Experimental results shown earlier in the chapter, indicate it would be desirable to use the 
low glucose DMEM at lg/L and have an intermittent feed of glucose solution to 
replenish.
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Culture using Dextran 
microcarrier
Culture using Vicryl 
disks with CMC
PBS rinse 
and add 
dextranase
Media
supernatant
Incubate and gentle 
stirring in the 
fermenter vessel
Waste
supernatant
Clarification step 
to retain the solid
Ultrafiltration
Gather the solid 
paste and blend 
together with 
concentrated media 
to form a gel that 
could be frozen
Harvest the entire 
contents of the reactor 
after the Vicryl disks 
have degraded and 
blend together to form 
a gel that could be 
frozen
(I) (II)
Figure 4.15 Process Flowsheet to indicate the unit operations required for the routes 
adopting (I) the dextran microcarrier, and (II) the Vicryl microcarrier.
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Additionally, rather than stopping the impeller and letting the microcarriers settle, in 
order to carry out the media exchanges it would be better to siphon the spent media at a 
slow flow rate constantly through a settling tube. This process stream could be filtered to 
ensure no particulates which could block the UFDF membranes and this then can be 
concentrated and diafiltrated remove the lactate and ammonia and buffer exchange the 
growth factor-rich solution into the fresh DMEM to recirculate back into the reactor. This 
should be able to supply the culture with nutrients needed and reduce the amount of 
expensive serum and media required, thus reduce costs even further.
The media used is certainly not cheap and this economic driver will dictate the use of 
powdered or liquid concentrate medium as shipment and storage of large volumes of 
complete medium is impractical. From a 10L reactor culture, over a period of 2 weeks, 
84L of complete media was utilized (personal communication with Mary-Ann Dowling, 
Smith &Nephew RC). This indicates that a 1000L culture would be utilizing at least 
8,400L of expensive complete media. Additionally, the ideal culture mode to operate 
would be in perfusion mode and this will need constant preparation of medium. Thus, 
application of liquid concentrates would allow media preparation to take place in-line, by 
automatic dilution of the concentrates with water of the appropriate quality.
Scale-up considerations would be the mass transfer and oxygen transfer limitations which 
would take place. This will be finely balanced with providing sufficient agitation to 
ensure adequate nutrient mixing and suspension of microcarriers, whilst avoiding 
shearing the cells from the microcarriers, especially, as the aggregates gets bigger over 
the course of time. Multiple impellers would be required at the larger scale. Intermittent 
sparging with air would be needed, thus investigation into the designs for the sparger 
would be required.
Ability to use a disposable reactor rather than the standard stainless steel STR would take 
out the CIP and SIP and speed up production.
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4.5 Conclusions
The experimental work here has shown that the culture of human dermal neonatal 
fibroblasts could be cultured on particulates successfully to generate the ECM and that 
cell expansion via the bulk reactor would be more efficient for large scale processes to 
satisfy potential demands. However, the extensive aggregation although favourable for 
biomass generation, made sampling difficult, and thereby making it difficult to monitor 
the cell density with any accuracy throughout the culture. Thus for the STR cultures, only 
the initial and final cell densities could be reported with confidence.
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CHAPTER 5
E c o n o m ic  m e t h o d o l o g y  a n d  Im p l e m e n t a t io n
5.1 Introduction
This chapter explains the methodology used in setting up the economic models to assess 
the potential of process alternatives for producing advanced wound healing products. 
Process planning early on can help to enhance manufacturing operations, and in the field 
of regenerative medicine, which is quite a new industry, ability to be able to address the 
questions regarding process economics can be quite beneficial. Experience from the 
bioprocessing industry showed that choices made early in the development process are 
hard to change later on due to regulatory constraints on process modification. When 
examining the technical feasibility for the process, the performance of the unit operations 
can be modelled based on experimental data, and this can be combined with business 
modelling to enhance decision-making in the manufacturing process.
Based on decision-support tools developed for the biopharmaceutical industry, the 
framework used is implemented via the spreadsheet software, MS Excel XP  (Microsoft, 
USA). By using easy accessible software, the models developed can be examined and 
adapted quite simply for other processes. This chapter will start with explaining how the 
software platform is used to implement the model and the cost appraisal. The last section 
will explain how risk is analyzed and implemented.
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5.2 Modelling Framework
The framework for capturing and organising process and cost data was adapted from 
Farid et al. (2000, 2005). Setting up the model initially required the creation of unit cost 
databases with the specifications of the resources within the facility being evaluated and 
their costs. The resources were identified and categorised as equipment, materials, 
utilities, and labour. Fig. 5.1 below is a schematic to explain the set up of the model.
Resource Unit Costs:
Equipment
Materials
Utilities
Labour
Manufacturing 01perations:
Product
handling
operations
Ancillary
operations
Mass balancing and 
resources required
Capital Investment Cost of Goods
-------►
TEPC Direct costs
Lang factor Variable costs
NPV
Cashflow over project 
lifetime
Figure 5.1 The hierarchical framework adopted.
Separate spreadsheets were created to define the task sequences and their resource 
requirements. The manufacturing operations were categorised as product-handling 
operations (e.g. cell culture) and ancillary operations to prepare the equipment (e.g. CIP)
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or intermediates (e.g. media preparation). This helped to ensure all relevant activities and 
hidden costs were captured in a transparent fashion. For each unit operation relevant 
design equations and short-cut mass balance models were encoded to compute the output 
of each step and the equipment sizes and numbers required to meet the demand. This is 
further discussed in section 5.3.1.
5.3 Data collection
Parameters in the process models have certain default values, which come from the 
following sources: industrial experts, historical data, literature, and vendors. For example, 
equipment costs relating to the disposable Wave bioreactor were obtained by consultation 
with the vendor, Wave Biotech. Certain equipment costs, which may not have exact 
quotes, were estimated using the sixth-tenths rule and the use of cost indices.
Scale-up factors: Cost2 = Costi
Size2 
Sizex j
where R < 1.
Inflation factors: Cost2 = Costi
r Inflation index. ^
Inflation _ index
There are certain caveats to the use of these indices, for example, the inflation index 
calculations become increasingly inaccurate as the time interval between the data points 
increases, thus a 5 year difference will result in a more accurate calculation than a 20 year 
one (Remer and Mattos, 2003). Additionally, scale-up factors can only be used in the 
capacity range for which the factors were developed.
Frequent discussions with experts were carried out (N.Medcalf, M.Smith, M.Dowling at 
Smith and Nephew RC, York, UK) to ensure data values were sensible for the 
manufacturing operations. They were also consulted to validate the structural modelling 
assumptions. Databases of the information on costs gathered are shown in Appendix C.
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5.3.1 Process models
The process alternatives presented in Chapter 6 each involved a series of operations that 
proceed from inoculum grow-up to fermentation and product recovery. The alternatives 
in Chapter 7 also required purification steps primarily by chromatography. This section 
presents the key principles behind the process models are used to calculate the 
composition of the process streams, and certain process variables. A summary is 
presented in Table 5.1. In general the rule of mass conservation is applied, in that the sum 
of the total process streams going in must equal the total of process streams out.
Inoculum grow-up of mammalian cells generally involves a vial of cells being seeded 
into roller bottles, which are passaged until the desired cell concentration is achieved. 
Roller bottle expansion is generally considered in terms of split ratio and knowledge of 
the final cell density achieved. From experimental work, a 1500cm confluent roller 
bottle will generate ~5x 107 human dermal fibroblasts.
Fermentation is a process step whereby substrates undergo a reaction to give cell growth 
and product. Thus this step can be modelled using mass-stoichiometry to describe the link 
between the substrates and the products over a cycle. Information such as the titre of 
product or cell density achievable can be found from pilot plant studies, historical records 
or literature sources, and these can be used facilitate a quick calculation of the output 
streams from a mass balance. The maximum size of the reactor for production fermenter 
was fixed at 1000L, thus depending on the demand, the spreadsheet was set to first 
increase the number of batches until the maximum is reached and then to increase the 
number of reactor trains. The 1000L reactor limit was set, because working with primary 
cell lines, means that it is not feasible to have too long a cell expansion train and 
therefore dictates the final size of reactor. Furthermore, the maximum size of a disposable 
reactor is 1000L with a 500L working volume.
Centrifugation is used to separate solids from liquids in component mixtures and 
typically used to remove cells from the liquid broth. Ultrafiltration is very often used to
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concentrate the process stream and diafiltration to allow for buffer exchange. 
Chromatography is used to purify the target product and typically considered to operate 
with the various stages of loading, wash, elute and regeneration of matrix. Knowledge of 
the number of column volumes, linear velocities and height of the columns are required 
and this can be taken from literature sources, manufacturer’s recommendations, or 
experimental work.
Table 5.1 Summary of key inputs for each process model
Unit Operations Process Models
Inoculum Grow 
up
Seeding densities, split ratio, final cell densities 
achieved.
Fermentation Stoichiometry, extent of reaction
Centrifugation Solids carry-over, Solids volume fraction in sediment
UFDF Flux, Rejection coefficients, Number o f Diavolumes
Chromatography Flowrates, Column volumes, yields, binding capacities
Equations utilised are shown in Appendix C.
5.4 Key output parameters
The main outputs from the model are the fixed capital investment (FCI), cost of goods 
(COG) and net present value (NPV). The following sections explain how they were 
calculated.
5.4.1 Fixed capital investment
The method to derive the fixed capital investment was from the approach proposed by 
Lang, (1948), who predicted the total plant construction cost based upon the delivered 
cost of plant equipment. The method was based on the analysis costs of previous projects, 
and subsequently derived ‘Lang Factors’ whereby multiplying this with the total 
equipment purchase cost quickly provides an estimate of the fixed capital cost.
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This is summarized by the equation:
FCI = TEPC x Lf
where TEPC = total equipment purchase cost 
L f = Lang factor
The proposed Lang factor accounts for cost factors for items such as the electrical work, 
piping, instrumentation, contractor’s fees etc. Depending on the type of plant that is to be 
installed, the value of the factor will vary, for example, chemical engineering plants 
typically will have lower values, ranging from 3 to 5. Biopharmaceutical plants are 
considered to required higher values of 4 to 8 because the need for specialised facilities, 
e.g. aseptic processing plant. Additionally, the variation will also occur depending on 
whether it is a disposable, hybrid or stainless steel plant. Derivation of the Lang factors is 
based on the method reported by Novais et al. (2001) and Petrides et al. (1995). Novais et 
al. (2001) reported that although the specific value for such a factor application to 
bioprocessing plants is not easily available from the literature it can be obtained from the 
sum of the individual factors that constitute capital investment. (Table.5.2)
Table 5.2 Individual factors, fi, for a stainless steel bioprocessing plant and the 
corresponding derived Lang factor (Novais et al., 2001).
5.4.2 Cost of Goods
The cost of goods was defined as the cost of manufacturing, therefore it does not include 
the sales and distribution costs. The COG model used was based on Farid, 2000 and 
shown in Table 5.3.
The direct costs i.e. variable costs were based upon utilization by each of the unit 
operations. The indirect, i.e. fixed costs were estimated from the fixed capital investment. 
The term general utilities was to account for the HVAC systems and the aseptic 
requirements since the direct utilities did not account for the ongoing utility charges in 
running the facility.
Table 5.3 Breakdown of the COG/g model used (Farid et al., 2000)
The indirect raw materials accounted for miscellaneous material costs such as safety 
clothing, aseptic gowning requirements. Labour was treated as a function of utilization, 
i.e. the cost for the number of man-hours required for that task, and not as an annual 
fixed-salary based staff.
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5.4.3 Cashflow model and Net present value (NPV)
A spreadsheet taking in account of the costs and revenue was set up. (See Appendix C). 
The total annual cost of goods was then fed into this spreadsheet to produce a cashflow to 
enable the calculation of NPV. Income was based on the amount produced multiplied by 
the sale price. Sales prices were determined based on information on commercial 
products currently on the market and adjusted based on expected market capture. 
Working capital was assumed at 15% of the FCI and was expected to be recouped at the 
end of the 10 year lifetime. Sales and distribution costs were assumed at 3% of the sales 
revenue. Corporation tax of 30% was applied.
The net present value (NPV) was chosen as the main output for the economic parameter 
to determine whether the project was considered economically feasible or not. This is a 
standard method to determine the profitability between competing projects and required a 
cash-flow to be generated. The simplified cashflow analysis was generated assuming that 
target sales would be reached in all years for the 10 years of operation.
A discount rate was also required to discount the future cash flows to their present values. 
Most companies take the weighted average cost of capital after tax, or the use of higher 
discount rates used for riskier projects (personal communication, Dr. K. Sutherland). The 
following equation defines the calculation for NPV.
n r
n p v  = Y - ± j—
T i l  + iY
where t = time of the cash flow
n = total time of the project 
i = discount rate
C, = cashflow at that point in time
If the NPV is positive, i.e. greater than zero, then the project is deemed economically 
feasible and it is then recommended to the company to invest in the project.
5.5 Dealing with uncertainty: Risk Analysis and Monte Carlo simulation
Economic studies should also be able to point out the impact of potential changes and 
uncertainties on the expected output. This gives an idea on the robustness of the process, 
and how risky the process is as well. Thus, sensitivity analysis was carried out to 
determine the impact that the key variables and assumptions within the model had on the 
results. The extreme ends of the range of the variables were chosen to see the departure 
away from the base case value. The results from this were then shown graphically in 
tornado plots.
A Monte Carlo Simulation involves several iterations of the model and each one, a 
random number generator selects a value for each uncertain variable. Values are chosen 
within specified ranges for each variable and with a frequency proportional to the shape 
o f the probability distribution associated with each variable. The process models created 
utilised triangular distributions for the key uncertainties. Usually 1,000 to 10,000 cases 
were needed to reach convergence in the output distributions. The Monte Carlo 
simulations were set up using code written in Microsoft VBA which manipulated the 
models in MS Excel XP. The speed to run the iterations ensured that the calculations 
required were carried out in a day. The Monte Carlo simulations were used to obtain 
frequency distributions of the key economic metrics, COG and NPV. This enabled 
potential risk against the reward to be analysed more clearly.
5.6 Conclusions
This modelling approach allows the user to compare process alternatives to be compared 
in terms of yield, resource demands, cost and profitability. The next two chapters present 
the results of the economic analyses using the model to compare different flowsheets for 
producing advanced wound healing products.
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CHAPTER 6
E c o n o m ic  A s s e s s m e n t  o f  M a n u f a c t u r in g  
S t r a t e g ie s  f o r  A d v a n c e d  W o u n d  h e a l in g  
P r o d u c t s
6.1 Introduction
In parallel with the experimental work presented in Chapter 5, an economic evaluation of 
manufacturing strategies was also carried out. As highlighted earlier, the 1st generation of 
tissue-engineered (TE) skin substitutes are regarded as interactive drug delivery systems 
(Harding et al., 2002) providing cytokines and growth factors to the wound bed. Hence it 
is possible to envisage the 2nd generation products as bioactive ECM reformulated as a 
gel or patch. Consequently, the assumption that the 2nd generation TE skin products do 
not need to be administered as flat skin equivalents to be effective opens the door to 
several possible bioreactors designs as successors to the conventional planar devices. In 
this chapter, a simple multi-criteria decision making technique was used to score the 
alternative designs in order to select the most promising designs for further investigation. 
These selected designs were then subjected to a more rigorous economic evaluation 
which was extended to incorporate the impact of uncertainties on the cost and 
profitability. Stochastic modelling with Monte Carlo simulations was used to minimise 
the risk of incorrect conclusions due to variability in the assumptions that form the basis 
of the models such as process parameters such as cell yields and product yields. This 
strengthens the key conclusions that can be drawn from the economic evaluation.
The structure of this chapter is as follows: Section 6.2 presents the assessment o f the 
various bioreactor designs using a MCDM technique; Section 6.3 covers the background
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to the more detailed case study and in Section 6.4 the deterministic analysis of the 
problem is presented. The uncertainties in the problem are then identified, and addressed, 
using a sensitivity scouting analysis in Section 6.5. Monte Carlo simulation is then used 
to imitate the randomness inherent in the problem and this is presented in Section 6.6. 
Finally, Section 6.7 examines the scenario o f different scales of operation.
6.2 Assessment of Bioreactor Designs
The bioreactor designs considered were:
a) microcarrier-based: Stirred Tank Reactor, Wave disposable bioreactor, and 
fluidised bed reactor
b) non-microcarrier-based: Roller bottles, spiral film reactor, plate heat exchanger 
method and multi-unit reactor (e.g. Cell factory, Cell cube)
As can be seen from this list, both stainless steel and disposable options were evaluated. 
The use of disposable equipment is attractive since it allows for a lower initial capital 
burden, and the possibility of spreading the costs over a plant’s life. There is an 
increasing acceptance of the use of disposables in the biopharmaceutical industry sector, 
and this trend is set to grow, as more suppliers enter the disposables market. Thus the 
possibility o f adopting a plant based on disposable components for the generation o f 
tissue-engineered products is an interesting alternative for investigation.
6.2.1 Methodology
Multi-criteria decision-making (MCDM) methods provide a formal mechanism for 
explicitly including qualitative and non-financial aspects of performance in the 
evaluation. In this chapter the additive weighting sum technique was used to screen for 
the most preferred designs in terms of both financial and operational feasibility. A set of 
financial and technical criteria were compiled through discussions with industrial experts. 
In addition to the relative magnitude of the production cost, several operational criteria 
such as scalability, ease of control, and validation were considered key factors affecting
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the decision. A summary of the criteria used is given in Table 6.1. Each of these criteria 
was assigned a weighting according to their relative importance of 1 to 3. Then each 
individual criterion was then given a relative score of 1-3, with 1 being the worst 
outcome and 3 the best outcome. The scores given by a panel of six academic and 
industrial experts were averaged, and the results of this are further shown in the following 
section in Table 6.2. The total score for each alternative was obtained as the weighted 
sum of all the criteria values. The financial and operational scores was then normalised 
and results are plotted in Fig. 6.1
Table 6.1 Criteria used in the analysis of bioreactor designs
Criteria
name
Criteria description
Financial Projected cost 
per kg
Cost o f biomass per kg wet weight, in the 
condition ready to undergo formulation into 
the product
Operational Scaleability Ability to expand the scale o f the process to 
achieve 250 kg/year, and inclusion of  
flexibility into the scheduling.
Validation
burden
Combination o f the perceived difficulty and 
duration o f validation to meet FDA 
requirements, and the probability o f success.
Control o f 
process
Expectation o f the ability to reproduce the 
culture conditions and control the product 
composition through control o f the culture 
environments of the cells. Ability to 
manipulate growth conditions.
Versatility Ability o f the process system to accommodate 
changes to the cell types other than just 
fibroblasts and also to be able to be utilised 
with a range o f cell support materials.
Patent Issues Probability of being able to acquire the rights 
to sell the product and potential to prevent 
others from replicating the product.
R&D burden Combination of the perceived difficulty and 
duration of the research and development. 
Consideration of the likelihood of success and 
the ability to demonstrate early proof of 
concept.
Operability Perceived robustness of the process
The weighting was given from an industrial perspective on the relative importance of 
each criterion to the company, Smith and Nephew after extensive discussion. Thus
92
projected costs/kg was perceived to be the most important criterion and thus given a 
weighting of 3, in comparison patent issues were felt to be of lesser importance and given 
a 1. This is because process patents are notoriously difficult to defend and Smith and 
Nephew had broad patents for its existing products, Dermagraft and Transcyte.
6.2.2 Results and Discussion
From Table 6.2, it can be seen that multi tray units do not score favourably in terms of 
operability and control of process because o f the perceived difficulty in retrieving the 
product; it would be undesirable to run an enzymatic solution to harvest since that would 
digest away the product, thus operability scores a low 1. It was perceived that STR with 
microcarrier technology would have better scalability than the Wave reactor thus this was 
given a score of 3, and the Wave reactor a score of 2 because the maximum working 
volume that a Wave reactor can have is 500L.
Table 6.2 Compiled averaged scores obtained from the panel.
Criteria Weighting
Current
existing
process Microcarrier based designs Non-microcarrier designs
Roller
bottle
Stirred
Tank
Wave
reactor
Fluidised
Bed
Spiral
reactor
Plate heat 
exchanger
Multi- 
Tray units
Operability
[Hi =3/Med=2/Lo=l]
1 2 2 2 2 1 2 1
Scaleability
[Hi =3/Med=2/Lo=ll
2 2 3 2 2 1 1 2
R&D burden
[Hi =l/Med=2/Lo=31
2 3 2 2 2 1 1 3
Validation burden 
[Hi =l/Med=2/Lo=31
1 3 2 2 2 2 2 2
Projected cost/kg 
[Hi =1 Mcd-2'Lo=31
3 1 2 2 2 2 3 1
Control of process 
[Hi =3'Mcd=2/Lo=ll
2 1 3 3 3 2 2 1
Patent Issues
[Hi -3 Med=2/Lo=ll
1 2 2 2 2 3 2 2
Versatility
[Hi =3 Med=2/Lo=lj
2 2 3 2 2 1 2 2
Total 26 34 30 30 22 27 25
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From the aggregate weighted scores in Table 6.2, it can be seen that STR was the most 
favoured route with the highest total score. Additionally, the microcarrier based designs 
had the higher scores when compared to others.
100
80
7 0 -
6 0 -
50 -
15 40 -
^  30 ■o
2 0 -
+->
<L>e
ZJ
CO
60 80 1000 20 40
Financial Saving
Figure 6.1. Normalised plot to show the assessment o f the reactors. The horizontal axis is 
the financial saving and the vertical axis is the operational benefit. Reactors, which fall 
into quadrant A, are the most desirable as it has a high score for the financial saving and 
the operational benefit as well. •  denotes Roller bottles, o Multi-unit reactor, x Fluidised 
bed, ■ Plate reactor, □ STR, A Spiral film reactor, and A denotes Wave reactor.
Fig.6.1 compares the operational and financial weighted normalised scores for each 
alternative. It can be seen that there is a trade-off between operational benefit and
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financial saving. The figure shows 4 quadrants labelled A, B, C and D; reactors which 
fall into the top right quadrant A are the most desirable and those in the bottom left 
quadrant D are the least desirable. The conventional roller bottle method for cell 
expansion and extracellular matrix production has a low financial saving score but a 
moderate operational benefit score. The reactors in quadrant A are microcarrier-based 
suspension reactors with the exception of the plate reactor, which is non-microcarrier. 
However, the plate reactor suffers from a low operational benefit score when compared to 
the microcarrier-based reactor options. The microcarrier-based suspension reactors has a 
higher score overall compared to the non-micocarrier based reactors and were deemed to 
best satisfy the criteria listed in the table.
From this initial analysis, the optimal reactor was the stirred tank, followed closely by the 
Wave Bioreactor as can be seen from the Fig 6.1. The following case study compares the 
processes based on roller bottles to microcarrier-based methods in stirred tank fermenters 
and Wave Bioreactors for the production of the bulk ECM product for the preparation of 
an advanced wound healing product.
6.3 Case study I Background: Roller bottle vs. Microcarrier Technology
Four flowsheets were proposed based on different bioreactor designs for the production 
of bulk TE-ECM product: Manual and automated roller bottle (RB) routes containing a 
biodegradable mesh, vs. two microcarrier-based routes, either using stirred tank 
fermenter (STR) or disposable wave bioreactor. These are shown in Fig 6.2.
Roller bottle (RB) technology is a simple, tried and trusted method for the cultivation of 
mammalian cells and can be used easily for the manufacture of biosynthetic skin 
substitutes. The transparency of the roller bottles allows quick visual inspection and 
microbial bottles that are contaminated can be quickly discarded. The losses caused by 
contamination can be addressed by applying corrective action, preventative action 
(CAPAs) before too much money has been wasted and by spreading the losses over a
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campaign of production this avoids the peaks and troughs caused by the large individual 
batches going down as associated with STR and the Wave bioreactor route.
RB Route STRAVave route
Resurrection of cells Resurrection of cells
Ceil Expansion:
RB culture 
trypsinisation
Cell Culture:
RB containing 
biodegradable mesh 
28 days culture
Harvesting;
Cut open RB
Pour out contents into a
sterile vessel
Cell Expansion I ;
RB culture 
trypsinisation
*Cell Expansion II:
Cell culture in 50L working vol seed reactor 
Biodegradable microcarrier
500L working vol production reactor 
Biodegradeable microcarriers 
28 days culture
*Production Cell Culture;
Cells on microcarriers allowed to settle 
Media pumped out.
Microcarriers degrade 
Biomass can now be harvested.
*Harvest:
Figure 6.2 Flowsheet of the Roller Bottle (RB) Process and the microcarrier-based 
processed using STRs or disposable Wave Bioreactors. * indicates the choice o f either 
the STR or the Wave bioreactor.
RBs also offer the advantage of being disposable, thus avoiding the need for ancillary 
cleaning and sterilising steps but incurring high consumable costs. However, the 
disadvantages are quickly realised for large scale manufacturing, which requires aseptic 
handling of numerous bottles; these are more pronounced for the manual manipulation of 
RBs where the risk of contamination and yield inconsistency is high and investment in
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skilled labour can escalate or adoption of automation is required. The disadvantages 
related to skill labour are alleviated with the use o f automated RB systems whereby the 
robotic arms are responsible for all the critical handling steps such as inoculation, media 
exchanges and harvesting. Such systems are currently used for the manufacture of 
Amgen’s EPO. The operator merely removes the RB from the incubator onto the input 
tray of the laminar flow hood which is then rolled into the hood by a conveyor belt. The 
robotic arm in the hood then implement the media removal and additions and an operator 
is then required to move the processed roller bottle back into the incubator. This reduces 
the risk of repetitive strain injury on the operators, and increases the amount each 
operator can then process. The microcarrier-based routes in fermenters are less labour- 
intensive and hence the risk of contamination is lower. In addition, scaling up and 
automation are easier to apply and environmental conditions (e.g. temperature, pH, DO) 
can be finely controlled.
Conventional stainless steel STRs were compared to disposable Wave bioreactors that 
comprise disposable bags placed on a stainless steel rocking cradle, which tilts to 
generate motion of the liquid similar to waves. The trade-off between the advantages of 
disposables, such as a potentially lower capital investment, faster turnaround and 
elimination of CIP and SIP steps, and the potential disadvantages, such as increased 
consumable costs, and floor space for the rocking devices were analysed. This analysis 
compares the bulk production costs; formulation and packaging are not included since 
they will be the same for all options.
6.4 Deterministic analysis
6.4.1 Set up of the model
A process economic model was set up in MS Excel XP  (Microsoft Corp, Washington) as 
described in previous chapter, to assess the feasibility of each manufacturing option using 
the following metrics: number of batches required to meet demand, cost of goods (COG),
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and the profitability indicator net present value (NPV). The model comprised of 
spreadsheets defining the process characteristics that fed into a COG model, which in 
turn fed into a cashflow model to compute NPV. The flow of information through the 
model is illustrated in Fig. 6.3.
Inputs
Outputs
Excel economic models and 
databases of unit resource costs
Net present value
Capital investment COG/batch, or COG.year 
or COG/g
Provide mass balance data, e.g. cell yields, 
binding capacities, product yields etc.
Specify product and ancillary task sequences
Indicate resource requirements for each task
Figure 6.3 Schematic indicating the flow of information through the tool
For each option, the process characteristics were specified in terms of the product- 
handling activities as well as the ancillary activities required to prepare equipment (e.g. 
CIP, SIP, mesh prep) and intermediates (e.g. media prep) as has been suggested by other 
authors (Farid et al., 2000, 2005; Lim et al, 2005a and b). For each activity the resources 
required, such as equipment, materials, staff and utilities were estimated. Companies 
were consulted for verification of quantities of materials required and the activity 
sequences. Short-cut mass balance models were used to determine the composition of 
each output stream. Equipment sizes and numbers, to meet market demand, and task 
durations were calculated using yields derived from experimental data from Chapter 4. A
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database o f unit resource costs was compiled through consultation with several vendors 
and literature sources (as presented in Chapter 5, Table 5.1)
The COG model used was based on conventional chemical engineering facilities but with 
modifications to account for the additional demands placed on the manufacture such as 
the requirement of aseptic techniques and added cost of HVAC systems. (The breakdown 
of the COG/g model is presented in Chapter 5, Table 5.3). The Fixed Capital Investment 
(FCI) was established using the Lang factor method where the total equipment purchase 
cost was multiplied by the Lang factor. The Lang factor was derived based on Novais et 
al. 2001. See Appendix C which shows the spreadsheet for the derivation. The standard 
10-year depreciation period was assumed for the COG calculation. Media was assumed 
purchased sterile, and the preparation consisted of adding the supplements to the basal 
media aseptically.
Table 6.3 lists the key assumptions and the input values for each process route, which has 
been validated through discussion with industrial experts. The scale for the process was 
decided based on analysing the market information and then process flowsheets were 
devised based on literature information, experimental data and discussion with the 
engineers from Smith and Nephew, La Jolla. Thus, inputs such as product demand, the 
sequence of the production and ancillary unit operations, resources required, and cost 
data were investigated first. By examining the sales figures for the approved skin- 
substitute products out on the market, a product demand based on these figures was then 
estimated. The input value was estimated to be 100kg of TE-product. From experimental 
work carried out into culturing fibroblasts, the doubling time of fibroblasts was calculated 
to be 55 hours. Additionally, the ECM to cells ratio was determined to be 3:5. This was 
used as a basis to determine what scale of operation to meet the 100kg annual demand. 
This allowed the estimation of how many cells were required for the 100kg scale, and 
thereby determined the size and number of production vessels.
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Table 6.3 Key assumptions for the aRB, mRB, STR and Wave route
Key Assumptions Input Value 
for mRB/aRB
Input Value for 
STR/Wave
Cells to ECM matrix ratio 3:5 3:5
Cell density in the mesh (cells/ cm2) 1 x 105 -
Cell density in STR/Wave culture 
(cells/mg of microcarrier)
3.5 x 105
Area of biodegradable mesh in each RB 1500cm2 -
Microcarrier concentration - 10g/L
Cost of biodegradable carrier 1.5* cost of commercial 
carrier
Serum used in the media 10% w/v 10% w/v
Time of each batch run 53 days 58 days
Labour requirement 1 skilled worker can maintain 30 RBs, 
automation increased this 90 RBs
No. of production reactors - 4 for STR, 3 for Wave
Working volume of seed reactor and 
production reactor
50L and 500L
Maximum no. of batches per year 10* 12
Lang factor 8.6, 3.1 8.1, 14.5
Annual product demand (kg) 100 100
Duration of the project (years) 10 10
Turnaround time (hours) 12 8 for STR, for Wave
Size of facility (m2) 1500 1500
Sales Price (£/g) 200 200
*each batch consists o f thousands of RBs. (All processes were designed to produce an output o f 100kg TE- 
ECM to meet the anticipated market demand.)
For the roller bottle processing route, this meant, knowing the number of total cells 
required based on the cells to ECM ratio allowed working out the number of seed roller
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bottles required to inoculate the production roller bottles. Additionally, from 
experimental work, a confluent RB generates ~50 x 106 cells.
Thus the total number of roller bottles used for the entire roller processing was calculated 
based on the equation:
Total RBs used in the expansion = 1-S (N/(1S)) + No. of seed RBs required. (6.1)
where S = Split ratio 
N = no. of whole expansions
Inputs for the target cell density were 1 x 105 cells/cm2 for the RB process routes, and 3.5 
x 105 cells/mg of microcarrier for the microcarrier routes. This in turn was also 
interlinked to the area that is available for the cells to grow, as human dermal fibroblasts 
are anchorage dependent. Thus the area of biodegradable mesh used in the rolled bottles 
was assumed to be 1500cm2, and the microcarrier concentration in the STR and Wave 
options was assumed to be lOg/L. The facility size of 1500m2 was assumed in all cases.
Calculations indicated that this would require a total production capacity of 83,333 RBs, 
in the RB route, versus 3571L in the STR and Wave routes. For the STR and Wave case, 
multiple bioreactors were used as they offer flexibility o f operation, and a degree of 
robustness in the case of batch failures. This modular design minimises the production 
disruption (Rouf, 2000). Thus, for the base case, multiple STR bioreactors at 500L 
working volume were modelled rather than increasing the reactor size. Additionally, it is 
undesirable to have too long a reactor train, since these are primary cells, and therefore 
high passage numbers should be avoided. To account for the faster turnaround time with 
the disposable Wave bioreactor, three was thought to be required as opposed to the four 
stirred tank reactors. The Wave bioreactor consists of a fixed rocking cradle (investment 
cost) and a disposable cellbag (consumable cost), and is available in working volumes of 
up to 500L.
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In order to model the effect of automation of roller bottle processing, certain additional 
assumptions were required, such as the number of RBs a robotic arm could operate 
within a timed duration. One of the leading companies in this field, the Automation 
Partnership (TAP) was consulted with regard to the cost o f Cellmate, and its capabilities. 
Additionally, Tecan Ltd. was also consulted on the cost of the robotic arms as well, and 
the footprint o f the equipment. Bernard et al. (2004) states that the Cellmate from the 
Automation Partnership (TAP) is capable of processing between 10 and 500 roller bottles 
or tissue culture flasks containing as many as 10 different cell lines a day and that each 
Cellmate can handle up to 2 to 3 times the amount of work a skilled worker can 
comfortably handle. Hence, the assumption that the use of the Cellmate increases the 
throughput of each operator by 3 times was used in the case study. The use of automation 
improves upon the existing manual tissue culture methods by increasing throughput, 
reduce the risk of contamination due to operator error, and reduce risk of repetitive strain 
injuries.
The key assumptions for the NPV calculations required the inclusion o f the sales price for 
the product in order to calculate what the perceived revenue could be. Sales price was 
determined based on the price o f the products out on the market. Thus the sales price o f 
the TE-product per g was determined based on the information that the sales price of the 
formulated products on the market was estimated at £300/g; this was based on a piece of 
Dermgraft, which costs $475 for a patch, and $1159 for Apligraf. As the costing exercise 
carried out was only taking into account of the bulk product, and not the formulation or 
packaging, a more realistic sales price of £200/g was set for the cashflow analysis. The 
NPV was calculated assuming a plant operating life of 10 years, and a discount rate of 
10%.
6.4.2 Results and Discussion of the deterministic analysis
The annual direct costs on a task basis for the manual RB, automated RB, STR, and 
Wave routes are illustrated in Fig. 6.4. The breakdown of the direct and indirect costs of 
the annual COG are shown in Fig 6.5.
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Figure 6.4 Comparison of the annual direct cost of goods per gram (COG/g) on a task 
basis, for the RB method (manual and automated), the Wave Bioreactor method and STR 
method, to produce the same product output of 100kg per year.
Most of the costs can be seen to accrue during the production reactor culture stage; the 
manual RB costs are significantly higher than the aRB, STR and the Wave routes. 
Examining Fig. 6.5 demonstrates that this can be attributed to the higher labour demands 
when operating such huge numbers of RBs; the impact o f automation in reducing labour 
costs can be seen when one compares the manual RB route to the automated RB route 
(Fig.6.4 and 6.5). Furthermore, the RB processes use more media than the other two 
microcarrier processes and this is because more media exchanges are required to account 
for loss of moisture due to evaporation, and to reduce the build-up of lactate waste, 
making the culture environment undesirable as it lowers the pH considerably. This 
contributes to higher materials and utilities costs in Fig. 6.5.
The production reactor step has a slightly higher cost in the Wave route compared to the 
STR route. This is because of the higher consumable costs due to the use of disposable 
cellbags retailing for £312 for the small scale and £1200 for the largest size of 1000L
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which has an operating volume of 500L. On the other hand, the STR route consumes 
extra resources for its CIP and SIP operations, which are eliminated in the disposable RB 
and Wave routes.
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Figure 6.5 Breakdown for relative total annual cost o f goods for the RB (manual and 
automated), STR and Wave routes. The labour component ( □ )  comprises the costs of 
operating labour, supervisors, QC and QA and general management. The materials and 
utilities costs ( □  ) are displayed together. The indirect costs ( H ) consist of general 
utilities, depreciation, insurance, local taxes and general maintenance costs. The costs are 
displayed relative to the manual RB process.
The aRB, STR and the Wave routes can be seen to offer significantly lower costs 
compared to the manual RB route (37%, 28% and 20% respectively, if  manual RB is 
100%). The ratio of direct costs to indirect costs differs considerably and the mRB route 
is dominated by direct costs (materials, utilities, labour) whereas indirect costs dominate 
in the STR route. The indirect costs are proportional to the capital investment required 
which is highest in the STR case (see Table 6.4 or Fig 6.5). Interestingly, the graph
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indicates that the STR and the Wave routes have similar materials and utilities costs. 
Although the Wave route has higher consumable costs, the utilities and chemical costs 
are lower given the lack of CIP and SIP operations. Therefore, when compared to the 
STR option the cost reduction in the Wave route can be attributed to a significant 
reduction in indirect costs as well as a slight reduction in labour costs.
Table 6.4 Summary of the economic parameters for comparison of the process routes.
Economic
indicators
Manual
RB
Automated
RB
STR Wave reactor
FCI (£) million 14.70 20.24 22.98 13.83
Annual COG (£/g) 260.70 97.49 73.97 51.47
NPV (£million) -37.15 29.86 38.40 53.35
IRR (%) N/A 27.68 29.66 48.83
Payback time 
(years)
N/A 2.7 2.5 1.4
Table 6.4 summarises the results o f the economic metrics used to compare the various 
methods. The Fixed Capital Investment (FCI) is highest for the STR route, followed by 
the automated RB route, manual RB route and then the Wave route. The significantly 
large quantity of roller racks needed to process the roller bottles in each batch contribute 
to the high FCI values for the RB processes. The automated RB has a higher FCI than the 
manual RB route given the robotics required. The upfront cost of half a million pounds 
for one these units (e.g. Cellmate) does seem daunting, but there are potential savings to 
be gained since fewer expensive highly skilled labour are required. Dutton and Fox 
(2006) also showed this trend in their life cycle cost analysis. The Wave route has the 
lowest FCI, of which most of the cost is attributed to the rocking cradle for the reactor, 
and any remaining supporting equipment.
The NPV is negative for the manual RB route, and positive for the automated RB, STR 
Wave routes at a 10% discount rate. A positive NPV indicated a worthy investment and a
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negative NPV denoted a loss, therefore, the more positive the NPV, the more profitable 
the process. In industry, an IRR above the 30% mark is considered a profitable project. 
To conclude, the deterministic analysis suggests that Wave is the most economically 
feasible because of its higher NPV (~£ million) and an IRR that exceeds the 30% 
benchmark.
By examining comparative cost ratios shown in Table 6.5 for the different process routes 
at the 100kg scale of operation relative to the automated RB process route, it can be seen 
that automation allows the RB process route to compete with the bulk reactor routes. A 
similar conclusion was drawn by Archer and Wood (1992), however, the difference in the 
labour requirement between the manual and automated operation is greater in this 
scenario, and a further difference lies in the STR and Wave routes having higher labour 
requirements than the automated RB route. O f course, the results are case study specific 
and highly dependent on the assumptions made and the scale of operation. This led to 
further analysis to examine the impact of changing the scale of operation and this is 
explored in the Section 6.7.
Table 6.5 Comparative cost ratios
RB Automated RB STR Wave
Annual output 1 1 1 1
FCI 0.7 1 1.1 0.7
Materials Cost 1 1 0.2 0.2
Labour Cost 31 1 1.3 1.3
COG/g 2.7 1 0.8 0.5
6.5 Sensitivity analysis
Since several variables were considered in the case study, it was important to determine 
which had the most impact on the NPV and hence were the key profitability drivers.
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6.5.1 Setting up the sensitivity analysis
For each key variable in the model, the best case and worst case scenarios were run to 
monitor the impact on NPV. The variables examined along with their worst and best 
values are shown in Table 6.6. These results are then plotted as tornado diagrams.
Table 6.6 Scenario setups for RB, STR and the Wave
Input variab le W orst B ase B est
mRB/aRB/STR/WA VE
Cells to ECM ratio 10:1 3:5 1:10
Sales Price (£/g) 150 200 250
mRB and aRB -  specific
Cell density in mesh (cells/cm2) 1 x 104 1 x 105 1 x 106
Mesh Area (cm2) 850 1500 2150
Mesh Cost (£/m2) 14.56 11.64 8.73
STR/Wave -  specific
Cell density in suspension (cells/mg carrier) 3.5 x 104 3.5 x 105 3.5 x 106
Microcarrier concentration (g/L) 5 10 15
Cost of biodegradable microcarrier (£/g) 7.20 5.40 3.60
Process route specific -Lang factor
mRB 9.60 8.60 7.60
ARB 4.10 3.10 5.10
STR 9.13 8.13 7.13
WAVE 15.47 14.47 13.47
Additionally, the effect of the scale of operation will affect the type of process route 
chosen tremendously, thus, additional modelling was set up to look varying scales of 
annual production of 1kg, 10kg, 1000kg, and 10,000kg. By examining the NPV across 
the different scales of operation, the most suitable for each scale can be identified.
6.5.2 Results and discussion
Tornado diagrams are used to illustrate the sensitivity of the variables on NPV in Fig 6.6.
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Figure 6.6 Tornado diagrams showing the %Change in NPV from the base case for the 
three processes. Plot a) is the manual Roller bottle option, b) is the automated Roller 
bottle option c) is the Stirred tank reactor and d) is the Wave reactor option. (■) denotes 
best case, (□) denotes worst case scenario.
This highlights that the NPV is most sensitive to the cell density in all cases, followed by 
the Cells:ECM ratio and then either, the mesh area (RB routes), or the microcarrier 
concentration (STR and Wave routes). Additionally, it can be seen from the plots, that the
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worst-case scenario has more impact and cause more deviation from the base, than the 
best-case scenario.
Alterations to the cell density achieved in the mesh is a very important factor, since a 
reduction in the cell yield achievable means an increase in the number of RBs required to 
be processed, and thus the costs escalates. The increase in the cell density in the mesh by 
a factor of ten reflects a decrease of RBs by a factor of ten as well, i.e. a reduction of 
80,000 RBs to 8000 RBs. For the Wave Bioreactor, a decrease in the cell density reached 
in suspension by 10-fold, means that the number of runs needed is increased by a factor 
of 10. Therefore, this not only leads to an increase in the direct costs, but an increase in 
the fixed capital costs, since more rocking cradles are needed to meet the sheer number of 
runs needed. This also becomes a case of scaling out rather than scaling up, since the 
largest operating volume the Wave bioreactor can provide is 500L.
A similar situation exists for the STR method since the maximum runs a reactor train can 
process annually are 12 runs. Additionally, the reactor train cannot be too long, as it is 
undesirable to reach high passage numbers, as the cells maybe considered too old. 
Therefore when the cell density drops by 10-fold, the number of reactor trains needed is 
increased in order to meet the necessary number of runs, again, leading to a massive 
increase in fixed capital costs.
Next, it can be seen from Fig 6.6 that the cell to ECM ratio is also very important. In the 
RB situation, this is because it affects the scale of the operation tremendously, and in the 
STR situation, it means more runs are needed when the ratio drops. A similar situation 
also happens in the Wave route. However, the impact is not as drastic when compared to 
cell density. The area of the mesh will also affect the number of roller bottles required. 
Likewise, a similar situation exists with the impact the microcarrier concentration has 
upon the process. Since a reduction in the concentration o f microcarrier means less area 
available for the cells to proliferate and therefore a lower yield so more runs are needed. 
Changes in the sales prices, mesh cost, microcarrier costs and Lang factor only have a 
minor impact on the NPV.
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To further confirm the rankings of the process route, stochastic analyses were carried out 
as described by the next section.
6.6 Stochastic analysis
6.6.1 Setting up the Stochastic analysis
Having identified the key uncertainties in the sensitivity analysis, triangular probability 
distributions were assigned to the key uncertain inputs using the worst and best case 
values as the minimum and maximum values of the distribution. The Monte Carlo 
simulation technique was then used to determine the distribution of possible outcomes for 
the NPV. Since the cost models were set up in Excel, VBA macros were written to allow 
the running of Monte Carlo simulations. 10,000 iterations were used; the running average 
o f the results was monitored to ensure convergence was reached.
6.6.2 Results and discussion of the stochastic analysis
Fig. 6.7 illustrates the cumulative probability distribution plot for the NPV for each 
process route at the 100kg scale. From Fig 6.7, it can be seen that the probability of 
obtaining a negative NPV is greater for the manual RB route than the STR or Wave 
routes. This reinforces that the manual RB route is infeasible at this scale for the 
assumptions made. The automated RB route lies between the manual RB and the bulk 
reactor routes. Further examination of Fig 6.7 illustrates that the STR and Wave routes 
have much narrower NPV distributions implying they are more robust processes.
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Figure 6.7 Cumulative distribution plots of the three options overlapped. (—0 —) denotes 
the automated RB route, (— ♦ —) denotes manual RB, STR, and (— ▲ --) denotes
the Wave route.
Having examined the rankings at the base case demand of 100kg, the impact of scale was 
explored.
6.7 Impact of Scale
6.7.1 Setting up the analysis
Spreadsheets were set up to determine the COG and NPV at demands 1kg, 10kg, 100kg, 
1000kg and 10,000kg. The deterministic impact of the demand on the equipment 
requirements are summarised in Table 6.7. Monte Carlo simulations were then run using 
the triangular distributions identified with the values in Table 6.6 to compute the 
expected COG and NPV and their probability distributions.
I l l
Table 6.7 Impact of demand on the equipment requirements for the Deterministic 
analysis at the varying scales of operation
Annual Output 1kg 10kg 100kg 1,000kg 10,000kg
RB processes
No. of RB s/year 833 8,333 83,333 833,333 8,333,333
No. of roller racks (each 
can accommodate 80 
RBs)
2 15 151 1510 15104
No. of Cellmates 1 2 11 111 1111
B ulk reactor processes
No. of STR process 
trains, and operating no. 
of batches required a 
year
1,1 1,1 1,8 6,
max 12
60,
max 12
No. of WAVE process 
trains, and operating no. 
of batches required a 
year
1,1 1,1 1,8 6,
max 12
60,
max 12
Working volume of 
WAVE/STR reactor
100L 500L 500L 500L 500L
6.7.2 Results of scale analysis
The impact of changing the demand and hence scale of operation on the expected NPV 
and COG is summarized in Table 6.8 and Fig.6.8. Table 6.8 shows that the manual roller 
bottle route can never reach profitability compared to the bulk reactor routes, and the 
disposable Wave route is always more profitable to operate in comparison to the STR 
route at the scales explored.
Interestingly, these results highlight that the ranking of the process alternatives is highly 
dependent on the scale of operation, at the smaller scale the automated RB route is more 
cost effective than the STR and the Wave routes. As the roller bottle systems are very 
easy to set up, thus the obvious advantage of the quicker to market with the RB process 
route makes it quite attractive at the small scale, especially the automated RB process.
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However, adoption of the bulk fermenter routes is much more favourable if the demand is 
higher.
Table 6.8 Impact of changing the scale of operation upon the choice of process routes
Scale
Route Parameter 1kg 10 kg 100kg 1,000kg 10,000kg
mRB
Expected COG 
(£/g) 1561 456 304 284 284
Expected NPV 
(£ million) -7.8 -15.9 -57.2 -468.1 -4689.0
aRB
Expected COG 
(£/g) 1545 292 114 104 101
Expected NPV 
(£ million) -6.5 -6.7 20.3 248.2 2669.0
STR
Expected COG 
(£/g) 3079 749 98 50 44
Expected NPV 
(£ million) -17.9 -35.9 26.6 571.5 6062.9
WAVE
Expected COG 
(£/g) 2165 571 74 43 40
Expected NPV 
(£ million) -12.4 -23.0 42.3 610.6 6293.8
Figure 6.8 shows that as the scale of operation increases, the bulk reactor routes are still 
the most favourable options. The difference at the 10kg scale and 1kg scale for the STR 
route is attributed to the difference in the size of the reactor required. Since for 1 kg 
production, the production vessel required is 100L, but for the 10kg production, the 
fermenter size increases to the 500L working volume. This size was set as the upper 
limit, since to get any bigger requires a long reactor train which was considered an 
undesirable for the primary cell line for making a TE product. Thus as the scale increases 
further, the only option to cope with production is to increase the number of reactor 
trains, rather than the size of the reactor. The Wave bioreactor however, merely uses 
differently sized bags, and the cost difference between the sizes of the rocking cradles is 
not as big as the differences in the cost of the stainless steel vessels for the STR routes at 
the smaller scale.
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Figure 6.8 Ratio of the expected COG/g ratios across the operational scale of 1 kg to 
10,000kg relative to the automated RB route. The bold black line denotes the automated 
RB case and the denotes manual RB, (--■ —) for the STR, and (-- A —) for the
Wave reactor route.
By examining the p(NPV>0) (Fig 6.9), as the scale of operation increases this becomes 
higher whereas at the lower end of the operation, the risk of failure to reach profitability 
is a lot higher. The best the manual roller bottle can ever achieve is -40%  success, 
whereas automation is able to double this and makes it more comparable to the STR and 
WAVE routes.
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Figure 6.9 Plot of the p(NPV>0) vs. output for the various process routes. (♦) denotes 
manual RB, (0) denotes automated RB, (■) denotes STR route, and (A ) denotes Wave 
route.
6.8 Conclusions
In conclusion, from the case study presented, the use of disposable Wave bioreactor 
technology could greatly benefit the process of producing bulk material for skin 
substitute products, and automation can lead to a massive reduction in costs if  the choice 
of roller bottle technology is applied. However, a main limiting factor for these processes 
can be attributed to the general higher cost of media for mammalian cells and longer 
culture duration required, especially when compared to microbial cultures. Thus the next 
chapter examines the process economics for the production of growth factors targeting 
the wound market via microbial routes.
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CHAPTER 7
A ss e s s in g  M a n u f a c t u r in g  s t r a t e g ie s  f o r
GROWTH FACTOR PRODUCTION
7.1 Introduction
Alternatives to skin substitutes for treating chronic wounds include topical application of 
growth factors formulated as either a gel or spray. Growth factors are polypeptides which 
control cellular growth, differentiation and proliferation, and protein production. They are 
also referred to as cytokines and are the mediators of the multiple cellular processes of 
wound healing. Growth factors are required to promote tissue regeneration by inducing 
angiogenesis. The controlled release o f growth factors for tissue regeneration will play a 
strong part as one of the essential technologies of the future in regenerative medicine 
(Tabata, 2003). This chapter evaluates the process economics behind the production of 
growth factors using recombinant technology.
Growth factors have been applied topically to chronic wounds giving variable results, and 
this is partly due to the complexity o f the actions these growth factors or cytokines can 
instigate. Fergerson and O’Kane (2004) reported that by manipulating the various levels 
of the factors TGF-pl, TGF-p2, TGF-P3 and PDGF, healing can be accelerated and more 
impressively, scar-free healing promoted. KGF-2 (Repifermin) developed by Human 
Genome Sciences as a potential treatment for cancer therapy induced mucositis 
demonstrating that KGF-2 contributes towards healing of tissues containing 
keratinocytes. They are currently in Phase 2 Clinical Trials. Additionally, Amgen has 
also completed a Phase 3 clinical trial o f KGF-1, which is similar to Repifermin showing 
the ability of KGF-1 to reduce the duration and incidence of oral muscositis.
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Renovo (Manchester, UK) has a portfolio of therapeutic products targeted at wound 
healing. Among this portfolio are therapeutics based on the use of growth factors. Juvista 
(TGF-P3) and Prevascar (IL-10) are its lead products currently in phase II clinical trials. 
Tissue Repair Company (TRC), a San Diego based pharmaceutical company has focused 
on the development of growth factor therapeutics for the potential treatment o f chronic 
diabetic wounds. The lead product Excellarate is currently in clinical trials.
To date, the only growth factor products to have penetrated the market and have active 
sales are Regranex gel (Johnson and Johnson, New Jersey) and Fiblast spray (Kaken 
Pharmaceuticals Co., Tokyo) (Table 7.1). Regranex (rPDGF) and Fiblast (rbFGF) are 
both single growth factor treatments for foot ulcers and in 2004, they reached sales of 
$160million and ¥3.4 billion respectively. Harding et al. (2002) commented that in future 
growth factors may be administered sequentially or in a combination for increased 
efficacy.
Table 7.1 Production methods used to produce the commercial topical growth factors
Product Company Product and Process 
Description
Cost Year
approved
Sources
Regranex
gel
Johnson and 
Johnson
Topical application 
containing a secreted 
growth factor rPDGF
Kept refrigerated .
Derived from Yeast.
£275 
for a
15g
tube
1998 www.rxlist.com
www.reeranex.com
Fiblast
spray
Kaken
Pharmaceuticals
Topical application 
containing a bound 
growth factor rbFGF
Freeze-dried powder, 
reconstituted upon 
usage.
Derived from E.coli
£60 
pounds 
for a 
500ml 
spray
2001 Annual Report 
from Kaken 
Pharmaceuticals
This chapter characterises and compares the process economics of growth factor 
production in yeast versus E.coli. The critical trade-offs and success factors are identified 
for both single growth factor therapies and multiple growth factor therapies.
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7.2 Case Study Background
The active ingredient in Regranex gel is PDGF (Platelet derived growth factor) and this is 
expressed using the yeast Sacchromyces cerevisiae in a secretory manner. Yeast cells 
possess secretion machinery and the ability to perform post-translational modifications; 
these advantages ensure bioactive product is expressed and simplifies the downstream 
processing. Other growth factors have been produced using E. coli (Meagher et al., 1994; 
Wu et al., 2005), however this tends to result in the formation of inclusion bodies (IBs). 
Advantages are the higher levels o f expression that can be achieved, ease of IB isolation 
by host cell disruption and centrifugation, and the stability of the IBs (Graumann and 
Premstaller, 2006). Unfortunately, inclusion bodies can make bioprocessing difficult and 
increase the number of unit operations (namely solubilisation and refolding) compared to 
the growth factors which can be secreted instead. A process economics study was 
therefore set up to assess the financial impact of the relative merits and limitations of 
processes based on yeast and E.coli expression systems.
The yeast route was further extended to compare production in stainless steel fermenter 
versus disposable Wave bioreactors. The marketed growth factors are currently produced 
in stirred tank reactors. Typically, processes in industry for microbial systems have used 
stainless steel fermenters and not the disposable Wave bioreactor, because of oxygen 
transfer limitations. However, Mikola et al. (2007) reported the use of the Wave 
bioreactor for successful yeast cultivation, and obtained kLa values of 60 h '1, thus a 
process route using the disposable Wave bioreactor was considered as an alternative to 
the stainless steel STR.
The process descriptions were derived from literature searches, and existing approved 
products on the market, Regranex gel and Fiblast Spray. Fig. 7.1 and 7.2 illustrate the 
process flowsheets derived based on the papers published by Chiron Corporation (Barr, 
1998) and British Biotechology Ltd. (Cook, 1992) for the production of PDGF from 
yeast. Additionally, the chromatograpy steps are based on the purification process 
patented by Scios Nova Inc (Shadle, 1994) for bFGF.
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For the E.coli route, the traditional route for inclusion body processing was chosen (Fig. 
7.2). However, there can be other routes; Lee et al. (2006) showed that IB processing can 
be intensified by using chemical extraction compared to the traditional route of 
homogenisation, centrifugation and resuspension for the production of GM-CSF. 
However, it is important to remember that chemical extraction will also have to contend 
with proper waste stream disposal routes, for example, Triton X-100 is toxic to aquatic 
life and must be disposed of through specialist waste contractors.
Seed Fermentation I ;
Clarification;
Centrifugation, discard cells, retain supernatant
Ion-Exchange Chromatography:
SP-Sepharose column
Ion-Exchange Chromatography:
Weak cation exchange column
Inoculum Grow-up:
shake flasks
Hydrophobic Interaction Chromatography:
Phenyl-Sepharose column
Induction o f growth factor 
Growth factor secreted into the media for 6 days
Product Fermentation:
Concentration:
Tangential flow ultrafiltration.
5-10 fold concentration o f supernatant
Figure 7.1 Flowsheet for the production of growth factors using the Yeast route 
(Secretory, STR and Wave)
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Growth factor secreted into the media, 1 day
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Figure 7.2 Flowsheet for the production of growth factors using the E.coli route (Non- 
secretory, STR)
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7.3 Deterministic Analysis
7.3.1 Methodology
Microsoft Excel XP was set up as described by Chapter 5, and a database of required 
information was gathered from contacting vendors and companies. Table 7.2 lists the key 
assumptions made to model the scenario.
Table 7.2 Assumptions for the case base for the three process routes
YEAST-STR YEAST-WAVE E.COLI-STR
Annual Production (g) 600 600 600
Production bioreactor 
size (L)
6000, 4500 
(working volume)
1000, 500 
(working volume)
1000, 750 
(working volume)
Duration of 
Fermentration (day)
6 6 1
Sales Price per gram 
of API (£)
146,666 146,666 146,666
No. of Production 
bioreactors
1 9 1
Total number of 
batches
21 181 2
Titre (mg/L) 10 10 1000
Lang Factor 8.1 4.18 8.1
Overall Process Yield 0.95^ 0.95^ 0.958
In order to determine the scale of operation, the demand was derived based on the annual 
sales of Regranex gel. The number o f tubes sold resulted in the predicted annual demand 
of API of 600g. This was based on the description that Regranex gel tube is 15 g, and the 
active ingredient in the gel is 0.01%.
The sizing of the production reactor was based on calculation of the annual culture broth 
required given the titre, overall yield and the number of batches that could be processed
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in a year. The maximum annual number of batches per process train was determined as 
21 batches for yeast and 24 batches for E. coli based on the duration of the processes and 
the number of working days in a year. Thus if the annual production of 600g could not be 
matched by 1 process train operating at the maximum, the model then increased the 
number of process trains to match this. However, as the Wave reactor has an upper limit 
of 1000L, this meant the requirement of 9 Wave reactors to feed into a DSP chain. For 
the E.coli scenario, because of the possibility of the higher titre, this meant, you could 
have either a bioreactor of 100L, operating 15 batches a year, or alternatively by having a 
1000L reactor, 2 batches would give the required amount. Thus if this forecasted annual 
production of 600g increases the facility could easily accommodate or if only 2 batches 
are required, then consideration of choosing a contract manufacturer could be more 
favourable than building a facility where only 2 batches are required. For the sake of 
comparison for this Chapter, the scenario of operating 2 batches in a facility with 1000L 
reactor was chosen for the E.coli scenario. Fermentation for yeast culture was 6 days 
based on the information published by Cook et al. (1992), and 1 day for E. coli as is 
typical for is. coli processes (Sivakesava et al. 1999, Kim et al. 2007).
Growth factor titres of lOmg/L and lg/L were assumed for the yeast and E.coli routes. 
There values were based on literature sources reporting varying titres for growth factors, 
some as little as 0.62mg/L to 133mg/L for yeast secreted growth factors (Siemeister, 
1996; Joo-Hyung Heo, 2002; Soler, 2003; Barr, 1998; Wu, 2005). Titres reported for E. 
coli generally are in g/L as oppose to mg/L, but ranges of lOmg/L to 9.7g/L have been 
reported for different growth factors. (Soler et al., 2003; Seeger et al., 1995; Hu et al., 
2004)
In order to generate a cashflow to calculate the economic profitability indicator, NPV, a 
perceived sales price was required to determine the income. The sales price per gram of 
growth factor was derived from the sales price of Regranex gel and Fiblast spray. As each 
gel tube for Regranex gel was 15g, and sold for £275, of which 0.01% was the active 
ingredient, this gave the estimated sales price £183,333 per gram for the API. It was
122
assumed that the bulk product would command 4/5 of the sales price of the final 
formulated product.
The Lang factor was derived as described in previous chapters, based on the method, 
reported by Novais et al., (2001). Calculation of overall process yield was simplified by 
assuming 0.95n, where n is the number of unit operations. Thus this takes into account the 
extra steps that the E.coli process consisted of.
7.3.2 Results and Discussion
Comparison o f the economic indicators across the three processing routes showed that the 
E.coli route was the most profitable route with the lowest COG/g, FCI and highest NPV 
and this is mainly attributed to the fact that the E.coli route can achieve the lg/L titre 
mark, thereby decreasing the number of batches required and the size of reactor. This also 
showed the economy of scale. The Yeast-WAVE route was the most unfavourable 
because of the size limitation of the reactor, which meant the increasing the number of 
rocking cradles and the number of batches required. The Yeast-STR had the higher FCI 
due to the higher Lang factor but when compared to the WAVE there is the reduction in 
COG/g and higher NPV which showed the benefit of the economies of scale, whereby 
less batches are required.
Table 7.3 Summary of COG/g, FCI and NPV across the three routes
COG/g (£) FCI (£ millions) NPV (£ millions)
Yeast-STR 17,202 35.3 302.5
Yeast-WAVE 45,363 25.5 235.4
E.coli- STR 5,656 11.7 345.8
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7.3.2.1 Total Equipm ent Purchase Costs (TEPC)
Examining the breakdown of the equipment costs in terms of ratios as shown by Fig 7.3 
indicated that DSP formed the majority of the cost for the STR options when compared to 
the Wave option. The difference between the Yeast-STR and E.coli-STR was due to 
higher titre of the E.coli and this was examined further in the sensitivity analysis. Yeast 
WAVE had the higher USP when compared to the Yeast STR was due to the requirement 
of 9 production bioreactors versus one production reactor.
a) Yeast-STR b) Yeast-WAVE
A U X AUX
5%
DSP
74%
c) E.coli-STR
Figure 7.3 Breakdown of the equipment costs for the three processing routes, a) Yeast- 
STR, b) Yeast-WAVE, and c) E’.C6>//-STR. USP = Upstream processing equipment, DSP 
= Downstream processing equipment, and AUX = Auxiliary equipment.
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1 3 .2.2 Annual COG/g
The breakdown of the annual COG/g in terms of direct and indirect costs for the three 
process routes is shown by Fig. 7.4. The ratio o f direct to indirect costs is dominated by 
the indirect costs for the Yeast-STR (17:83), and E.coli-STR (3:97) routes whereas direct 
costs dominate in the Yeast-WAVE route (71:29). This is due to the disposable nature of 
the Yeast-WAVE route which lowers the FC1 and hence the indirect costs whilst also 
increasing the materials costs due the increased use of Cell bags, and other miscellaneous 
costs such as general tubing usage. The higher indirect costs in the stainless steel routes 
are a reflection of the higher FCI required. The lower direct costs contributions in the 
E.coli STR route relative to the Yeast-STR route can be attributed to the higher titre 
which allows for the lower number of batches and smaller reactor size and culture.
E.coli-STR
Yeast-STR
Yeast-WAVE
0% 25% 50% 75% 100%
Figure 7.4 Comparison of the direct to indirect costs across the three routes with (■  ) 
Materials, ( D ) Labour, (a  ) Utilities and ( 1=1) Indirect costs.
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7.3.2.3 Direct COG/g
Breakdown of the direct costs onto a task basis (as shown by Fig 7.5) revealed that CIP 
and SIP were dominant costs. Although there is a reduction in the costs of the Yeast- 
WAVE route but the inflated costs of the upstream and higher media prep costs can be 
observed due to the need for 9 WAVE bioreactors working at full capacity. Thus this 
showed the economy of scale for the stainless steel route.
Yeast-WAVE
Yeast-STR
Figure 7.5 Annual direct cost of goods/g on a task basis for the Yeast-STR vs Yeast - 
WAVE.
Fig 7.6 shows the distribution of the direct costs between upstream (USP), downstream 
(DSP) and ancillary (ANC) activities. The breakdown ratio of the costs was very similar 
for both E.coli-STR and Yeast-STR. For the Yeast-WAVE there was the reduction in the 
ancillary unit operations cost which was balanced by the increase in the costs for USP.
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a) Yeast-STR b) Yeast-WAVE
c) E.coli-STR
Figure 7.6 Breakdown of the direct costs in terms of Upstream (USP), Downstream 
(DSP) and Ancillary (ANC) activities.
Overall, although the cost with E. coli route was the lowest, there was the uncertainty of 
how bioactive the product will be whereas the yeast route should give a bioactive product 
due the nature of the yeast organism possessing post-translational machinery. Thus 
sensitivity analysis on the effect of titre was carried out on the process routes that used 
yeast. Additionally, the effect of changing the scale of operation was examined, such as 
what happened when the scale doubled or halved.
7.3.3 Sensitivity Analysis
Sensitivity analysis was undertaken to examine the impact of titre upon the process routes 
as titre was a critical process economic driver. Additionally, the annual demand affects 
the scale of operation, and the number of batches required per year. Therefore the process 
models were used to examine what happened if the demand was halved, or doubled.
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Again, for the process models, the variables: fermenter size, and no. of reactors and the 
number of batches changed in response to the changes in demand or titre.
In the base case, the yeast routes were assumed to achieve a titre of lOmg/L, however, 
yeast expression systems have improved over the years, and typically result in much 
higher protein titres, with typical values of 4g/L for S. cerevisiae and 15g/L for P. 
pastoris being reported (Werner, 2005). The sensitivity analysis explored the impact of 
the following titires in the yeast routes: 1, 10, 100, and lOOOmg/L.
The impact of increasing titres in the facility size and running costs is summarised in 
Table 7.4. Increasing titre has a dramatic impact on the fermenter capacity required and 
moving from 1 to lOOOmg/L decreases the annual capacity from 775,413L to 775L.
Table 7.4 Impact of Titre on the USP:DSP (COG/g) ratio, and direct to indirect costs
(COG/g)
Titre (mg/L) 1 10 100 1000
Annual capacity required 
for the yeast routes (L)
775,413 77,541 7,754 775
Yeast-STR
Reactor size (L) 6000 6000 1000 1000
No. of batches 173 18 11 2
No. of reactor trains 9 1 1 1
Direct:Indirect ratio 25 : 75 17 : 83 14 : 86 3 : 97
USP:DSP ratio 16: 84 19 : 81 48 : 52 46 : 54
Yeast-WAVE
Reactor size 1000 1000 1000 1000
No. of batches 1551 156 16 2
No. of reactor trains 74 8 1 1
Direct:Indirect ratio 87 : 13 71 : 29 21 : 78 4 : 96
USP:DSP ratio 9 8 :2 87 : 13 3 9 :6 1 36 : 64
E.coli-STR
Reactor size
N/A
1000
No. of batches 2
No. of reactor trains 1
Direct:Indirect ratio 2 : 98
USP:DSP ratio 28 : 72
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For the Yeast-WAVE route, as the titre increased, the focus of the cost shifted from USP 
to DSP. This trend has been observed for monoclonal antibody production; Sommerfeld 
and Strube (2005) showed that increasing the fermentation titre 10 fold from 0.1 g to 
lg/L caused the ratio of USP:DSP to change from 55:45 to 30:70. The Yeast-STR does 
show this increase in DSP when comparing the O.lg to lg/L, but not for the lmg/L and 
lOmg/L and this was due to the changes in the number of batches, and size of 
fermentation. However, DSP is more of a dominant factor the Yeast-STR routes, as the 
ability to operate large tank sizes for the USP meant economy of scale. Overall, DSP cost 
more for the E. coli than the yeast routes because there are more DSP unit operations 
when compared at the same titre.
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Figure 7.7 COG/g for the three process options across titres. The solid line represents the 
STR-yeast and the dotted line is the WAVE-yeast. The symbol x marks the STR-E.coli 
option.
Additionally, the ratio of direct to indirect costs shifted towards indirect costs as the titre 
increased, simply because, as the number of batches decreased, process trains are
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decreased, and therefore the ratio of amount of direct costs decreased more dramatically, 
as opposed to the indirect costs.
Fig.7.7 shows the impact of changing the titre on the cost of goods. As the titre increased, 
the COG/g is reduced and there is a rapid change initially, and then a plateau is reached. 
Indeed, when the titre goes beyond lOOmg/L, the yeast processing routes are equally 
favourable as the E.coli route. Interestingly, above the lOOmg/L, the Yeast-WAVE route 
is more favourable than STR-routes, as the FCI is lower for the Yeast-WAVE route due 
to the ease o f installation of the flexible disposable fermentation system in comparison to 
the amount of stainless piping that is required for the STR routes.
The NPV analysis also showed the impact when the demand doubled or halved at the 
various titres. Fig. 7.8 presented the effect of titre upon NPV across the different scales 
for the STR-yeast route, and the Wave-yeast route as tornado plots. The general trend 
showed that for both STR and WAVE routes, as the demand rose, the effect o f the titre 
was more prominent, and when demand was halved, the impact o f titre was not as great. 
Additionally, with increasing titres, this meant less batches are required, thus this in 
effect, frees up time in the facility for other campaigns of other products.
a)Yeast-STR b)Yeast-WAVE
1000mg/L mm 1000mg/L
■ r i 1 OOmg/L lOOmg/L
1__MM lOmg/L a  ; lOmg/L
lmg/L ntmmmmm^ m lmg/L
-100 0 100 200 300 -100 0 100 200 300 400
% Change in NPV % Change in NPV
Figure 7.8 NPV for the a) STR-Yeast and b) WAVE-yeast across titres and 
demonstrating the effect of demand upon the NPV. |  denote doubling of the demand 
and Q  denote halving the demand.
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An additional consideration would be the scenario of multiple growth factor applications, 
since culture supernatant from human dermal fibroblasts has been used as a potential 
treatment in wound healing or as anti-ageing products. The culture supernatant contains a 
cocktail o f growth factors, examples of such products being commercialised are Epigrow 
(Clinical Cell Culture C3, Australia), Retivitx (Organogenesis US), Bio-restorative skin 
cream with PSP (Neocutis, Inc, US). Thus the next section examined the process 
economics of multiple growth factor application and compared this to the TE approach 
using dermal fibroblasts.
7.3.4 Multiple growth factor production
It was estimated that Dermagraft possessed 15 different growth factors thus this was 
compared to the microbial approach of producing 15 different growth factors in a multi­
product facility. As the levels of growth factors in the skin-substitute product were not 
fully identified or known, to rationalise the comparison, it was assumed that 8 patches for 
treating a chronic ulcer were equivalent to 56g of growth factor gel. (See Appendix C for 
full details on assumption). Thus by comparing to the 100kg of ECM matrix production, 
this meant that the annual amount of growth factor to be produced would be 15 lots of 
95g each growth factor. From this, it was calculated that a 200L reactor was required for 
fermentation, to process -120L to 150L for each batch o f growth factors. For the 
calculation of the NPV, the sales prices was assumed at the worst case scenario where the 
tube would still be sold for the same price, but containing 15 growth factors instead of 
one. This was calculated to be £9777 per gram of growth factors. [£275 for 15g tube, of 
which 0.15% contains the growth factors rather than 0.01%]
Table 7.5 presents a summary of the results of the multi-growth factor analysis. It 
displays the economic parameters, and shows that a multi-growth factor facility is very 
economically feasible and the most profitable route would be to go down the disposable 
route.
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Table 7.5 Multi-growth factor production via the 3 production routes
E.coli-STR Yeast-STR Yeast-WAVE
Inputs
Titre (g/L) 1 1 1
Number of GFs 15 15 15
Lang Factor 8.13 8.13 5.44
Reactor size (L) 200 200 200
Sales Price (£) 9,777 9,777 9,777
Economic parameters
Number of reactor 1 1 1
Total number o f batches 15 15 15
COG/g (£) 2,473 2,523 2,049
FCI (£ millions) 10.6 10.3 7.3
NPV (£ millions) 36.9 36.8 41.5
From the results presented by Table 7.5, the most favourable route for multi-growth 
factor production would be the Yeast-WAVE route, followed by the Yeast-STR and 
finally, E.coli-STR. Thus the results show that if  the titre was the same, yeast was 
preferable to the E.coli route. Furthermore, utilising the disposable WAVE route would 
need the reduction of CIP and SIP for the upstream processing, which is very attractive 
especially when producing 15 lots of different growth factors. The FCI is the highest for 
the E.coli-STR route because of the extra unit operations when compared to the yeast 
route.
NPV across the three routes are very similar, and the COG/g values are the same order of 
magnitude. As the Yeast-WAVE has the most positive NPV, and the lowest COG, this 
would indicate the Yeast-WAVE would be the most ideal route to choose. However, this 
would be dependent on achieving the necessary titre in the fermentation culture, and 
concerns with oxygen transfer limitations and being dependent on a sole supplier for the 
cellbags would mean choosing the Yeast-STR route.
Comparison of the NPV for the microbial growth factor approach to the TE-ECM 
approach from the previous chapter showed that making several growth factors from the 
microbial approach and recombining to form a growth factor gel was not as favourable.
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Table 7.6 summarises this and shows that they are in the similar region with a positive 
NPV.
To a certain extent, the NPV values are dictated by the sales price, thus instead of taking 
the worst case scenario for the price of the growth factor, this would then make the 
growth factor production using the microbial approach more favourable than the TE 
approach. However, the NPV values indicated that production of growth factors was 
commercially possible.
Table 7.6 Summary of the COG and NPV values for the different approaches
Annual
COG
(£millions)
NPV (£millions)
Automated
RB-TE
9.7 29.9
STR-TE 7.4 38.4
WAVE -TE 5.1 53.4
E.coli -STR 3.5 37.0
Yeast -STR 3.6 36.8
Yeast -W AVE 2.9 42.5
7.4 Conclusions
From the process simulation models, this shows that if  the titre of growth factor for the 
yeast processing route was above the lOOmg/L, then the process economics are more 
favourable than the IB processing route using E.coli, even when demand doubled. Indeed, 
assessing which processing route to take would probably depend on whether the growth 
factor produced via the E.coli IB route have the necessary bioactivity, otherwise, the 
default choice would be the yeast processing route.
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If the plant was to be making multiple growth factors then the disposable yeast 
processing route would be more favourable, however, the risk of only having a sole 
supplier for the cell bag would mean that the traditional STR route was chosen. For 
production o f growth factors aimed at treating wound-healing, the multifactorial 
complexity that exists means that combinations of growth factors would be the more 
desirable option. However, the analysis showed that to make the same number of 
different growth factors via the microbial approach was not as economically favourable 
as using the dermal fibroblasts to produce to the range of growth factors, but the 
difference was not as dramatic as imagined.
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CHAPTER 8
R e g u l a t o r y  Is s u e s
8.1 Introduction
This chapter examines the regulatory issues that are faced by the TE-products. The 
pioneering skin-substitute products first brought to market cited that regulatory barriers 
were one the main reasons for high cash-bum rate and by falling into the gap between the 
definitions o f a medical device/drug meant significant delays in obtaining approval 
(Naughton, 2001, Bouchie, 2002). There is a comprehensive need to prove the safety and 
efficacy of these cell-based therapy products and this presented a major challenge to the 
companies as well as the regulating bodies, but clearly, the ‘one size fits all’ solution 
does not apply and the clear guidelines needs to be established.
8.2 Autologous vs Allogenic
The first critical component to be decided in these TE-products will be the identification 
o f cell source: autologous vs allogenic. This will affect the manufacturing route, and the 
commercial strategy taken by the company, and additionally what regulatory path to take. 
Material from other mammalian sources has also been used in humans (xenogenic) but 
this has its potential risks (e.g. transmission of viruses crossing the species barrier). 
Autologous means using the cells obtained from the patient whereas allogenic focuses on 
the use of one or few donors to generate a supply for others. The autologous route is 
considered the more straight forward route because it is easier to comply with the 
regulatory and safety requirements in comparison to the allogenic route. By following the 
autologous route, this becomes more like a service based industry, and the patient 
actively seek out the treatment and relocate to the treatment centre, whereas the allogenic 
route will mean the product is transported to the patient, probably in the cryopreserved 
format. Autologous products are unlikely to require any long term tissue storage and thus
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cold preservation is likely to suffice. The allogeneic route offers the relative compatibility 
to large-scale manufacturing at single sites and part of the regulatory costs will be to 
prove the safety o f cell banking and expansion.
8.3 Regulatory frameworks
There is no specific regulatory framework for TE-products in the UK currently but 
reference should be m ade to the guidance document, A Code o f  practice fo r  the 
production o f  H um an-derived therapeutic products, 2002. It seems the situation in the 
UK is reviewed on case by case. Additionally, the Department o f Health have produced 
certain reference documents, which advises on the various actions required. The 
Guidance on the Microbiological Safety o f  Human organs, tissue and cell used in 
Transplantation, 2000, and A Code o f  practice fo r  tissue banks -  providing tissues o f  
human origin fo r  therapeutic purposes, 2001 should be consulted.
The announcement o f the Regulation o f  Advanced Therapies: Tissue Engineering, Cell 
therapy, and Gene therapy  on 16th November 2005 by the EC means a clearer way 
forward for the companies to take. The provisions in the proposal were that TE-products 
falling within the definition of medicinal product are to be regarded as advanced 
medicinal therapy product and grouped with gene therapy, and somatic cell therapy. The 
TE-product is defined as containing engineered cells or tissues and is presented to have 
properties o f treating or preventing disease in humans. It is proposed that a centralised 
Community marketing authorisation would apply, and a Committee for Advanced 
Therapies (CAT) should be established to give scientific advice on advanced therapy 
medicinal products.
In the US, the FDA has grasped the implications o f creating and implanting a product that 
contains cells as well as biomaterials and regulates on a case-by-case basis. In 1998, 
Genzyme’s Carticel was launched where chrondral cells removed from the patient are 
cultured and then reintroduced to repair the cartilage defect, marketed as a surgical 
device. The FDA had it withdrawn until a biologic license application had been made. 
Fig. 8.1 shows the blueprint for the FDA’s approach to regulating human cell and tissues
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in its Proposed Approach to Regulation o f  Cellular and Tissue-Based Products released 
in 1997. This document also outlines the determination of donor suitability. Additionally, 
proposed rules for good tissue practice and final rules on establishment registration and 
listing were issues in 2001.
Figure 8.1 Flow-chart to determine the regulatory pathway (361 HCT/P or 351 HCT/P).
A 361 HCT/P must comply with the tissue rules. A 351 HCT/P must comply with the 
tissue rules and premarket approval authorities (BLA/PMA). (Darin Weber, 2004)
In 2002, the FDA established a specific Office of Combination Products. The FDA’s 
Tissue Reference Task Group will assess the product’s primary mode of action and thus 
decide which agency (CBER, CDER, or CDRH) will take the lead in the regulation of the 
product. Additionally, the FDA also decided that should the TE-product contain 
biopharmaceuticals such as growth factors, cytokines, enzymes or immunomodulators, as 
well as cells and biomaterials it will be assessed by all three centers.
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Implications of the regulatory frameworks will ultimately dictate the level of revenue the 
company can make. In the States, if  classed as a biologic rather than a device, then 
reimbursement is available at the Average Selling Price plus 6%, allowing the customers 
to make some money upon acquisition of the product. This enhances product penetration 
into the market, plus additionally, under Medicare, procedures codes are billed in the 
region of $400-700 for the level o f debridement or surgical prep needed. This makes the 
use of the products more profitable for the centres, and ultimately leads to product 
uptake.
8.4 Conclusions
Although the microcarrier cultures could generate the biomass which could be formulated 
into gel, the problems with aggregation in culture makes the monitoring o f cell numbers 
very difficult and therefore compromising the ease of culture. From a regulatory point of 
view, this could cause problems, as the need to demonstrate control o f process is 
required. Thus ability to link the amount of nutrients are utilised by the cells and more 
understanding o f this could help then form a correlation between nutrient usage to cell 
numbers over the progress of the culture to demonstrate the necessary control o f process. 
However, because o f the varying regulatory burden from country to country, this makes 
the marketing of tissue-engineered products hard, and as such, until more rules become 
defined, charting uncertain territory will be one o f the key risks to be faced.
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CHAPTER 9
F u t u r e  W o r k
9.1 Introduction
As Archer and Williams (2005) wrote, it is time to study tissue production from an 
engineering point o f view. There is the need to consider what type of automation could be 
applied to each case. The application of economic modelling to enhance the decision 
making has been demonstrated here and could be applied to other tissue-engineered 
products. Depending on which organ is to be produced, the need to develop scalable 
automated systems for manufacturing will always exist. This chapter summarises the 
conclusions drawn from the previous chapters and points out the future developments that 
could further enhance the quality o f decision making, and the path for companies to take.
9.2 Summary of the technical and future work
The work in this thesis demonstrated that microcarrier culture is a viable and efficient 
way of culturing human dermal fibroblasts to generate extracellular matrix on a large 
scale. The use o f microcarriers opens up the variety of reactor configurations to give 
space savings and more efficient media utilisation, and ultimately a route for automated 
manufacture.
Future work is recommended to evaluate the potential of microcarrier culture for the cell 
expansion for other cell types. Critically, overcoming or controlling the aggregation that 
occurs would be required for this approach to ensure reliable measurements and thus, to 
have greater control. Ways to reduce the aggregation may be to alter the media utilised, 
impeller design and speeds. This could be coupled to shear studies to fully understand the
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flow profiles and avoid applying lethal stresses. The shear studies could also help explore 
aggregation studies. By controlling the level of shear applied, it may be possible to 
reduce the aggregation and also to stimulate growth and extracellular matrix production 
of the cells. Furthermore investigation into possible methods for improving the 
monitoring capabilities would be useful with the aim of more automated online 
monitoring.
Further investigation into the optimal culture duration is required. This would require 
clinical data on the required levels of collagen and growth factors for wound-healing. If 
collagen is not the most critical component, then it may be possible to shorten culture 
time. This would result in a more cost-effective option, a reduction in the risk of batch 
failures due to contamination, and allow more repeatable robust batches.
Different microcarriers were explored in this thesis: commercial smooth discs and 
microporous spheres, and biodegradeable discs made in-house. It would be ideal to work 
with a commercial biodegradable microcarrier that is designed to similar density to that 
of cells, or different degradation profiles to fit the culture time required. At present, no 
commercial biodegradeable microcarriers exist and so further studies on creating ones 
with robust characteristics would be useful. Indeed, having the microcarriers as 
biocompatible constructs would further reinforce the principle of the ‘the process is the 
product’.
The need for serum-free culture is required, and a process that avoids the use of raw 
materials of animal origin would be favoured by the regulatory authorities. Future work 
could investigate the nutrient needs of the cell line, and apply metabolic pathway analysis 
to determine the correct medium formulation at the right time. Application of factorial 
design to find the optimal conditions for growth and production of growth factors by the 
cells would be desirable. This would help define an operating space. Due to the high 
expense of these materials, scaling down to using microwells would be beneficial, 
especially when discovering the best media formulation. Therefore incorporating the
140
concept of quality by design to the design of these processes would also help to cope with 
the regulatory burden and risk.
9.3 Economic analysis summary and modelling improvements
The analyses presented in Chapters 6 and 7 highlighted the importance and benefits of 
linking technical data with process economic modelling to allow more rigorous 
evaluation o f various production methods that could be adopted. Chapter 6 presented an 
economic analysis o f different bioreactor designs for generation of skin substitute in the 
form of bioactive extracellular matrix (RBs, STR, and the disposable Wave bioreactor). 
This highlighted the advantages of using disposables such as the Wave bioreactor, to 
lower the initial upfront cost and thus allow the spread of the risk over the lifetime of the 
process as running costs. This is particularly attractive for an industry which many 
consider to have the risks of biopharmaceuticals and the profit margins of devices. If the 
regenerative medicine market were to adopt a service-based business model then the 
scale o f operation would indicate the use of automated RB type reactor processing route 
as this would be operating at the smaller scale of the spectrum, where speeding up 
production and trying to apply the ‘just-in-time’ manufacturing philosophy would be 
more appropriate. However, solving the transportation and storage issues would indicate 
the bulk scale up method where there would be a centralised manufacturing site and a 
distribution network of smaller warehouses/medical centres/hospitals.
Chapter 7 examined the process economics for the production of growth factors using 
recombinant technology (yeast vs E. coli) as alternatives to skin substitutes. Critical titre 
levels that needed to be reached in each expression system were identified. For treatments 
requiring multiple growth factors the recombinant production route was compared to 
using dermal fibroblasts to generate the growth factors. The latter route appeared more 
favourable though the difference was not as dramatic as imagined.
Final formulation costs were not included in the modelling, and this could be expanded 
upon. Additionally, sales and distribution costs were assumed to be 30% of the sales
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revenue based on the rule of thumb from chemical engineering cost appraisals. However, 
from discussion with experts in the industry this figure could be as high as 70% due to 
the need to ship at constant temperature and within a certain timeframe. Discussion with 
courier companies, and examining the technical processing required would allow 
sufficient modelling of this step. There is the need to consider the logistics for a 
distribution network required and the costs involved. Additionally, rules and regulations 
for shipping, certain security measures could impact upon the product in transit, all this 
will incur costs which should be modelled. Discussion with industry on pricing models 
would allow more precise prediction o f NPV, once additional costs for formulation are 
included.
Simplification of implementation o f the studies meant omission of certain factors. 
Namely, process validation and quality control activities were not modelled to the same 
extent as, say, direct materials cost. The need to have realistic estimates from industry as 
input in to validation is required.
Development of more sophisticated modelling software will allow more rigorous 
modelling of the manufacturing activities such as tracing the exact fermentation profile 
based on experimental data to calculate the media utilisation with more precision and 
future work could incorporate more risk analysis to assess uncertainties such as 
contamination rates, batch failures, and delays in a unit operation extending processing 
times. It is envisioned that such modelling efforts will become a critical component of 
process design when considering the needs of manufacture.
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APPENDIX B
This section provides a full description of the various protocols and assays mentioned in 
Chapter 3.
B l: Protocol for resurrection of frozen cells:
This protocol thaws one vial o f (HuFFs) human dermal foreskin fibroblasts and seeds the 
cells into lxT75 flask.
Record date thawed:
Passage 5, Date______________(Vials frozen at P5, so the first passage will be P6.)
Pull the following media for passaging o f the cells from the fridge prior to obtaining the 
vial:-
Complete DMEM medium, stored at 4°C , subsequently warmed to room temperature. 
Procedure:
1. Using a 25ml pipette, add 15 ml o f complete medium to the new 1 x T75 flask 
[Coming, Cat#430825, vented cap]
2. Label flask with HuFFs, passage number, initials, and date.
3. Place the flask into the CO2 incubator to equilibrate.
4. Turn the water bath on and set to 37°C.
5. Remove one vial from frozen, liquid nitrogen storage and place the vial into the 
styrofoam container of dry ice/normal ice. Transfer to the lab as soon as possible.
6. Rapidly thaw the vial in a 37°C in the water bath by a swirling motion for about 
2-3minutes. Avoid submerging the vial cap to avoid contamination from the 
water, which can travel up the wick threads. Wear a face shield during thawing. 
Time started thaw ing:_________________ am/pm
Time completed thaw ing:________________ am/pm
7. Wipe the vial with a tissue soaked in 70%(v/v) prior to opening.
8. Quickly transfer the cells to a 10ml centrifuge tube and add cold (4°C) complete 
medium slowly up to a total volume of 10ml.
9. Spin the cells in the Megfuge 1 .OR (Heraeus) at lOOOrpm (300g) for 5 minutes at 
4°C.
10. Remove the supernatant.
11. Gently resuspend the cells in 1ml pre-warmed complete medium by aspirating 
through a plugged sterile Pasteur pipette. Then further dilute the cell suspension 
to 5ml.
12. Now take a sample to assess the cell number and viability. (0.5 to 1ml sample)
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13. Now bring the 1 x T-75 flask from the incubator and add the cell suspension, thus 
the total volume in the flask is ~ 20ml.
14. Incubate at 37°C.
B2: Protocol for passaging and maintenance of cells:
This protocol passages 1 xT-75 flasks to 4 x T-75 flasks using a 1:4 split ratio. Any 
combination can be substituted and at 1:3 or 1:4 split ratio, confluent cultures are 
achieved after 2-3 days. A 1:6 split ratio will generate confluent cultures after 4-5 days.
Record the passage number and date. Passage , Date____________________
Reagents:
Complete DMEM medium 
Trypsin/EDTA
DPBS without Ca2+ and Mg2+, [Sigma Cat #D8537]
Procedure:
1. Add 17.5ml of complete medium to the new 4 x T-75 flasks
2. Label the flasks with HuFFs, passage number and date
3. Place the new flasks into the 37°C, 10%CC>2 incubator.
4. Remove the 1 xT-75 flask from the incubator. Time removed from 
incubator:________ am/pm
5. Observe the cells under the microscope and check for confluency, absence of 
microbial contamination, abnormal pH, excessive detached cells, or degeneracy of 
the cell monoloayer.
6. Remove the spent tissue culture medium from the tissue culture flask. Take a 
sample o f this.
7. Add 10ml of DPBS to the flask to rinse the sheet.
8. Remove the DPBS and discard.
9. Add 3ml of trypsin/EDTA. Rinse trypsin/EDTA over the cell growth surface and 
allow the flask to sit for about 5minutes. Occasionally rock the flask to ensure the 
even coating of trypsin. Inspect the cells frequently to observe the rounding up of 
the cells and lifting from the plastic.
Start time of trypsinization:__________________ am/pm
10. Gently tap the flask to dislodge the cells
11. Add 10ml of complete medium to the flask to quench the trypsin activity.
Time quenched:_______________________ am/pm
12. Transfer the contents of the flask to a 10ml centrifuge tube and spin at lOOOrpm 
(300g) for 5 minutes in the Megafuge 1.0R (Heraeus) at 4°C.
13. Remove the supernatant above the cell pellet
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14. Add 1 ml of the complete medium to gently re-suspend the pellet
15. Add 10ml of complete medium to the cell suspension to make up the required 
volume.
16. Take 2.5ml o f cell suspension and inoculate the 4 x T-75 flasks.
17. Using the remaining 1ml for cell counting.
B3: Protocol to determine the level of ammonia present in the media samples: 
Reagents:
Sodium phenate solution -  2.5g sodium phenate, 80mls of UHQ water, 7.5ml o f 4M 
NaOH. Make up to a final volume of lOOmls using UHQ water.
Sodium nitroprusside stock solution -  1% w/v sodium nitroprusside in UHQ water. 
Dilute to 1/100 (v/v) to use in assay.
Sodium hyperchlorite solution -  1.25ml o f sodium hypochlorite solution (10-14% 
w/v). Make up to lOOmls in UHQ water, -0.02M  in water.
Ammonium chloride standards -  Make up lOmM NH4CI as stock solution. Then in 
1.5ml eppendorfs, make a range of standards from 0 to 3.5mM concentrations, as 
shown in the table below.
Standards
(concentrations mM)
Microlitres o f 1 OmM 
NH4CI
Microlitres o f water
0 0 1 1000
0.5 50 950
1 100 900
1.5 150 850
2 200 800
2.5 250 750
3 300 700
3.5 350 650
All reagents were obtained from Sigma, UK.
Procedure:
Add the reagents in the following order and quantity into the wells of a microplate:
1. Sample/standard 8pl
2. Sodium phenate solution 80pl
3. Sodium nitrusside working solution 120 pi
4. Sodium hypochlorite solution 120pl
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Wrap the plate with foil immediately after the addition of the sodium hypochlorite 
solution and incubate for 30mins at room temperature. Read the plate at 640nm.
B4: Protocol to determine the level of VEGF present in the media samples: 
Reagents:
The Capture antibody is goat anti-human VEGF and is diluted with PBS.
The Detection antibody is biotinylated goat anti-human VEGF and diluted with 1% BSA 
in PBS, pH7.2-7.4 and 0.2pm filtered.
Streptavidin-HRP is diluted with 1% BSA in PBS, pH7.2-7.4 and 0.2pm filtered.
Standards are recombinant human VEGF and reconstituted and diluted with 1% BSA in 
PBS, pH7.2-7.4, 0.2pm filtered.
(The above 4 reagents are obtained from R&D Systems Cat. DY293, and prepare to the 
working concentrations as according to the instructions leaflet that comes with it.)
Substrate solution =1:1 mixture of Colour reagent A (H2O2) and colour reagent B 
(Tetramethylbenzidine) (R&D Systems, cat. DY999)
Stop Solution = 2N H2SO4 (Sigma, UK)
Block Buffer = 1% BSA, 5% Sucrose in PBS with 0.05% NaN3.
Wash Buffer = 0.05% Tween 20 in PBS (pH7.2-7.4).
Procedure:
1. Coat 96-well plate (e.g. COSTAR EIA plate Cat. No. 2592, or Nunc 
immunoplate) with 1 OOpl per well with the diluted capture antibody. Seal the 
plate with cling film and incubate overnight at room temperature in a humidified 
chamber.
2. Remove the capture antibody by washing the plate with Wash buffer. Wash three 
times to ensure the removal of the capture antibody. Invert the plate and blot 
against clean paper towels.
3. Cover the plates with 300ml per well o f blocking buffer and seal with cling film 
and place in the humidified chamber overnight in the cold room or in the 
refrigerator.
4. Remove the block buffer by washing the plates with the wash buffer. Wash three 
times. Invert the plates and blot against paper towels as before.
5. Add lOOpl of the sample/standards into the designated wells in the plate. Cover 
with adhesive strip and incubate for 2 hours at room temperature.
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6. Remove the sample/standards by washing the plates with the wash buffer. Wash 
three times. Invert the plates and blot against paper towels as before.
7. Add lOOpl of the Detection antibody to all wells in the plate. Cover with new 
adhesive strip and incubate for 2 hours at room temperature.
8. Remove the detection antibody by washing the plates with the wash buffer. Wash 
three times. Invert the plates and blot against paper towels as before.
9. Add lOOpl o f the diluted Streptavidin-HRP to all wells in the plate. Cover and 
incubate for 2 hours at room temperature away from direct light. (Advisable to 
cover with foil, and try to avoid light as much as possible).
10. Remove the Streptavidin-HRP by washing the plates with the wash buffer. Wash 
three times. Invert the plates and blot against paper towels as before.
11. Add 1 OOpl o f the Substrate solution to each well, and incubate for 20min at room 
temperature in the dark.
12. Add 50pl of Stop solution to each well. Gently tap the plate to ensure the
13. colour formation on the plate is homogeneous and the read the plate immediately 
at 450nm and either 540nm or 570nm. Then subtract the reading at 540nm/570nm 
from the 450nm, to take into account of optical imperfections on the plate.
NB. The washing steps must be observed to ensure good results.
B5: Protocol for LIVE/DEAD staining: 
Reagents:
LIVE/DEAD stain - Add 20pl of the ethidium dibromer and 5 pi of calcein AM to lOmls
o f PBS. (Molecular Probes, Cat. No. L3224, Lot No. 02E2-1).
Procedure:
1. If the sample is from the bioreactor, gently pipette it into a six-well plate.
2. Remove the spent media from the sample, and rinsed with PBS.
3. Then add the LIVE/DEAD stain incubated in the dark in the incubator at 37°C for 
30minutes.
4. Remove the stain by aspirating it off and gently cover the sample with PBS.
5. View under the confocal microscope using fluorescence.
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B6: Protocol for the preparation of the SEM samples
Reagents:
PBS
Formalin
100% ethanol, make a series of alcohol solutions, of 10%, 20%, 30%, 40%, 50%, 60%, 
70%, 80% and 90%.
Procedure:
1. Remove the media using a pipette and rinse with PBS to ensure removal o f media.
2. Fix the sample by addition o f formalin, (diluted at 10 parts PBS and 1 part 
formalin), and leave to fix for 2 hours.
3. Rinse 3 times with PBS, and then proceed with the alcohol rinses. (Taking it 
through an alchol dehydration series)
4. Rinse with 10%, 20%,30%,40%, 50%, 60%, 70%, 80%, 90%, and finally 100%. 
Leave it to soak for 20minutes between rinses.
5. Then final three rinses in 100% ethanol ans leave for overnight in 100% ethanol.
6. When ready to use, remove most of the alchol with pipette. Air dry and ready for 
SEM.
B7: Protocol for the preparation of the histology samples
1. Dehydrate the sample through an alcohol series, by rinses from 10% through to 
100% ethanol.
2. Processed in wax and embedded by placing the sample in chloroform first, leave 
for an hour and carry out three chloroform changes. This is to remove any traces 
o f moisture.
3. The using wax at 60°C, place sample into the wax for an hour, and carry out two 
wax changes. Use the R.A. Lamb embedding centre.
4. Allow the wax to solify, and samples can be processed when desired.
5. Using the Leica RM2165 rotary microtome, slice sections at 5micon thick. Float 
these out onto the waterbath at 45°C.
6. Each slides can put up to two sections.
7. Then load the slides once it is dry. Load the stains desired into the Autostainer.
8. Hit start button and collect the slides later for microscopy.
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B8: Protocol for the MTT Assay:
Reagents and prior preparation:
Establish the test cultures in 96-well microtiter plates using 0.2ml of growth medium and
up to 104cells/well. (This depends on proliferation of cell type)
Place in incubator for a period of time (1-3 days) so the cells reach exponential phase.
Prepare the dilutions in growth medium of the factors/drugs for testing, covering a range
of concentrations.
Prepare a solution o f MTT by dissolving 50mg/ml in 0.1 glycine buffer at pH 10.5.
Remove any particulates and sterilize through membrane filtration.
Procedure:
1. Remove the medium from the each of the wells and add the 0.2ml of the 
factors/drugs dilutions to the wells. Add medium to control wells.
2. Place the plates in the incubator for a period o f timed exposure.
3. Remove all medium from wells and replace with fresh medium with no 
drugs/factors. Repeat daily to have about 2-3 cell divisions
4. After the final feeding, add the MTT solution of 50pl and wrap the plate in foil 
and place into the incubator for 3-8 hours.
5. Remove medium from wells and dissolved the retained formazan by addition of
0.2ml o f DMSO, and then add 25pl of glycine buffer and read absorbance 
immediately in ELISA plate reader at 570nm.
B9: Protocol for the immunostaining of the tissue mass for collagen:
Reagents:
Wash Buffer -  PBS-Tween 20 (0.1 %)
Blocking Buffer -  10% swine serum in PBS-Tween 20 or 5% BSA in PBS-Tween 20
Primary Antibody -  Rabbit polyclonal to human collagen type I (Biogenesis)
Secondary Antibody -  Swine anti-rabbit IgG conjugated with FITC (DAKO) diluted in 
20% swine serum or 0.5% BSA in PBS-Tween 20
Mounting Media -  Vectorshield Mounting Agent with Propidium Iodide
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Procedure:
1. Wash the slides with PBS-Tween20 (0.1%)
2. Block the slides with 10% swine serum in PBS-Tween20 for 30 minutes at room 
temp.
3. Add the primary antibody diluted to 1:10 and incubate at room temperature for 2 
hours.
4. Wash three times use PBS-Tween20, and from this moment on, avoid direct light 
by keeping the slides covered in foil.
5. Add the secondary conjugate antibody and incubate for 30 minutes at room temp.
6. Wash the slides three times with PBS-Tween 20 and add a drop of Mounting 
Media and look under the microscope using fluorescence.
B10: Protocol for the hydroxyproline assay:
Reagents:
Papain Buffer (Store at 4°C, shelf-life of 3months)
1.42 g Sodium Phosphate, dibasic, and monobasic
0.0788g Cysteine Hydrochloride
0.1861g Ethylenediaminetetraacetic acid (EDTA)
Add 90 ml o f UHQ Water and stir until dissolved. Adjust pH to 6.5 using 1M HCL, and 
make up to a volume o f 100ml with UHQ water.
Papain solution (Made fresh on the day, and use on the day o f preparation)
0.0264g Papain (P4762 lOOmg, Sigma)
Add 25ml of papain buffer and stir until dissolved.
0.25M Sodium Phosphate pH6.5 (Store at 4°C, shelf life is 3months)
7.5g of sodium phosphate, monobasic, anhydrous. Dissolve in UHQ water and make up 
to a final volume of 250ml, making a solution of pH5.
8.875g of sodium phosphate, dibasic, anhydrous. Dissolve in UHQ water and make up to 
a final volume of 250ml, making a solution of pH9.
Add 125ml of the monobasic solution to the 80ml of dibasic solution. Check the pH is 
pH6.5, adjust the pH accordingly, by adding either the monobasic or dibasic solution.
Hydroxyproline assay Stock solution (Store at 4°C, shelf life is 3 months)
5g citric acid and 12g sodium acetate and dissolve in 65ml o f UHQ water 
3.4g of sodium hydroxide in 25ml o f UHQ water.
Mix two solutions together and add 1.2ml glacial acetic acid. Make up to 100ml of UHQ 
water. Add 5 drops of toluene.
Hydroxyproline assay Working solution (Store at 4°C, shelf life is 3 months)
15ml of isopropanol to 50ml of hyroxyproline stock solution.
Mix well and adjust to pH6, using conc. HC1. Make up to a final volume 75ml with UHQ 
water.
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Chloramine T solution (Store in glass container at room temp, shelf life 2 days)
Take 20ml of the hydroproline working solution and add 2.5ml of isopropanol.
Weigh out 0.3525g of chloramines T and add to the solution, and stir
p-Dimethylaminobenzaldehyde (p-DAB) solution (Store in a glass container at room 
temperature, shelf life is 2 days)
3.75g of pDab 
15ml of isopropanol 
6.5ml o f perchloric acid
Procedure:
Preparation o f the samples
1. Rinse the sample in PBS
2. Place the sample in the preweighed glass tube_____________________g_ and
freeze at -70°, or use liquid nitrogen
3. Dry the samples in the freeze drier, for about 2 days
4. Record the weight of the tube and sam ple,________________________and
calculate the dry-weight of the sample in grams.____________________g
5. Add the 0.5ml to 1ml o f papain solution and record volume used.________ ml
6. Incubate the samples in a 60°C oven overnight
7. Allow the samples to come to room temperature
8. Do not disturb the settled pellet, to dry and weigh for microcarrier weight
9. Retain supernatant for analysis.
10. Now take 250pl of the supernatant, and add 250pl of concentrated HC1 in Pyrex 
screw cap glass tube. Cap the vial tightly with a black phenolic PTFE lined screw 
caps and incubate overnight at 120°C.
11. Next day transfer the contents to small glass vials and incubate them uncapped at 
90°C until dry. Cool the sample to room temperature and dissolve the residue in 
lm l o f 0.25M sodium phosphate buffer.
Preparation of blanks and sample diluent
1. Heat the papain solution in the oven at 60°C.
2. Hydrolyse this blank solution with equal volume of conc. HC1.
3. Incubate at 90°C until dry and then redissolve with 0.25M sodium phosphate.
This hydrolysed papain solution (HPS) will act as the blank and as the diluent for 
samples and standards.
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Preparation o f Standards
Make up a stock of 1 mg/ml of hydroxyproline in UHQ water. Dilute down to lOOpg/ml 
with the hydrolysed papain solution. Prepare the standards in 1.5ml eppendorfs
Standard value(pg/ml) pi o f lOOpg/ml pi blank HPS
30 60 140
20 40 160
15 30 170
10 20 180
8 16 184
6 12 188
5 10 190
4 8 192
2 4 196
1 2 198
0 0 200
Now load the standards and samples into the 96 well plate.
Load 50 pi o f HPS as the blank 
Load 50 pi of the standards
Load 50 pi of the sample, and do a range of dilutions from neat to a 1 in 10.
Add 50 pi o f Chloramine T solution to each well and incubate for 20 min.
Add 50 pi of p-DAB solution to each well and incubate at 60°C for 30 min.
Ensure self-adhesive film and lids are placed over the wells to prevent 
evaporation.
Allow the plate to come to room temperature for 10 min and the read on the plate 
at 540nm.
% collagen in sample = (Cone, in ug/ml x Dil. factor x proportion of digest 
hydrolysed)/(Dry weight of the sample (g) x 0.143 x 1000,000) x 100%
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B ll:  Protocol for the DMB assay for the GAG quantification:
This assay is applied after the papain digestion step used for BIO.
Reagents:
1,9 Dimethylene blue (DMB) solution -  Dissolve 16mg 1,9-dimethylene blue, and 2g 
sodium formate, in 100ml o f UHQ water. Then add 5ml o f 100% ethanol, and 2ml formic 
acid. Make up this solution to 1000ml using UHQ water and store the solution in foil 
wrapped brown bottle at room temperature. (Shelf life of 3months)
Standards -  make a 1 mg/ml stock solution of chrondroitin-4-sulphate (Chrondroitin 
sulphate A, bovine trachea) in UHQ water. Dilute this to lOOpg/ml using the blank 
papain solution (i.e. 50pl o f stock solution and 450 pi o f blank papain solution). Prepare 
the standards in 1.5 ml eppendorf tubes from the diluted standard.
Standards
(concentrations pg/ml)
pi oflOOpg/ml of 
stock solution
pi of blank Papain 
Solution
0 0 100
5 5 95
10 10 90
15 15 85
20 20 80
25 25 75
30 30 70
40 40 60
50 50 50
75 75 25
Procedure:
1. Load the following reagents in the following order into a 96 well plate:
20pl blank papain solution or the papain digested sample or the standards 
200 pi o f 1,9-dimethylene blue (DMB) solution
2. Read the plate immediately using dual wavelength of 540nm (measurement) and 
595 nm (reference). NB. The GAG/dye complexes may start to precipitate with 
time and plates should be read within 10 minutes of addition of the DMB solution.
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B12: Range of suspension speeds used for the microcarriers:
1. Nunc 2D Microhex, minimum: 45rpm, maximum: 60rpm
2. Cytodex 2 microcarriers, minimum:60rpm, maximum:85rpm
3. Vicryl biodegradable discs, minimum:60rpm, maximum:85rpm ( this was 
chosen empirically, i.e. to keep suspending the discs as much as possible, 
and the maximum was chosen to be the same as the Cytodex 2 
microcarriers)
177
APPENDIX C
This section details on the cost and mass balance data used in Chapters 6 and 7. 
C l Cost data gathered for Chapters 6 and 7
Table C l: Resource cost information gathered for Chap 6.
Resource Cost
Equipment
70L fermenter, working volume 50L £56,366
700L fermenter, working volume 500L £559,606
C1P skid £73,200
Roller bottle apparatus £3,782
Cryogenic freezers -  150°C £18,849
Freezer -80°C £2,562
W ave reactor system 500 +KIT1000 $350,000 +$30,000
W ave reactor system 200 $105,000
Laminar flow hoods $2,800
CELLMATE £475000
Materials
Consumables
RB £3.78 /RB
Disposable CellBags -  200L £312 /unit
Disposable CellBags -  1000L £1200 /unit
Chemicals
DMEM £4/L
Glutamine £22/L
Serum £32.97/L
MEM (Non-Essential amino acids) £29/L
DPBS (buffer) £4.20 /L
Ascorbic acid £0.12 /g
Trypsin £1.10/L
Commercial microcarrier £3.60 /g
Biodegradable microcarrier £5.40 /g (see assumptions table)
Biodegradable mesh £11.64 / m2
Staff
Operator £30k/annum
Utilities
WFI £5.30/L
Steam £0.03/kg
Cooling water $0.001/L
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Table C2: Resource cost data gathered for Chapter 7.
Resource Unit Cost
Equipment
Shake flask incubator £7,000
Wave reactor system 500+KIT1000 £240,000
Wave reactor system 200EH £70,000
Centrifuge 1000L £100,000
Ultrafiltration Rig £37,500
Chromatography Rig. Diameter 11dm £140,000
Chromatography columns (height 1100mm) Diameter 0.7 £4,947
Diameter 1.0 £5,686
Diameter 1.4 £7,740
Diameter 2.0 £8,529
Diameter 2.5 £14,065
Diameter 3.0 £18,591
Diameter 3.5 £25,372
Diameter 4.5 £46,332
Vessel/Holding Tank 50L £2,600
1500L £20,000
CIP vessel £60,000
Materials
Consumables
Cell Bag 1000L
Cell Bag
Shake flasks 0.5L £30
Prostak UF Modules 0.93m2 £883
1.9 m2 £1763
Spiral Wound Ultrafiltration Module 3.7 m2 £3228
Ion Exchange Chrom. Matrix -  CM Sepharose £470/L
Gel Filtration Chrom. Matrix -  G25M £200/L
Affinity Chrom. Matrix -  Heparin Sepharose £4720/L
Chemicals
Media £5/L
PBS buffer £0.66/L
1.0M NaOH £1.80/L
1.0M NaCl £0.78/L
O.OlMTris/HCl £0.55/L
H3 PO 4  pH 1.5 £0.63/L
CIP Buffer £1.5/L
FCI is derived by multiplying the equipment purchase costs by a Lang factor, and this 
factor constitutes the sum of the individual factors f  to/io- Thus deriving Lang factor for 
a disposable situation would be the same but the factors can be calculated based on the 
disposable costs rather than conventional costs. See inserted spread sheet as example.
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Table C3: Derivation of Lang Factors
This method is based on Novais et al. (2001) where the Lang factor is the sum of the 
factors FI to F 10, multiplied by a contingency factor. Below is the example of the how 
the Lang factor (4.18) of the disposable plant using the Wave reactor is derived:
Process route
Equipment  
Cost of each 
process route
Ratio A 
(STR/WAVE)
Ratio B 
(WAVE/STR)
STR £4,336,883 0.67 1
WAVE £6,443,853 1 1.49
WAVE A B C D
Conventional
Disposable
on
conventional
Disposable
on
conventional Disposable on disposable
F1 Equipment 1.00 1.49 1.49 1.00
F2 Pipework 0.90 0.33 0.30 0.20
F3 Process control 0.37 1.00 0.37 0.25
F4 Instrumentation 0.60 0.66 0.40 0.27
F5 Electrical power 0.24 1.00 0.24 0.16
F6 Building works 1.66 0.80 1.32 0.89
F7 Detail 
Engineering 0.77 0.50 0.39 0.30
F8 Construction 0.40 0.75 0.30 0.20
F9 Commissioning 0.07 1.00 0.07 0.05
F10 Validation 1.06 0.50 0.53 0.36
Contingency factor 1.15 1.15 1.15 1.15
Lang Factor 8.13 6.21 4.18
Column A = individual (FI to F10) factors for a conventional stainless steel biotech plant 
(Source: Novais et al. 2001)
Column B = Relative change in factors FI to F 10 for a disposable plant relative to a 
conventional plant.
Column C = Factors (FI to F10) would be based on a conventional case i.e. Column A x 
Column B
Column D = Factors (F I  to F10) normalized to relative equipment costs for a disposable 
plant, (i.e. Column C divided by Ratio B)
Therefore the sum of Column D (FI to F10) multiplied by the contingency factor gives 
4.18 as the Lang factor to use.
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C2 Mass balance and demand data
C2.1 Mass balance calculations
This following table shows the various mass balances implemented into spreadsheets for 
various unit operations for the processing calculations in Chapter 7
Table C4 : Process models adopted for the various unit operations used in Chapter 7
Unit Operations Process Models
Fermentation Stoichiometry, extent of reaction,
Q-g- m ou< = m,n m , n l l mi<ing X X X  ‘
^lim
Centrifugation Solids carry-over, Solids volume fraction in sediment 
e-g- = { l ~ S ) x m SUe,
'" .su p  = W™ x
UFDF Flux, Rejection coefficients, Number o f Diavolumes
F V0( l - C F ~ l) r D x V 0 
e.g. J =  0 e.g. J  =
AT x n x t  AT x n x t
Chromatography Flowrates, Column volumes, yields, binding capacities 
H x C Ve.g t =
u
C2.2: Derivation of the amount of steam used for vessels
An example calculation for the deriving how much steam that might be used for SIP 
Amount of steam required for a 400L vessel:
At sterilization temperature o f 121°C, the pressure is 2.4 bar ( look in steam tables) 
V - 400L i.e. 0.4 nri 
R = 8.314 (Gas constant)
T = 121 °C
PV = nRT So n = PV/RT = 2.4 x 105 x 0 .4 / (8.314 x (  121+273)) = 29.3 moles
Moles = mass/mr therefore Mass o f steam needed = 29.3 x 18 = 527.4 kg of steam 
Thus expect to use about 528kg of steam and each need to use it before and after each 
batch run, therefore at 8 batches a year that is 8448kg per year
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C2.3: Demand data
A rationale was prepared based on market information and then the estimated demand 
was then calculated for the comparison of the growth factor with the TE-approach in 
Chapter 7. This is shown below:
Manufacture o f GF (Growth Factors) individually as a treatment to chronic wounds: 
Background information for what’s on the market:
Regranex gel (US): main active ingredient is rPDGF (recombinant Platelet-derived 
growth factor), secreted by yeast o f the strain Sacchromyces cerevisiae. This is a non- 
sterile, low bioburden gel. Price is £275 for a 15g tube, o f which 0.01% is the active 
ingredient, i.e. 1.5mg.
This product is sold by Johnson & Johnson, sales in 2004 was $160 million (£100 
million).
Fiblast spray (Japan): main active ingredient is rbFGF (recombinant basic fibroblast 
growth factor), loosely bound to the periplasm of the yeast strain Sacchromyces 
cerevisiae. This is sold in two vials -  one of solution and one freeze-dried active 
ingredient to be reconstituted with the solution vial. Thus 500ml spray with 500jag of 
rbFGF is ¥12,339.70 (£60.70).
This product is sold by Kaken Pharmaceutical, sales in 2004 was ¥3.4 billion. (£16.7 
million)
For a ulcer size of 4cm x 4cm, and treatment of 8 weeks:
DG (Dermagraft), 1 piece per week, thus total of 8 pieces of DG.
Regranex gel, 1 gram of gel used per day, thus total of 56g o f gel i.e. 4 tubes.
[ length o f gel applied daily = 4cm x 4cm /4 = 1 g , 15 g per tube, 56/15 = 3.7 tubes, i.e. 4 
tubes. ]
so 8 units of DG is about 4 tubes, i.e. each piece of DG is 2 tubes.
So if comparison to previous ECM project of making 100kg production,
100kg is about 126,904 units o f DG [ = 100*1000/0.788], each piece of DG weighs 
0.788 g
so 126904 units of DG is about 63,452 tubes of GF gel.
therefore if each tube has 15 g o f gel and at 0.01%w/w active of each single GF
Then 63,452*15*0.01% = 95.178 g
So, demand of growth factor is 95200mg of growth factor.
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C3 C alculating Cashflow and the NPV
Spreadsheet was set up as shown below and the net cashflow was utilized to then feed 
into the NPV calculation and the cumulative cashflow to calculate payback time.
Table C5: Example of spreadsheet set up to calculate cashflow
Year -1 0 1 to  9 10
Production (kg)
Sales price per kg
S a le s  r ev en u e
Sales and Distribution Cost
FCI N/A N/A N/A
Working capital N/A N/A N/A
Total indirect costs
Total direct costs
Total running costs
Gross Profit
Interest
Profit before Tax
Corporate Tax @ 30%
Profit After Tax
Depreciation Recouped
Working Capital Recouped N/A N/A N/A
N et C a sh flo w
C u m u la tive  C a sh flo w
Y ear -1 Net cashflow
YearO Net cashflow
Total 1 Year-1+year0 Y ear-1+year0 Year-1 +year0 Year-1 +year0 Year-1 +year0
Y ear 1 Net cashflow
Y ear 2 Net cashflow
Y ear 3 Net cashflow
Y ear 4 Net cashflow
Y ear 5 Net cashflow
Year 6 Net cashflow
Y ear 7 Net cashflow
Year 8 Net cashflow
Y ear 9 Net cashflow
Year 10 Net cashflow
Total 2 Sum (Y ear 1:year S u m (Y ear 1:year Sum (Y ear 1:year Sum (Y ear Sum (Y ear
_______ _________ 10) ______________ 10) 10) 1 :y e a r 10 1:year 10)
NPV : to calculate the values in the blank spaces in the table shown above : 
= Base case x (l+(discount factor)year.
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